Antimicrobial Agents and Methods

Carrier bacteria with episomal DNA encoding antimicrobial agents efficiently transfer and express toxic agents in target cells to kill pathogens, promoting growth and improving FCR in animals and plants.

JP7588602B2Active Publication Date: 2024-11-22FOLIUM FOOD SCI LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021567824
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-12
Filing Date
2020-05-10
Publication Date
2024-11-22
Estimated Expiration
2040-05-10

AI Technical Summary

Technical Problem

Current methods for controlling pathogenic bacteria such as Salmonella and Pseudomonas in animals and plants are inefficient and do not effectively promote growth or improve feed conversion ratio (FCR) in livestock.

Method used

Utilizing carrier bacteria containing episomal DNA that encodes antimicrobial agents toxic to target cells but not to carrier cells, which can conjugatively transfer and express the agents in target cells to kill or inhibit their growth, thereby promoting growth and improving FCR.

Benefits of technology

The method effectively reduces pathogenic bacteria populations and enhances growth or weight in animals and plants, while improving FCR by up to 10% compared to control groups.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588602000060
    Figure 0007588602000060
  • Figure 0007588602000061
    Figure 0007588602000061
  • Figure 0007588602000062
    Figure 0007588602000062
Patent Text Reader

Abstract

The present invention relates to means for effecting conjugation between bacteria, and in particular to carrier bacteria containing antibacterial agents and methods of use. The carrier bacteria are capable of conjugatively transferring DNA encoding the agent into target cells. The present invention further relates to promoting growth or feed conversion in animals. The present invention further relates to killing Salmonella or inhibiting the growth or proliferation of Salmonella.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to means for effecting conjugation between bacteria, in particular the present invention relates to carrier bacteria containing antibacterial agents and methods of use. The carrier bacteria are capable of conjugative transfer of DNA encoding the agent into a target cell.

[0002] The invention further relates to the promotion of growth or feed conversion ratio (FCR) in animals.The invention further relates to the killing or inhibition of the growth or proliferation of Salmonella.The invention further relates to the killing or inhibition of the growth or proliferation of Pseudomonas, useful for example in promoting plant growth, dry weight, wet weight, or crop production. [Background technology]

[0003] DNA sequences controlling extrachromosomal replication (ori) and transfer (tra) are distinguishable from each other. Thus, replication sequences generally do not control plasmid transfer and vice versa. Both replication and transfer are complex molecular processes that utilize plasmid- and host-encoded functions. Bacterial conjugation is the unidirectional horizontal transfer of genetic information from one bacterium to another. The transferred genetic material can be a plasmid or it can be part of a chromosome. Bacterial cells carrying conjugative plasmids contain surface structures (sex pilus) that are involved in the coupling of donor and recipient cells and the transfer of genetic information. Conjugation involves cell-cell contact and the transfer of genetic attributes can be mediated by many plasmids. Of all natural transfer mechanisms, conjugation is the most efficient. For example, the F plasmid of E. coli, the pCFlO plasmid of Enterococcus faecalis, and the pX016 plasmid of Bacillus thuringiensis employ different mechanisms for the establishment of mating pairs, the sizes of the mating aggregates vary, and they have different host ranges in Gram-negative (F) and Gram-positive bacteria (pCFlO and pX016). Their plasmid sizes are also different, 54, 100, and 200 kb, respectively. However, notably, these conjugation systems share a crucial feature in common: they can sustain conjugative transfer in liquid media and often reach transfer efficiencies approaching 100% in a very short time. Thus, the conjugation process allows protection of the plasmid DNA against environmental nucleases and very efficient delivery of the plasmid DNA to the recipient cell. Conjugation functions are naturally encoded by the plasmid. Numerous conjugative plasmids (and transposons) are known that can transfer related genes within one species (narrow host range) or between many species (broad host range). Transmissible plasmids have been reported in a number of Gram-positive genera, including but not limited to pathogenic strains of Streptococcus, Staphylococcus, Bacillus, Clostridium, and Nocardia. The early steps of conjugation generally differ between Gram-negative and Gram-positive bacteria.The role of some transfer genes in conjugative plasmids from Gram-negative bacteria is to provide pilus-mediated cell-cell contact, formation of the conjugative pore, and related morphological functions. Pili do not appear to be involved in initiating conjugation in Gram-positive bacteria. Summary of the Invention [Means for solving the problem]

[0004] The present invention relates to Provided is a (e.g., non-medical or medical) method for enhancing the growth or weight of a subject, the subject comprising bacterial target cells, the method comprising administering to the subject a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells, wherein the first DNA is transferred to the target cells and the agent is expressed, thereby killing or reducing the growth or proliferation of the target cells in the subject and enhancing the growth or weight of the subject.

[0005] In one embodiment, A method is provided for enhancing the growth or weight of a subject (e.g., non-medical or medical), the method comprising administering to a subject a plurality of carrier cells, the subject comprising bacterial target cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells but not to the carrier cells, the carrier cells being capable of conjugatively transferring DNA into the target cells for expression of the agent in the target cells, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject and enhancing the growth or weight of the subject.

[0006] Advantageously, the FCR in the subject is improved (i.e. enhanced), i.e. the FCR number is reduced. When the method of the present invention is carried out in a group of subjects (e.g. a group of animals such as livestock animals), the FCR is reduced in individuals in the group, or the average FCR is reduced in the group. The reduction can be evaluated as a comparison with the FCR before administration of carrier cells, or compared with the average for animals of the same species, age group, and raised on the same level or the same diet. Those skilled in the art are familiar with the standard FCR for livestock animals, such as piglets, pigs, sheep, cattle (dairy or beef cattle), fish, crustaceans, poultry (e.g. chickens (broilers or layers), geese, ducks, or turkeys), etc.

[0007] The present invention also provides a carrier cell, The cells are bacterial cells that contain a first episomal DNA encoding an antibacterial agent that is toxic to bacterial target cells but not toxic to carrier cells, and the carrier cells are capable of conjugatively transferring the DNA into the target cells for expression in the target cells of the antibacterial agent, thereby killing the target cells, and the target cells are Salmonella cells and the carrier cells are Enterobacteriaceae cells.

[0008] 1. A composition comprising a plurality of carrier cells for use in a method comprising administering cells to a subject for treating infection by pathogenic bacterial target cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antibacterial agent that is toxic to the target cells but not to the carrier cells, the carrier cells being capable of conjugatively transferring DNA into the target cells for expression of the agent in the target cells, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antibacterial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject, the target cells being Salmonella cells and the carrier cells being Enterobacteriaceae cells.

[0009] A non-medical method of killing zoonotic bacterial target cells in an animal (optionally a livestock animal), the method comprising administering to the animal a plurality of carrier cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antibacterial agent that is toxic to the target cells but not to the carrier cells, the carrier cells being capable of conjugatively transferring DNA into the target cells for expression in the target cells of the agent, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antibacterial agent thereby killing or reducing the growth or proliferation of the target cells in the subject, the target cells being Salmonella cells, and optionally the carrier cells being Enterobacteriaceae cells.

[0010] a DNA (optionally for use in the methods of the invention) that can be introduced into a target cell and that encodes a plurality of guide RNAs or crRNAs of a CRISPR / Cas system, and that is operable with a Cas nuclease in the target cell such that the guide RNAs or crRNAs recognize a plurality of protospacer sequences contained in the target cell genome; (a) the protospacer sequence comprises one or more pathogenicity island nucleotide sequences of the target cell genome; (b) the protospacer sequence comprises one or more invading gene sequences of the target cell genome; (c) the protospacer sequence comprises one or more secretion system gene sequences of the target cell genome; and / or (d) DNA, wherein the protospacer sequence comprises one or more nucleotide sequences of genes selected from avrA, sptP, sicP, sipA, sipD, sipC, sipB, sicA, invB, ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, mgtC, cigR, pipA, pipB, pipC, sopB, and pipD of Salmonella (optionally selected from invB, sicP, sseE, pipA, pipB, pipC, hilA, marT, and sopB of Salmonella), and their orthologs or homologs.

[0011] The present invention also provides the following configuration.

[0012] In the first configuration: a carrier bacterial cell comprising a first episomal DNA, the DNA encoding a nucleic acid sequence of interest (NSI) or encoding an antimicrobial agent that is toxic to the target bacterial cells but not to the carrier cells, the carrier cell capable of conjugatively transferring the DNA into the target cells for expression of the agent in the target cells, and optionally (a) the carrier cell contains a second DNA that is different from the first DNA, the second DNA containing or encoding a first factor required for replication of the first DNA; (b) the first DNA does not contain or encode said first factor, and the first DNA is non-autonomously replicating in the absence of the first factor, but is capable of replicating in a carrier cell in the presence of the first factor provided by the second DNA; (c) a carrier bacterial cell, the cell comprising genes encoding one or more conjugation factors sufficient for conjugative transfer of the first DNA into the target bacterial cell.

[0013] In an embodiment, the present invention usefully recognizes the advantage of using an antimicrobial agent that acts by recognizing a target sequence in the target cell genome but not in the carrier cell, which frees up the ability of the first DNA to replicate freely in the carrier cell without toxicity to the carrier cell.

[0014] In the second configuration: DNA encoding an NSI or encoding an antibacterial agent that is toxic to a target bacterial cell but not to a carrier cell that can carry the DNA for conjugative transfer into the target cell, wherein the first DNA does not contain or encode a first factor required for replication of the first DNA, and the first DNA lacks components required for conjugative transfer of the first DNA into the target bacterial cell.

[0015] In the third configuration: A method for enhancing the growth or weight of a human or animal subject, the method comprising administering a plurality of carrier cells according to the present invention to a microbial population of the subject, the microbial population comprising target cells, and a first DNA is transferred from the carrier cells to the target cells for expression in the target cells to produce an antibacterial agent, thereby killing or reducing the growth or proliferation of the target cells (e.g. Salmonella cells) in the subject.

[0016] In the fourth configuration: A method for enhancing the growth or weight of a plant, the method comprising administering a plurality of carrier cells according to the present invention to a microbial population of the plant, the microbial population comprising target cells, and a first DNA is transferred from the carrier cells to the target cells for expression in the target cells to produce an antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells (e.g. Pseudomonas cells) in the plant.

[0017] In the fifth configuration: A method for reducing a biofilm contained in an object or contained on a surface, wherein the biofilm comprises target cells (e.g., Pseudomonas cells), the method comprising administering to the biofilm a plurality of carrier cells according to the present invention, wherein a first DNA is transferred from the carrier cells to the target cells for expression in the target cells to produce an antibacterial agent, thereby killing or reducing the growth or proliferation of the target cells in the biofilm.

[0018] In the sixth configuration: 1. A method for replicating a first DNA (e.g. contained in a conjugative plasmid) to produce multiple copies of said DNA, the method comprising culturing a plurality of carrier bacterial cells according to the invention, replicating said first DNA in the cells, and optionally isolating the multiple copies of the first DNA from the carrier cells.

[0019] In the seventh configuration: 1. A method for killing or reducing the growth or proliferation of a plurality of target bacterial cells, comprising: (a) obtaining a sample of carrier cells according to the present invention or obtained by the method of the sixth aspect, (b) contacting the sample of carrier cells with a plurality of target bacterial cells to cause conjugation of the carrier cells with the target cells; and (c) transferring a copy of the first DNA from the carrier cell to the target cell by conjugative transfer, whereby an antimicrobial agent is provided in the target cell, killing the target cell or reducing the growth or proliferation of the target cell; (d) the first DNA is not replicable (or substantially not replicable) in the target cell; The method includes:

[0020] In the eighth configuration: A pharmaceutical composition, a composition for livestock growth promotion, a zoonotic disease control agent, a biocide for administration to livestock, a soil conditioner, a herbicide, a fertilizer for plants, a composition for sterilizing food or foodstuffs, a dental composition, a personal hygiene composition or a disinfectant composition (e.g. for household or industrial use) comprising a plurality of carrier cells according to the invention.

[0021] In the ninth configuration: In a first aspect, A method for promoting the growth of an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering a guided nuclease system or a component thereof to the animal and introducing the system or component into a target bacterium contained in the animal, wherein the guided nuclease is capable of recognizing and modifying (e.g., cleaving) a target nucleotide sequence contained in the target bacterium, thereby killing the target bacterium or inhibiting the growth or proliferation of the target bacterium to promote the growth of the animal.

[0022] The method is a non-medical method, in which the presence of the target bacteria in the animal allows for inhibition of the growth of the animal, thus reducing the burden of such bacteria in the animal and promoting growth.

[0023] In a second aspect, A method for increasing feed conversion ratio (FCR) in an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering a guided nuclease system or a component thereof to the animal and introducing the system or component into a target bacterium contained in the animal, wherein the guided nuclease is capable of recognizing and modifying (e.g., cleaving) a target nucleotide sequence contained in the target bacterium, thereby killing the target bacterium or inhibiting the growth or proliferation of the target bacterium and increasing the FCR of the animal.

[0024] The method is a non-medical method, in which the presence of target bacteria in an animal allows for an increase in the FCR of the animal, thus reducing the burden of such bacteria in the animal and enhancing the FCR (i.e. reducing the FCR count).

[0025] In a third aspect, 1. A method for promoting the growth of an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering to the animal an antibacterial agent that is toxic to Salmonella bacteria, such that Salmonella target bacteria contained in the animal are exposed to the agent and killed, or the growth or proliferation of the target bacteria is inhibited, thereby promoting the growth of the animal.

[0026] The method is a non-medical method, in which the presence of the target bacteria in the animal allows for inhibition of the growth of the animal, thus reducing the burden of such bacteria in the animal and promoting growth.

[0027] In a fourth aspect, 1. A method for increasing the feed conversion ratio (FCR) in an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering to the animal an antibacterial agent that is toxic to Salmonella bacteria, wherein Salmonella target bacteria contained in the animal are exposed to the agent and killed, or the growth or proliferation of the target bacteria is inhibited, thereby increasing the FCR of the animal.

[0028] The method is a non-medical method, in which the presence of target bacteria in an animal allows for an increase in the FCR of the animal, thus reducing the burden of such bacteria in the animal and enhancing the FCR (i.e. reducing the FCR count).

[0029] In the tenth configuration: In a first aspect: 1. A method for enhancing plant growth, dry weight, wet weight, or crop production, wherein the plant comprises a microbial population including a target bacterium, the method comprising contacting the microbial population with an antimicrobial agent that is toxic to the target bacterium, wherein the target bacterium is killed or growth or proliferation of the target bacterium is inhibited, thereby increasing plant growth, dry weight, wet weight, or crop production.

[0030] In a second aspect, 1. Use of an antimicrobial agent that is toxic to a target bacterium in a method in which the target bacterium contained in the microbial population of a plant is contacted with the agent, thereby killing the target bacterium or inhibiting its growth or proliferation to enhance plant growth, dry weight, wet weight, or crop production.

[0031] In a third aspect, 1. A method for increasing yield in a plant, the plant comprising a microbial population including a target bacterium, the method comprising contacting the microbial population with an antimicrobial agent that is toxic to the target bacterium, wherein the target bacterium is killed or growth or proliferation of the target bacterium is inhibited, thereby increasing plant growth, dry weight, wet weight, or crop production.

[0032] In a fourth aspect, 1. Use of an antimicrobial agent that is toxic to a target bacterium contained in the microbial population of a plant in a method in which the target bacterium is contacted with the agent, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited in order to increase crop yield of the plant.

[0033] In a fifth aspect, 1. A method for increasing chlorophyll in the leaves of a plant, wherein the plant contains a microbial population including a target bacterium, the method comprising contacting the microbial population with an antimicrobial agent that is toxic to the target bacterium, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited and chlorophyll in the leaves of the plant is increased.

[0034] In a sixth aspect, 1. Use of an antimicrobial agent that is toxic to a target bacterium contained in a plant's microbial population in a method in which the target bacterium is contacted with the agent, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited in order to increase chlorophyll in the leaves of the plant.

[0035] In a seventh aspect, 1. A method for increasing the greening of a plant, the plant comprising a microbial population including a target bacterium, the method comprising contacting the microbial population with an antimicrobial agent that is toxic to the target bacterium, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited, thereby increasing the greening of the plant.

[0036] In an eighth aspect, 1. Use of an antimicrobial agent that is toxic to a target bacterium contained in the microbial community of a plant in a method in which the target bacterium is contacted with the agent, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited to increase the greening of the plant.

[0037] In a ninth aspect, 1. A method for reducing a biofilm in a plant (e.g., a leaf biofilm), wherein the plant contains a biofilm comprising a target bacterium, the method comprising contacting a microbial population with an antimicrobial agent that is toxic to the target bacterium, whereby the target bacterium is killed or the growth or proliferation of the target bacterium is inhibited, thereby reducing the biofilm on the plant.

[0038] In a tenth aspect, The use of an antimicrobial agent that is toxic to a target bacterium in a method in which the target bacterium contained in a plant biofilm (e.g., a leaf biofilm) is contacted with the agent, thereby killing the target bacterium or inhibiting its growth or proliferation in order to inhibit the plant biofilm.

[0039] Optionally, the target bacterium is a Pseudomonas bacterium, such as a P syringae or P aeruginosa bacterium, or any other Pseudomonas bacterium disclosed herein.

[0040] Optionally, the agent is a guided nuclease system or component thereof, such as any such system or component disclosed herein for modifying (e.g., cleaving) a target nucleic acid sequence contained in a target bacterium.

[0041] Optionally, the plant is any plant disclosed herein.

[0042] Optionally, the chlorophyll is chlorophyll a and / or chlorophyll b.

[0043] Optionally, the agent is comprised in a carrier cell of the invention and said contacting comprises contacting the cell with the carrier cell. [Brief description of the drawings]

[0044] [Figure 1] PCR performed on recipient colonies. From left to right: 1) plasmid pFSMobC* (control), 2) plasmid pFSMobC* in S17 (control), 3) a colony from an exconjugant plate (Cm30+Nal25), 4) a second colony from an exconjugant plate (Cm30+Nal25). [Diagram 2] FIG. 1 shows the survival effect of conjugally delivered pFSMobSal7 on Salmonella enteritidis FS26. [Diagram 3] Figure 1. Number of Salmonella in the cecum 7 days post-infection. N=15 birds per group. [Figure 4] Figure 1 shows the frequency of detection of Salmonella in the cecum 7 days after infection, N=15 birds per group. [Diagram 5] FIG. 1 shows carcass weights of 6-week-old birds. [Figure 6] Figure 1. Number of Salmonella (CFU / g) in crop digesta 7 days after challenge, N=9 birds, P=0.03. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] The present invention relates to means for effecting conjugation between bacteria, in particular the present invention relates to carrier bacteria containing antibacterial agents and methods of use. The carrier bacteria are capable of conjugative transfer of DNA encoding the agent into a target cell.

[0046] The invention further relates to the promotion of growth, weight, or feed conversion ratio (FCR) in animals.The invention further relates to the killing of Salmonella or the inhibition of growth or proliferation of Salmonella.

[0047] Thus, there is provided a method (e.g., non-medical or medical) for enhancing the growth or weight of a subject, wherein the subject comprises bacterial target cells, and the method comprises administering to the subject a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells, wherein the first DNA is transferred to the target cells and the agent is expressed, thereby killing or reducing the growth or proliferation of the target cells in the subject and enhancing the growth or weight of the subject.

[0048] Advantageously, the FCR is increased in the subject. Optionally, the FCR is increased (i.e., decreased) by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%, such as 2-6% or 2-5% (e.g., 2, 3, 4, 5, or 6%), compared to the FCR of the subject before administration of the agent or carrier cells. Optionally, the FCR is increased by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%, such as 2-5% (e.g., 2, 3, 4, or 5%), compared to the FCR of a control subject of the same species and sex that has not received the agent or carrier cells. In one embodiment, the subject is a bird, poultry, chicken, turkey, goose, or duck (preferably chicken), and the FCR number is decreased by an amount of 0.03-0.07, such as 0.04-0.06, such as 0.04, 0.05, or 0.06. Thus, for example, compared to a control bird, the control bird has an FCR of 1.7 (g feed / g bird), and the subject bird after treatment using the present invention has an FCR of 1.64-1.66. A control bird (e.g., chicken) of the same species, sex, and age as the subject of the present invention, raised on the same diet (feed), does not receive the treatment of the present invention. The birds may be from the same batch. Thus, in one embodiment, the bird (e.g., chicken) has an FCR of 1.64-1.66, and the subject is treated by the method of the present invention.

[0049] In one example, the method is performed on a group of subjects (e.g., subjects of the same species, e.g., a group of livestock animals, e.g., a flock of poultry or a herd of cattle or sheep). In this example, the average FCR of the group is enhanced by the method (i.e., the FCR number is reduced) compared to a control group of animals of the same species, subspecies, or type, or compared to the average FCR of the group before treatment with the method. The control group can be a group of animals of the same species, average age, and sex ratio as the group of the invention, raised on the same diet. For example, the group of the invention and the control group are both a flock of poultry (e.g., chickens) that share a common ancestor, for example, going back one, two, or three generations. The flock can be a flock of broiler chickens or a flock of egg-laying hens. For example, the group of the invention and the control group are both a herd of beef cattle or a herd of dairy cattle that share a common ancestor, for example, going back one, two, or three generations.

[0050] FCR, FE, and ECI In animal husbandry, the feed conversion ratio (FCR) is a ratio that measures the efficiency with which an animal's body converts animal feed into a desired output. For dairy cows, for example, the output is milk, while for animals raised for meat (e.g. beef cattle, pigs, chickens, and fish), the output is meat and therefore the body mass gained by the animal, expressed as the final weight of the animal or the mass of processed output. FCR is the input mass divided by the output (i.e. the mass of feed per mass of milk or meat). In some industrial sectors, the feed efficiency (FE), which is the output divided by the input (i.e. the reciprocal of FCR), is used. These concepts are also closely related to the efficiency of conversion of ingested food (ECI). FCR is widely used in pig and poultry production, while FE is more commonly used in cattle. As FCR is a ratio, it is dimensionless, i.e. it is not affected by the units of measurement used to determine FCR. Animals with low FCR are considered to utilize the feed efficiently.

[0051] Preferably, the enhancement produced by the present invention is an increase in body mass in a subject. Instead of enhancing FCR, the present invention may be a method for enhancing feed efficiency (FE) in a subject, or for enhancing efficiency of conversion of ingested food (ECI) in a subject.

[0052] The FCR may be calculated using the dry weight of the feed or may be calculated on an as-fed wet weight basis.

[0053] In one embodiment, the FCR, FE, or ECI number is changed by 0.2, 0.5, 1, 1.5, or 2. For example, the FCR is reduced by 1, 1.5, or 2.

[0054] Conversion ratio for livestock beef cattle As of 2013 in the United States, an FCR of 4.5 to 7.5 calculated on liveweight gain is in the normal range, with an FCR of greater than 6 being typical. Thus, in an embodiment of the present invention, the or each animal is a beef cattle and the FCR number of the animal (or the average FCR of the animal) is reduced by the method (calculated using the liveweight of the animal) to less than 6, such as 5.5, 5, 4.5, 4, or less than 3.5 (optionally, the FCR or average FCR is 3.5 to 5.9, such as 4 to 5.5).

[0055] dairy cow In the United States, the price of milk is based on protein and fat content, and therefore FCR is often calculated taking this into account. Using FCR calculated based solely on the weight of protein and fat in the milk obtained from the animal as of 2011, an FCR of 13 is poor and an FCR of 8 is very good. Thus, in the present example, the or each animal is a dairy cow, and the FCR number of the animal (or the average FCR of the animal) is reduced by the present method to less than 11, 10, 9, or 8 (and optionally greater than 5 or 6), where FCR is the FCR of milk obtained from the animal treated by the method of the present invention, and FCR is calculated using the combined weight of protein and fat in the milk.

[0056] Another way to address pricing based on protein and fat is to use energy corrected milk (ECM), which adds a normalizing factor assuming a certain amount of fat and protein in the final dairy product. The formula is (0.327 x milk mass) + (12.95 x fat mass) + (7.2 x protein mass). In dairy farming, feed efficiency (ECM / intake) is often used instead of FCR (intake / ECM). A FE below 1.3 is considered questionable. Thus, in the present example, the or each animal is a dairy cow, and the FE number of the animal (or the average FE of the animal) is increased by the method by more than 1.3, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, or 3 (and optionally not more than 4 or 5). Optionally, the FE is increased by more than 1.3, 1.5, 1.6, but not more than 1.7.

[0057] FE based solely on the weight of milk is also used. An FE of 1.30 to 1.70 is normal. Thus, in the present example, the or each animal is a dairy cow, and the animal's FE number (or the average of the animals' FE) is increased by the method to more than 1.3, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, or 3 (and optionally not more than 4 or 5). Optionally, the FE is increased to more than 1.3, 1.5, 1.6, but not more than 1.7.

[0058] Pig As of 2011, commercially used pigs in the UK and Europe had FCRs calculated using weight gain of about 1 for piglets and ending at about 3 at slaughter. As of 2012, in Australia, using processed weight for output, an FCR of 4.5 calculated using the weight of processed meat was about good, 4.0 was "good" and 3.8 was "very good". As of 2012, in the US, commercial pigs had FCRs calculated using weight gain of 3.46 at 240-250 pounds, 3.65 at 250-260 pounds, 3.87 at 260-270 pounds and 4.09 at 280-270 pounds. Thus, in the present example, the or each animal is a piglet and the FCR number of the animal (or the average FCR of the animal) is reduced to 1 or less by the present method, and the FCR is calculated using the weight gain of the animal. Thus, in an example of the present invention, the or each animal is a pig up to 3 months of age, the FCR number of the animal (or the average FCR of the animal) is reduced by the method to 1 or less, and the FCR is calculated using the weight gain of the animal. Thus, in an example of the present invention, the or each animal is a pig from greater than 3 months to 6-7 months of age, the FCR number of the animal (or the average FCR of the animal) is reduced by the method to 3 or less (e.g., 1-3), and the FCR is calculated using the weight gain of the animal. The piglet may be 1.5-3 months old, and the pig to be slaughtered may be greater than 3 months to 6 months old. Thus, in an example of the present invention, the or each animal is a pig whose weight is 240-250 pounds, the FCR number of the animal (or the average FCR of the animal) is reduced by the method to 3.5 or less (e.g., 3.4 or less, but optionally 3 or 2.5 or more), and the FCR is calculated using the weight gain of the animal. Thus, in the present example, the or each animal is a pig whose body weight is between 250 and 260 pounds, and the FCR number of the animal (or the average FCR of the animals) is reduced by the present method to 3.7 or less (e.g., 3.65 or less, but optionally 3 or 3.5 or more), where the FCR is calculated using the body weight gain of the animal.Thus, in an example of the present invention, the or each animal is a pig whose body weight is between 260 and 270 pounds, the FCR number for the animal (or the average FCR for the animal) is reduced by the present invention to 3.9 or less (e.g., 3.8 or less, but optionally 3.7 or 3.5 or more), and the FCR is calculated using the weight gain of the animal. Thus, in an example of the present invention, the or each animal is a pig whose body weight is between 280 and 270 pounds, the FCR number for the animal (or the average FCR for the animal) is reduced by the present method to 4.1 or less (e.g., 4 or less, but optionally 3.8 or 3.9 or more), and the FCR is calculated using the weight gain of the animal.

[0059] Sheep Some data for sheep shows variation in FCR. The FCR (kg feed dry matter intake per kg live mass gain) for lambs is often in the range of about 4 to 6. Thus, in the present example, the or each animal is a sheep, and the FCR number of the animal (or the average FCR of the animals) is reduced to 6 or less (e.g. 4 to 6) by the method, and the FCR is calculated using kg feed dry matter intake per kg live mass gain of the animal.

[0060] poultry As of 2011 in the United States, broiler chickens typically have an FCR of 1.6 based on weight gain and mature at 39 days. At about the same time, the FCR based on weight gain for broilers in Brazil was 1.8. Thus, in the present example, the or each animal is a poultry (e.g., a broiler chicken) and the FCR number of the animal (or the average FCR of the animal) is reduced by the method to 1.9, 1.8, 1.7, 1.6, or less (e.g., between 1.9 and 1.5, or between 1.8 and 1.6), and the FCR is calculated based on weight gain. Optionally, the FCR is calculated when each animal is between 35 and 40 days old, e.g., 39 days old.

[0061] For egg-laying chickens in the United States as of 2011, the FCR is about 2, with each hen laying 330 eggs per year. Thus, in the present example, the or each animal is a poultry (e.g., egg-laying hens, e.g., chickens), and the FCR number of the animal (or the average FCR of the animal) is reduced by the present method to 2 or less (e.g., 2 to 1.5), with the FCR calculated based on weight gain. Thus, in the present example, the or each animal is a poultry (e.g., egg-laying hens, e.g., chickens), and the number of eggs laid by the animal (or the average number of eggs laid by the animal) is greater than 330 eggs per year (or pro rata for different time periods), for example greater than 340, 350, or 400 eggs per year (or pro rata for different time periods).

[0062] carnivorous fish The FIFO ratio (or fish-in-fish-out ratio) is a conversion ratio applied to aquaculture, where the first number is the mass of caught fish used to feed farmed fish, and the second number is the mass of farmed fish obtained. FIFO is a method to express the contribution of caught wild fish used in aquafeed as a ratio compared to the amount of farmed fish used for food. The content of fishmeal and fish oil in aquafeed has continuously decreased over time as the aquaculture industry has grown and more feed has been produced, but the annual supply of fishmeal and fish oil is finite. By calculation, the overall feed aquaculture FIFO has decreased from 0.63 in 2000 to 0.33 in 2010 and 0.22 in 2015. In 2015, almost 4.55 kg of farmed fish were produced for every kg of wild fish caught and used in feed. Although the fish used in the production of fish meal and fish oil are not used for human consumption, they contribute to global food production through their use as fish meal and fish oil in aquafeed.Thus, in an example, the method of the present invention enhances (i.e. increases) the FIFO ratio when the animal is a fish (e.g., salmon, tilapia, or catfish).For example, the FIFO is increased to 0.3, 0.4, 0.5, 0.6, 0.7, or 0.8, 1, 1.5, or 2 or more.For example, the fish is salmon or catfish, and the FIFO is increased to 1, 1.5, or more than 2 (optionally not more than 2 or 2.5).For example, the fish is tilapia, and the FIFO is increased to 1.5 or more than 2 (optionally not more than 2 or 2.5).

[0063] The increase in growth or weight can be an increase (increase) in milk production or yield, for example an average increase for the group of the present invention compared to a control group. The control group can be a group of animals of the same species, average age, sex ratio, and fed the same diet as the group of the present invention. For example, the subject here can be a dairy cow.

[0064] The increase in growth or weight can be an increase (increase) in egg production or yield, for example the average increase for the group of the invention compared to a control group. The control group can be a group of animals of the same species, average age, sex ratio and fed the same diet as the group of the invention. For example, the subjects here can be egg-laying hens.

[0065] The increase in growth or weight can be an increase (increase) in meat production or yield, for example the average increase for a group of the invention compared to a control group. The control group can be a group of animals of the same species, average age, sex ratio, and fed the same diet as the group of the invention. For example, the subjects here can be dairy cows, poultry (e.g. chickens), fish, shellfish, sheep, or pigs.

[0066] The increase in growth or weight can be an increase (increase) in fat production or yield, for example, an average increase for the group of the present invention compared to a control group. The control group can be a group of animals of the same species, average age, and sex ratio as the group of the present invention, fed the same diet. For example, the subjects herein can be dairy cows, poultry (e.g., chickens), fish (e.g., salmon, tilapia, or catfish), crustaceans, sheep, or pigs.

[0067] The increase in growth or weight can be an increase (increase) in fur or leather production or yield, for example the average increase for a group of the invention compared to a control group. The control group can be a group of animals of the same species, average age, sex ratio and fed the same diet as the group of the invention. For example, the subject here can be a cow.

[0068] In one example, the subject is a crustacean, which may be selected from shrimp, crayfish, crab, lobster, clams, scallops, oysters, prawns, and mussels.

[0069] The subject may be any subject disclosed herein. The subject may be a livestock animal, such as a bird (e.g., poultry, or chicken or turkey), or a pig. Alternatively, the subject may be a human, such as a human suffering from an eating disorder (e.g., anorexia), or an underweight human, such as where the human has a body mass index (BMI) of less than 18.5, 18, 17, 16, or 15. For example, the human has mild anorexia (i.e., the human has a BMI of less than 17.5), moderate anorexia (i.e., the human has a BMI of 16-16.99), severe anorexia (i.e., the human has a BMI of 15-15.99), or extreme anorexia (i.e., the human has a BMI of less than 15).

[0070] In one alternative, the subject is a plant, for example, the target bacterium is a plant pathogenic bacterium. In one example, the target bacterium is a Pseudomonas, for example, P syringae or P aeruginosa.

[0071] In one option, the target cell is an archaeal cell, for example, the target cell is a methanogen cell.

[0072] For example, the target cell is a methanogen. For example, the target cell is Methanobacterium bryantii Methanobacterium formicum ·Methanobrevibacter arboriphilicus ·Methanobrevibacter gottschalkii ·Methanobrevibacter ruminantium Methanobrevibacter smithii ·Methanococcus chunghsingensis Methanococcus burtonii Methanococcus aeolicus Methanococcus deltae ·Methanococcus jannaschii ·Methanococcus maripaludis ·Methanococcus vannielii ·Labrean methanocorpusculum ·Methanoculleus bourgensis (Methanogenium olentangyi and Methanogenium bourgense) ·Methanoculleus marisnigri ·Methanoflorens stordalenmirensis

[34] ·Methanofollis liminatans ·Methanogenium cariaci ·Cold methanogeny ·Organophilic methanogenium ·Methanogenium wolfei ·Methanomicrobium mobile ·Methanopyrus kandleri ·Methanoregula boonei ·Methanosaeta concilii ·Methanosaeta thermophila ·Methanosarcina acetivorans ·Methanosarcina barkeri ·Methanosarcina mazei ·Methanosphaera stadtmanae ·Methanospirillium hungatei · Methanothermobacter defluvii (Methanobacterium defluvii) ·Methanothermobacter thermautotrophicus(Methanobacterium thermoautotrophicum) ·Methanothermobacter thermoflexus(Methanobacterium thermoflexum) ·Methanothermobacter wolfei(Methanobacterium wolfei) Methanothrix sochngenii The cell species includes one or more cells selected from the group consisting of:

[0073] Optionally, the target cells are not pathogenic to the subject, for example when the method is a non-medical method, hi one example, the method is a cosmetic method.

[0074] For example, the target cells are methanogenic cells, and optionally the subject is a livestock animal, preferably a ruminant, or bovine (e.g., beef or dairy cow). By reducing methanogenic cells in such animals, the present invention may in one embodiment increase the body weight of the animal (e.g., increase the yield of meat from the animal) and / or increase the yield of milk or another product of the animal, such as fur or fat.

[0075] In one example, the target cells are selected from E. coli, Salmonella, and Campylobacter cells. In one example, the target cells are E. coli, Salmonella, or Campylobacter cells. In one example, each animal is a chicken (e.g., a broiler or layer hen) and the target cells are Salmonella or Campylobacter cells. In one example, each animal is a bovine (e.g., a beef or dairy cow) and the target cells are methanogen cells.

[0076] In one example, the target cell is selected from the group consisting of Mycoplasma (e.g., Mycoplasma mycoides (e.g., Mycoplasma mycoides subsp. Mycoides), Mycoplasma leachii, or Mycoplasma bovis), Brucella abortus, Listeria monocytogenes, Clostridium (e.g., Clostridium chauvoei or Clostridium septicum), Leptospira (e.g., L. canicola, L. icterohaemorrhagiae, L. grippotyphosa, L. hardjo, or L. Pomona), Mannheimia haemolytica, Trueperella pyogenes, Mycobacterium bovis, Campylobacter spp. (e.g., Campylobacter jejuni or Campylobacter coli), Bacillus anthracis, E. coli (e.g., E. coli O157:H7), or Pasteurella multocida (e.g., Pasteurella multocida B:2, E:2, A:1, or A:3). Optionally, in this example, the subject or animal is a livestock animal, such as a cow, sheep, goat, or chicken (preferably a cow).

[0077] Optionally, for example when the subject is an animal (e.g. a domestic or wild animal), the target cell is a zoonotic bacterial cell, such as a cell of a species selected from Bacillus anthracis, Mycobacterium bovis (e.g. when the animal is a bovine), Campylobacter spp (e.g. when the animal is a poultry animal), Mycobacterium marinum (e.g. when the animal is a fish), Shiga toxin producing E. Coli (e.g. when the animal is a ruminant), Listeria spp (e.g. when the animal is a bovine or ovine), Chlamydia abortus (e.g. when the animal is a ovine), Coxiella burnetii (e.g. when the animal is a bovine, ovine or caprine), Salmonella spp (e.g. when the animal is a poultry animal), Streptococcus suis (e.g. when the animal is a porcine), and Corynebacterium (e.g. C ulcerans) (e.g. when the animal is a bovine).

[0078] In one example, a plurality of carrier cells described herein (e.g., carrier cells of any configuration, aspect, example, or embodiment described herein) are administered to a subject, where the carrier cells comprise DNA encoding the agent.

[0079] In one example, each animal is a chicken (e.g., a broiler or layer hen) and the target cells are Salmonella or Campylobacter cells. In one example, each animal is a cow (e.g., a beef or dairy cow) and the target cells are methanogen cells.

[0080] Thus, in one embodiment, Provided is a method (e.g. non-medical or medical) for enhancing the growth or weight of a subject, the method comprising administering to the subject a plurality of carrier cells, the subject comprising bacterial target cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells but not toxic to said carrier cells, the carrier cells capable of conjugatively transferring DNA into the target cells for expression of the agent in the target cells, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject and enhancing the growth or weight of the subject.

[0081] Optionally, the target cells are Salmonella cells. In one example, the target cells include S. enterica and / or S. typhimurium cells; optionally, the S. enterica is S. enterica subsp. enterica. Optionally, the method kills a plurality of different S. enterica subsp. enterica serovars; optionally, each serovar is selected from the group consisting of Typhimurium, Enteritidis, Virchow, Montevideo, Heidelberg, Hadar, Binza, Bredeney, Infantis, Kentucky, Seftenberg, Mbandaka, Anatum, Agona, and Dublin. Optionally, the method kills S. enterica subsp. enterica serovars Typhimurium, Infantis, and Enteritidis. Optionally, the method kills S. enterica subsp. enterica serovars Typhimurium and Enteritidis. Optionally, the method kills S. enterica subsp. enterica serovars Typhimurium and Infantis. Optionally, the method kills S. enterica subsp. enterica serovars Enteritidis and Infantis. The most prevalent serovars in chickens are Salmonella Enteritidis, Salmonella Infantis, and Salmonella Typhimurium. Generally, similar serovars of Salmonella (S. Enteritidis and S. Typhimurium) are found in infected humans and chickens. By killing Salmonella in livestock animals, the invention is useful for reducing the pool of zoonotic bacteria available for transmission to humans (e.g., by eating livestock or products produced from livestock, such as meat or dairy products for human consumption).

[0082] Advantageously, the carrier cells are Enterobacteriaceae cells, optionally E. coli cells. As illustrated in the examples below, the inventors have surprisingly found that (i) antimicrobial agents can be efficiently transferred from such cells to Salmonella target cells both in vivo and in vitro, and (ii) 100% killing of Salmonella was possible when the agent was transferred from Enterobacteriacae cells to Salmonella cells by conjugation. Even more surprisingly, DNA encoding the guided nuclease antimicrobial agent was able to kill 18 Salmonella spp. serovars, including Typhimurium, Infantis, and Enteritidis, which are clinically and zoonotically important. Optionally, the method kills S. enterica subspecies enterica serovars Typhimurium and Enteritidis serovars. Optionally, the Enterobacteriaciae cells are cells of an Enterobacteriaciae species as shown in Table 5.

[0083] Importantly, the reduction of target cells was observed in the GI tract of the subject. Thus, optionally, the method reduces target cells in the gastrointestinal tract of the animal. Optionally, the method reduces target cells in the jejunum, ileum, colon, liver, spleen, or cecum of the animal; optionally, the animal is a bird, and the method reduces target cells in the cecum of the bird. This may be important for reducing the spread of zoonotic or other harmful target strains in the feces of subjects, such as livestock animals. Thus, in one example, the method is performed on a herd of subjects (e.g., a flock or a flock, such as a flock of pigs or a flock of birds), and the spread of cells of the target species is reduced in the flock. The inventors have demonstrated this in a flock of poultry using the present invention to kill Salmonella, where a guided nuclease is used to cleave multiple protospacer sequences in the target cells, thereby killing the cells and reducing the spread of the cells in the flock.

[0084] Thus, in one example, the method is performed in a group of animals (optionally a pack or herd), some or all of the animals comprising the target cells, and the spread of cells of the target species is reduced in the group, or from the group to a second group of animals.

[0085] Optionally, the first DNA is contained in a plasmid, for example, the plasmid contains the RP4 origin of transfer (oriT). The plasmid can be any type of plasmid disclosed herein.

[0086] The agent may be any antimicrobial agent disclosed herein, preferably a guided nuclease programmed to cleave one or more target sequences in a target cell. Suitable nucleases may be TALENs, meganucleases, zinc finger nucleases, or Cas nucleases. For example, the agent comprises one or more components of a CRISPR / Cas system (e.g., Cas nuclease and / or guide RNA or crRNA) operable in a target cell to cleave a protospacer sequence contained in the target cell, and optionally the target cell comprises a first and a second strain of a bacterial species, each strain comprising a protospacer sequence, and cells of the strain are killed. For example, the system is operable to cleave at least three different protospacer sequences contained in the cell genome. Optionally, each or some of the protospacer sequences are contained in a pathogenicity island contained in the cell. As shown in the examples, this is highly effective in killing the target cell. Optionally, the agent is operable to cleave multiple different protospacer sequences contained in the target cell genome. Optionally, the agent comprises one or more components of a CRISPR / Cas system operable in the target cell to cleave at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 distinct protospacer sequences contained in the target cell genome (e.g., contained in a chromosome of the target cell).

[0087] In one embodiment, the agent is (a) comprising a guided nuclease capable of recognizing and modifying a target nucleic acid sequence, the target sequence being contained in an endogenous chromosome or episome of the target cell but not in the carrier cell, and the nuclease modifies the chromosome or episome to kill the target cell or inhibit the growth or proliferation of the target cell; and / or (b) encoding a guide RNA or crRNA of the CRISPR / Cas system that operates with a Cas nuclease in the target cell to cleave a protospacer sequence contained in the target cell;

[0088] Also provided is a carrier cell (optionally for use in the methods of the invention), which is a bacterial cell comprising a first episomal DNA encoding a bactericidal agent that is toxic to a bacterial target cell but not toxic to the carrier cell, and which is capable of conjugatively transferring the DNA into the target cell for expression in the target cell of the antibacterial agent, thereby killing the target cell, and wherein the target cell is a Salmonella cell and the carrier cell is an Enterobacteriaceae cell.

[0089] Also provided is a composition comprising a plurality of carrier cells for use in a method comprising administering cells to a subject for treating infection by pathogenic bacterial target cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells but not to the carrier cells, the carrier cells being capable of conjugatively transferring DNA into the target cells for expression in the target cells of the agent, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject, and the target cells being Salmonella cells and the carrier cells being Enterobacteriaceae cells. In one alternative, the method treats or reduces a symptom of infection by a pathogenic target cell.

[0090] Any administration of cells to a subject herein can be oral administration. Any administration of cells to a subject herein is preferably to the GI tract. Any administration of cells to a subject herein can be systemic, nasal, or inhalation administration.

[0091] Also provided is a non-medical method of killing zoonotic bacterial target cells in an animal, the method comprising administering to the animal a plurality of carrier cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to the target cells but not to the carrier cells, the carrier cells being capable of conjugatively transferring DNA into the target cells for expression in the target cells of the agent, the first DNA being transferred from the carrier cells to the target cells for expression in the target cells to produce the antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject, the target cells being Salmonella cells, and optionally the carrier cells being Enterobacteriaceae cells.

[0092] The animal can be any animal disclosed herein, for example a domestic animal, a domesticated animal, or a wild animal (eg, a bat or a bird).

[0093] Optionally, any of the methods herein reduce Salmonella in the gastrointestinal tract of a subject. Optionally, the target cells include various Salmonella spp. types that are killed.

[0094] In any aspect, configuration, example, concept, or embodiment, the carrier cell, target cell, or DNA is a carrier cell, target cell, or DNA as defined in any other aspect, configuration, example, concept, or embodiment.

[0095] The present invention also provides a DNA that can be introduced into a target cell, encoding multiple guide RNAs or crRNAs of a CRISPR / Cas system, which can be manipulated with a Cas nuclease in the target cell such that the guide RNAs or crRNAs recognize multiple protospacer sequences contained in the target cell genome, optionally wherein the target cell is a Salmonella cell or a cell of a species disclosed in Table 5; (a) the protospacer sequence comprises one or more pathogenicity island nucleotide sequences of the target cell genome; (b) the protospacer sequence comprises one or more invader gene sequences of the target cell genome; (c) the protospacer sequence comprises one or more secretion system gene sequences of the target cell genome; and / or (d) DNA is provided, wherein the protospacer sequence comprises one or more nucleotide sequences of Salmonella (e.g., S. enterica) genes selected from avrA, sptP, sicP, sipA, sipD, sipC, sipB, sicA, invB, ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, mgtC, cigR, pipA, pipB, pipC, sopB, and pipD (optionally selected from invB, sicP, sseE, pipA, pipB, pipC, hilA, marT, and sopB), or orthologs or homologs of said genes.

[0096] Homolog: A gene, nucleotide, or protein sequence that is related to a second gene, nucleotide, or protein sequence by descent from a common ancestral DNA or protein sequence. The term "homolog" can apply to the relationship between genes that have been separated by a gene duplication event or to the relationship between genes that have been separated by a gene duplication event.

[0097] Orthologs: Orthologs are gene, nucleotide, or protein sequences in different species that have evolved by speciation from a common ancestral gene, nucleotide, or protein sequence. Orthologs usually retain the same function during evolution.

[0098] "Orthologue or homologue of said gene" means that the protospacer may be a sequence contained in a gene of the target cell genome, the gene being an orthologue or homologue of a Salmonella gene selected from avrA, sptP, sicP, sipA, sipD, sipC, sipB, sicA, invB, ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, mgtC, cigR, pipA, pipB, pipC, sopB, and pipD (optionally selected from invB, sicP, sseE, pipA, pipB, pipC, hilA, marT, and sopB).

[0099] Optionally, the DNA is a first DNA for use in the methods of the invention.Preferably, the target cell is a Salmonella cell, for example a S. enterica cell, such as a Salmonella enterica subsp. enterica serovar Enteritidis cell.

[0100] Optionally, any Salmonella herein is Salmonella enterica subspecies enterica serovar Typhimurium strain LT2.

[0101] Optionally, the target cell is a cell of a species disclosed in Table 5 other than a Salmonella species, and the sequence in (d) is a sequence of a gene selected from avrA, sptP, sicP, sipA, sipD, sipC, sipB, sicA, invB, ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, mgtC, cigR, pipA, pipB, pipC, sopB, and an ortholog or homolog of pipD (optionally selected from invB, sicP, sseE, pipA, pipB, pipC, hilA, marT, and sopB) of Salmonella (e.g., S. enterica).

[0102] The DNA may comprise one or more CRISPR spacers, each spacer consisting of a nucleotide sequence of a secretion system gene (optionally the Salmonella type III protein secretion system or the SPI-1 or SPI-2 secretion system), or a T3SS locus gene, or up to 10, 9, 8, 7, 6, 5, 4, 3, or 2 nucleotides different therefrom.

[0103] Optionally, the DNA (e.g., the DNA of the carrier cell) encodes multiple guide RNAs or crRNAs of the CRISPR / Cas system, the guide RNAs or crRNAs being operable with Cas nucleases in the target cell to recognize multiple protospacer sequences contained in the target cell genome, the target cell being a Salmonella cell, and the protospacer sequences include one or more nucleotide sequences of genes selected from invB, sicP, and sseE. For example, the protospacer sequences include nucleotide sequences of genes invB, sicP, and sseE. In one example, the DNA also encodes a Cas, such as Cas9, Cas3, Cpf1, Cas12, Cas13, CasX, or CasY. In one embodiment, the Cas is type I, type II, type III, type IV, type V, or type VI Cas, preferably type I or type II Cas. In one example, the DNA also encodes Cas3 and associated Cascade proteins (e.g., CasA, B, C, D, and E). Optionally, Cas (and now Cascade) is E. coli Cas (and Cascade).

[0104] Optionally, the target cell gene encodes a chaperone or secreted effector protein, such as a protein encoded by a pathogenicity island or a type III protein secretion system (optionally a T3SS locus such as the SPI-1 and SPI-2 secretion systems of Salmonella).

[0105] The DNA may comprise one or more CRISPR spacers, each spacer being a repeat of 20-40, 25-35, or 30-35 consecutive nucleotides of a gene contained in the genome of the target cell, e.g. (a) avrA, sptP, sicP, sipA, sipD, sipC, sipB, sicA, invB, ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, mgtC, cigR, pipA, pipB, pipC, sopB, and pipD of Salmonella, or homologs or orthologs thereof; (b) a gene contained in a pathogenicity island contained in the genome of the target cell; (c) a secretion system (e.g., a type III protein secretion system) gene contained in the target cell genome It consists of:

[0106] Optionally, the DNA is contained in a plasmid that includes an origin of transfer (oriT) and an origin of replication (oriV) operable in a bacterial host cell for replication of the DNA. Optionally, the first DNA is contained in a plasmid, the plasmid including an RP4 origin of transfer (oriT) and / or a p15A origin of replication.

[0107] Optionally, the DNA comprises SEQ ID NO: 15, and optionally the DNA is contained in a plasmid in a carrier bacterial cell for conjugation into a Salmonella target cell. In one example, the DNA of the invention is contained in a conjugative plasmid or phagemid.

[0108] In one example, the DNA comprises a CRISPR repeat sequence and a spacer sequence, (e) each repeat sequence comprises SEQ ID NO: 16; and / or (f) the spacer sequence comprises one, two, or three sequences selected from SEQ ID NOs: 17 to 19 and their complementary sequences; Optionally, the DNA is contained in a plasmid in a carrier bacterial cell for conjugation into a Salmonella target cell.

[0109] Optionally, the DNA comprises (optionally in 5' to 3' order): SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19. Optionally, the DNA comprises one or more (e.g., at least three) spacer sequences shown in Table 6.

[0110] In one example, the DNA encodes Cas3 and optionally one or more Cascade proteins (e.g., one or more of CasA, B, C, D, and E). In one embodiment, the first DNA encodes Cas3 and CasA, B, C, D, and E. In one embodiment, the first DNA encodes E. coli Cas3 and CasA, B, C, D, and E. Optionally, the guided nuclease (e.g., Cas3) is an IA, -B, -C, -D, -E, -F, or -U type Cas.

[0111] In one example, the agent in any configuration, example, option, or embodiment herein comprises one or more components of a CRISPR / Cas system operable in a target cell to cleave a protospacer sequence contained in the target cell.

[0112] In one example, the system is operable to cleave at least three different protospacer sequences contained in the target cell genome, in one embodiment, each or some of the protospacer sequences are contained in a pathogenicity island contained in the target cell.

[0113] In one example, the agent in any configuration, example, option, or embodiment herein is (a) comprising a guided nuclease capable of recognizing and modifying a target nucleic acid sequence, the target sequence being contained in an endogenous chromosome or episome of the target cell but not in the carrier cell, and the nuclease modifies the chromosome or episome so as to kill the target cell or inhibit the growth or proliferation of the target cell; and / or (b) encoding the guide RNA or crRNA of the CRISPR / Cas system that works with a Cas nuclease in the target cell to cleave a protospacer sequence contained in the target cell;

[0114] Optionally, the DNA comprises a constitutive promoter for expression of the guide RNA or crRNA. Optionally, the DNA comprises a constitutive promoter for expression of a Cas nuclease operable in the target cell with the guide RNA or crRNA to modify (e.g., cleave) a protospacer sequence of the target cell genome.

[0115] Optionally, the Cas, Cascade protein, gRNA, and crRNA are, respectively, Cas, Cascade protein, gRNA, and crRNA of E. coli K12 (MG1655). Optionally, the DNA lacks nucleotide sequences encoding Cas1 and Cas2 proteins.

[0116] The invention also relates to carrier bacteria encoding desired proteins or RNA (e.g., encoding antibacterial agents) and methods of use. In embodiments, the agent can be transferred to the target cell by conjugation of the carrier cell (to which the agent is not toxic) with the target cell, where the agent is toxic to the target cell and kills the target cell. In other embodiments, the growth or proliferation of the target cell is reduced (e.g., at least 40, 50, 60, 70, 80, or 90% compared to growth in the absence of the agent). Each carrier cell contains episomal DNA encoding an antibacterial agent that is toxic to the target bacterial cell but not toxic (or less toxic) to the carrier cell. The invention finds use in controlling or killing target bacteria that are pathogenic, for example, to humans, animals, or plants. The invention finds use in controlling or killing zoonotic target bacteria, for example, in animals (e.g., livestock animals). For example, the carrier cells may be included in a pharmaceutical for treating or preventing a disease or condition in humans or animals; a growth promoter administered to animals to promote the growth of the animals; to kill zoonotic bacteria in animals, for administration to livestock as a pesticide; a pesticide applied to plants, or a fertilizer for plants.

[0117] The advantage of the present invention is that carrier cells can be used as producer cells in which DNA encoding antimicrobial agents can be replicated. Another advantage of the present example is that further replication of DNA is avoided in target cells that do not contain one or more factors required for such replication. Thus, a scheme is envisaged in which factors are present in carrier cells (and DNA encoding agents is replicated to provide many copies for subsequent conjugative transfer into target cells) and DNA is not further replicated in target cells, which is useful for containing the action of antimicrobial agents, for example, in the environment, or in the human or animal body, or in (or on) plants. Containment may be necessary to avoid undesired killing of non-target cells, or generally to control overdosing and / or administration of killing activity regimes.

[0118] It is important that the first DNA is replicable in the carrier cell (but not in the target cell), in which case the drug is not toxic to the carrier cell, while being toxic to the target cell. In certain embodiments, to achieve this selectivity, the present invention uses sequence-specific killing of the target cell. To this end, in one example, the first DNA encodes a guided nuclease that can be operated in the target cell to recognize and cleave a target sequence in the chromosome of the target cell, thereby killing the cell or reducing the growth or proliferation of the cell. This is advantageous over the use of other types of toxic drugs that are less discriminatory in their action and can kill some species or strains (e.g., perhaps also to some extent toxic to the carrier cell). By using guided nucleases (e.g., TALEN or Cas nucleases), they can be programmed to recognize target sequences that are present in the target cell genome (e.g., contained in the chromosome or episome of the target cell) but not present in the genome of the carrier cell.

[0119] Thus, in this case, the replication of the first DNA can occur freely in the carrier cell without the risk of killing the cell or reducing its growth or proliferation due to the replication of the encoded agent and the sequence encoding the agent.Thus, in the example where the first DNA encodes a guided nuclease, the guided nuclease can recognize and cleave the target nucleic acid sequence contained in the genome (e.g., chromosome) of the target cell, and the target cell is not present in the carrier cell.

[0120] A particularly useful example is where the first DNA encodes a Cas nuclease (e.g., Cas9 or Cas3) operable in the target cell together with a guide RNA or crRNA, where the RNA is operable to guide the Cas to a target sequence, where the Cas modifies (e.g., cleaves) the target sequence, whereby the target cell is killed or the growth or proliferation of the target cell is inhibited. In one embodiment, the first DNA encodes a Cas and a guide RNA or crRNA. In another embodiment, the first DNA encodes a guide RNA or crRNA but does not encode an associated Cas. In this embodiment, the RNA is operable in the target cell together with an endogenous Cas encoded by the target cell genome, where the RNA is operable to guide the Cas to a target sequence, where the Cas modifies (e.g., cleaves) the target sequence, whereby the target cell is killed or the growth or proliferation of the target cell is inhibited. In this sense, the agent may include components of the CRISPR / Cas system (e.g., Cas nuclease, CascadeCas, crRNA, guide RNA, or tracrRNA). Thus, the present invention usefully recognizes the advantage of using an antibacterial agent that acts by target recognition in the target cells but not in the carrier cells, which extends the ability of the first DNA to freely replicate in the carrier cells without significant toxicity to the carrier cells.

[0121] Plasmid examples The method of delivery of any agent, such as the CRISPR-Cas system (or its components), may be by bacterial conjugation, a natural process in which a donor bacterium transfers DNA from itself to a recipient bacterium. The donor bacterium has elaborated surface structures, thus pilus, through which it is believed to deliver DNA, like a syringe or straw. The donor pilus binds to the surface of the receiving recipient, and this event triggers the process of DNA transfer. A plasmid is suitable for this conjugation process, and the plasmid contains the DNA encoding the agent of the present invention.

[0122] Transfer of DNA by conjugation can only occur for "susceptible recipients" but generally not for recipients containing similar types of plasmids. Because conjugation involves bridging of the pili, the bridges can attach the bacterium to the donor bacterium rather than to the recipient. This can result in a futile cycle of transfer of plasmid DNA to itself. Thus, plasmids naturally encode incompatibility factors. One is a surface-arranged protein that blocks the binding of the pili to bacteria that display surface proteins, such as the bacterium itself or any other bacterium that contains the same plasmid. In addition, plasmids naturally encode another incompatibility system that tightly regulates the copy number of the plasmid inside the bacterium. Thus, even if a conjugation event manages to escape surface exclusion and initiate conjugational DNA transfer, the recipient will block the plasmid from becoming established, since the plasmid already maintains its current copy number and will not accept and maintain additional undesired copies.

[0123] In one example of the invention, the DNA encoding the agent is contained in a plasmid. In one embodiment, the plasmid is a member of a plasmid incompatibility group and the target cell does not contain a plasmid of said group. Optionally, the plasmid of the invention is a member of incompatibility group P (i.e., the plasmid is an incP plasmid). It is extremely rare for Salmonella to contain incP plasmids, and therefore this incP plasmid is useful when the target cell is a Salmonella cell. For example, within Enterobacteriaceae, the following is a non-exclusive list of possible plasmids that may be used for delivery: IncFI, IncFII, IncFIll, IncFIV, IncFV, IncM, Inc9, InclO, Incl, IncA, IncB, IncC, IncH, IncIa, InclIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and / or IncW. Thus, optionally, the target cell is an Enterobacteriaceae cell and the DNA of the invention is contained in a plasmid, the plasmid being selected from IncFI, IncFII, IncFIll, IncFIV, IncFV, IncM, Inc9, InclO, Incl, IncA, IncB, IncC, IncH, IncIa, InclIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and IncW plasmids.

[0124] In one example, the carrier cell of the present invention comprises two or more plasmids, each of which comprises a DNA of the present invention encoding an antimicrobial agent, a first of said plasmids being a member of a first incompatibility group and the target cell does not comprise a plasmid of said first group, and a second of said plasmids being a member of a second incompatibility group and the target cell does not comprise a plasmid of said second group. For example, the carrier cell comprises an incP plasmid encoding an anti-target cell CRISPR / Cas system or a component thereof (e.g. encoding a first crRNA or guide RNA that targets a first protospacer sequence of the target cell genome), and the carrier cell further comprises an incF1 plasmid encoding an anti-target cell CRISPR / Cas system or a component thereof (e.g. encoding a second crRNA or guide RNA that targets a second protospacer sequence of the target cell genome), and the protospacers comprise different nucleotide sequences. For example, the protospacers are comprised in different genes of the target cell genome. For example, the protospacers are comprised in one or more pathogenicity islands of the target cell genome. Optionally, the target cell is an Enterobacteriaceae cell. Optionally, the carrier cell comprises a group of plasmids, including 2, 3, 4, 5, 6 or more different types of plasmids, each of which can be conjugatively transferred into the target cell, and the plasmids encode different components of different drugs or antibacterial agents. For example, the plasmids encode different cRNAs or gRNAs that target different protospacers contained in the target cell genome. For example, the group of plasmids comprises up to n different types of plasmids, and the plasmids are members of up to n different incompatibility groups, such as a group selected from IncFI, IncFII, IncFIll, IncFIV, IncFV, IncM, Inc9, IncO, Inc, IncA, IncB, IncC, IncH, IncIa, IncIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and IncW. For example, n is 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0125] For example, the carrier cell comprises (i) a first plasmid encoding a first type of CRISPR / Cas system or encoding a component of said system that targets a first protospacer contained in the target cell genome, and (ii) a second plasmid encoding a second type of CRISPR / Cas system or encoding a component of said system that targets a second protospacer contained in the target cell genome, the first and second types being different. For example, the first type is a type I system and the second type is a type II system (e.g., the first plasmid encodes Cas3, Cascade, and a crRNA or guide RNA operable with Cas3 and Cascade in the target cell to modify the first protospacer, and the second plasmid encodes Cas9 and a crRNA or guide RNA operable with Cas9 in the target cell to modify the second protospacer). In one option, Cas3 and Cascade are encoded by endogenous target cell genes, and the first plasmid encodes a crRNA or guide RNA operable with endogenous Cas3 and Cascade in the target cell to modify the first protospacer. In one option, Cas9 is encoded by endogenous target cell genes, and the second plasmid encodes a crRNA or guide RNA operable with endogenous Cas9 in the target cell to modify the second protospacer. Optionally, Cas3 and Cascade are encoded by endogenous target cell genes, and Cas9 is encoded by the second plasmid.

[0126] In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type I CRISPR / Cas system (or a component thereof, e.g. Cas3 or crRNA or gRNA) and a second plasmid encoding a type III CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type I CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type IV CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type I CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type V CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type I CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type VI CRISPR / Cas system (or a component thereof).

[0127] In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type II CRISPR / Cas system (or a component thereof, e.g. Cas9 or crRNA or gRNA) and a second plasmid encoding a type III CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type II CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type IV CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type II CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type V CRISPR / Cas system (or a component thereof). In place of type I and type II systems, the invention alternatively provides in one embodiment a first plasmid encoding a type II CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type VI CRISPR / Cas system (or a component thereof).

[0128] Instead of type I and type II systems, the present invention alternatively provides in one embodiment a first plasmid encoding a type V CRISPR / Cas system (or a component thereof, e.g. Cas12a or crRNA) and a second plasmid encoding a type III CRISPR / Cas system (or a component thereof). Instead of type I and type II systems, the present invention alternatively provides in one embodiment a first plasmid encoding a type V CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type IV CRISPR / Cas system (or a component thereof). Instead of type I and type II systems, the present invention alternatively provides in one embodiment a first plasmid encoding a type V CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type V CRISPR / Cas system (or a component thereof). Instead of type I and type II systems, the present invention alternatively provides in one embodiment a first plasmid encoding a type V CRISPR / Cas system (or a component thereof) and a second plasmid encoding a type VI CRISPR / Cas system (or a component thereof).

[0129] In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type I CRISPR / Cas system (or a component thereof). In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type II CRISPR / Cas system (or a component thereof). In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type III CRISPR / Cas system (or a component thereof). In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type IV CRISPR / Cas system (or a component thereof). In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type V CRISPR / Cas system (or a component thereof). In place of the type I and type II systems, the present invention alternatively provides in one embodiment a first and second plasmid, each encoding a type VI CRISPR / Cas system (or a component thereof).

[0130] Optionally, the plasmid is a member of a different incompatibility group, e.g., a group selected from IncFI, IncFII, IncFIll, IncFIV, IncFV, IncM, Inc9, InclO, Incl, IncA, IncB, IncC, IncH, IncIa, InclIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and IncW. In one example herein, the target cell is an Enterobacteriaceae cell.

[0131] Embodiment Thus, by way of example, the invention provides the following embodiments.

[0132] 1. A carrier bacterial cell comprising a first episomal DNA, said DNA comprising a nucleic acid of interest (NSI) encoding a protein of interest (POI) or an RNA of interest (ROI) for expression in a target bacterial cell, the carrier cell being capable of conjugatively transferring the DNA into a target cell for expression of the POI, ROI, or agent in the target cell; (a) the carrier cell contains a second DNA that is different from the first DNA, the second DNA containing or encoding a first factor required for replication of the first DNA; (b) the first DNA does not contain or encode said first factor, and the first DNA is non-autonomously replicating in the absence of the first factor, but is capable of replicating in a carrier cell in the presence of the first factor provided by the second DNA; (c) the carrier cell contains genes encoding one or more conjugation factors sufficient to effect conjugative transfer of the first DNA into the target bacterial cell; Carrier bacterial cells.

[0133] In the first option, embodiment 1 comprises: Provided is a carrier bacterial cell comprising a first episomal DNA, the DNA comprising a nucleic acid of interest (NSI) encoding a protein of interest (POI) or an RNA of interest (ROI) for expression of the POI or ROI in a target bacterial cell, the carrier cell being capable of conjugatively transferring the DNA into a target cell for expression of the POI or ROI in the target cell.

[0134] In a second alternative, embodiment 1 is A carrier bacterial cell is provided that contains a first episomal DNA, the DNA encoding an antibacterial agent that is toxic to target bacterial cells but not toxic to the carrier cell, and the carrier cell is capable of conjugatively transferring the DNA into the target cell for expression of the agent in the target cell. In one example, the agent comprises a guided nuclease capable of recognizing and cleaving a target nucleic acid sequence contained in the genome of a target cell, the target sequence not being contained in a carrier cell, and thus in this sense the antibacterial agent is toxic to the target bacterial cells but not to the carrier cells.

[0135] for example, Provided is a carrier bacterial cell comprising a first episomal DNA, said DNA encoding an antimicrobial agent that is toxic to a target bacterial cell but not toxic to said carrier cell, said carrier cell being capable of conjugatively transferring DNA into a target cell for expression of the agent in the target cell, said agent being a component of a CRISPR / Cas system that is operable in the target cell to modify a target nucleic acid sequence contained in the target cell genome (e.g. contained in a chromosome of the target cell).

[0136] Another example is a carrier bacterial cell containing a first episomal DNA, said DNA encoding an antimicrobial agent that is toxic to the target bacterial cells but not to the carrier cell, the carrier cell being capable of conjugatively transferring the DNA into the target cell for expression of the agent in the target cell; (a) the carrier cell contains a second DNA that is different from the first DNA, the second DNA containing or encoding a first factor required for replication of the first DNA; (b) the first DNA does not contain or encode said first factor, and the first DNA is non-autonomously replicating in the absence of the first factor, but is capable of replicating in a carrier cell in the presence of the first factor provided by the second DNA; (c) the carrier cell contains genes encoding one or more conjugation factors sufficient to effect conjugative transfer of the first DNA into the target bacterial cell; A carrier bacterial cell is provided.

[0137] An example is also Provided is a carrier bacterial cell comprising a plasmid containing a first DNA, the DNA encoding a guided nuclease capable of recognizing and modifying a target nucleic acid sequence, the carrier cell capable of conjugatively transferring the plasmid into a target cell for expression of the nuclease in the target cell, the target sequence being contained in an endogenous chromosome or episome of the target cell but not in the carrier cell, and the nuclease being capable of modifying (e.g., cleaving) the chromosome or episome to kill or inhibit the growth or proliferation of the target cell.

[0138] Optionally, the nuclease is a Cas nuclease, a meganuclease, a zinc finger nuclease, or a TALEN.

[0139] Optionally, the nuclease is a Cas nuclease of a type I, II, III, IV, or V CRISPR system.

[0140] An example is also Provided is a carrier bacterial cell comprising a plasmid comprising a first DNA, said DNA encoding a component of a CRISPR / Cas system capable of recognising and modifying a target nucleic acid sequence, wherein the carrier cell is capable of conjugatively transferring the plasmid into a target cell for expression of the component in the target cell, whereby the expressed component forms part of the system in the target cell, wherein the target sequence is contained in an endogenous chromosome or episome of the target cell but not in the carrier cell, and wherein the system is capable of modifying (e.g. cleaving) the chromosome or episome to kill or inhibit the growth or proliferation of the target cell.

[0141] In one embodiment, the component is a guide RNA or crRNA capable of hybridizing to a target sequence in a target cell. The system is It may be a type I, II, III, IV, or V CRISPR system.

[0142] Optionally, (a) the carrier cell comprises a second DNA different from the first DNA, the second DNA comprising or encoding a first factor required for replication of the first DNA; (b) the first DNA does not contain or encode said first factor, and the first DNA is non-autonomously replicating in the absence of the first factor, but is capable of replicating in a carrier cell in the presence of the first factor provided by the second DNA; (c) the carrier cell contains genes encoding one or more conjugation factors sufficient to effect conjugative transfer of the first DNA into the target bacterial cell.

[0143] The second DNA may be contained in a chromosome or an episome (eg a plasmid) of the carrier cell. Any of the methods of the invention may use a carrier cell of any of these embodiments.

[0144] Advantageously, the cell is for treating or preventing infection of a target cell in a human or animal subject (e.g. chicken, cow, pig, fish or crustacean). Advantageously, the carrier cell is a cell of a species that is probiotic for said subject or probiotic for humans or animals (e.g. chicken). For example, the carrier cell is a probiotic E.coli cell. For example, the carrier cell is a probiotic Bacillus cell. In one example, the target cell is a cell of a species that is pathogenic for said subject or pathogenic for humans or animals (e.g. chicken). Advantageously, the first DNA encodes one or more guide RNAs or one or more crRNAs that can hybridize to the respective target nucleic acid sequences in the target cell, the target sequences being comprised in an endogenous chromosome and / or an endogenous episome of the target cell. For example, the first DNA encodes 2, 3, 4, 5, 6, 7, 7, 9, or 10 (or more than 10) different gRNAs or different crRNAs that hybridize to their respective target sequences, and the target sequences are different from each other. For example, three different gRNAs or crRNAs are encoded by the first DNA. For example, two different gRNAs or crRNAs are encoded by the first DNA. For example, three different gRNAs or crRNAs are encoded by the first DNA. For example, four different gRNAs or crRNAs are encoded by the first DNA. For example, three different gRNAs or crRNAs are encoded by the first DNA. For example, five different gRNAs or crRNAs are encoded by the first DNA. For example, six different gRNAs or crRNAs are encoded by the first DNA. For example, seven different gRNAs or crRNAs are encoded by the first DNA. For example, eight different gRNAs or crRNAs are encoded by the first DNA. For example, nine different gRNAs or crRNAs are encoded by the first DNA. For example, 10 different gRNAs or crRNAs are encoded by the first DNA. For example, 11 different gRNAs or crRNAs are encoded by the first DNA.For example, 12 different gRNAs or crRNAs are encoded by the first DNA. For example, 13 different gRNAs or crRNAs are encoded by the first DNA. In one example, the target cell is a Salmonella cell (e.g., the subject is a chicken). In one example, the target cell is an E. coli cell. In one example, the target cell is a Campylobacter cell (e.g., the subject is a chicken). In one example, the target cell is an Edwardsiella cell (e.g., the subject is a fish or crustacean, such as a catfish, or a shrimp, or a prawn). In one example, the target cell is an E. coli cell.

[0145] In one alternative herein, the carrier cell and the target cell are archaeal cells. In one alternative herein, the carrier cell and the target cell are yeast cells, and "mating" should rather be read as referring to yeast "mating", e.g., the second DNA is contained in the chromosome of the carrier yeast cell.

[0146] In a preferred example, the NOI encodes an antimicrobial agent that is toxic to target bacterial cells but not to carrier cells. In one example, the POI is an antibiotic, an antibody, an antibody chain, or an antibody variable domain. In one example, the ROI is a guide RNA or crRNA that can be operated in a target cell with an associated Cas (e.g., a Cas nuclease that targets and cleaves a protospacer sequence contained in the chromosome or episome of the target cell). In one example, the RNA is an siRNA that can hybridize to an endogenous target nucleic acid sequence of the target cell to silence its transcription and / or translation.

[0147] The carrier cell comprises a chromosomal or second episomal DNA that is different from the first DNA. Thus, for example, the second DNA is comprised in a chromosome of the carrier cell. In another example, the second DNA is comprised in a plasmid of the carrier cell.

[0148] 2. The carrier cell of embodiment 1, (d) the first DNA lacks components necessary for conjugal transfer of the first DNA into the target bacterial cell; (e) A carrier cell comprising said component, said component being contained in or encoded by a second DNA or a third DNA contained in the carrier cell.

[0149] The third DNA may be contained in a chromosome or an episome (e.g., a plasmid). When explicitly referred to in embodiment 2 below, the components refer to components necessary for conjugative transfer, as the context will make clear.

[0150] 3. The carrier cell of embodiment 2, wherein said component is comprised in the Mpf or Dtr module. For example, the module is an RK2, RP4, or R6K tra module. Optionally, the component is included in an Mpf (mating pair formation) module, such as an RK2 or RP4 tra1 module or a homolog thereof. Optionally, the component is included in a Dtr (DNA transfer replication) module, such as an RK2 or RP4 tra2 module or a homolog thereof.

[0151] 4. The carrier cell of embodiment 2, wherein said components are encoded by operons of the Mpf (eg tra1) or Dtr (eg tra2) modules. For example, the module is an RK2, RP4, or R6K tra module. Optionally, the module is an Mpf (mating pair formation) module, such as an RK2 or RP4 tra1 module or a homolog thereof. Optionally, the module is a Dtr (DNA transfer replication) module, such as an RK2 or RP4 tra2 module or a homolog thereof.

[0152] The Mpf operon of RP4 or RK2 is the tra2 operon (including the trb genes trbBCDEFGHIJKL) with the gene traF. The gene traF is contained in RK2 or RP4 in the tra1 operon (with traJXIHG). Thus, in one embodiment, the components are genes selected from trbB, trbC, trbD, trbE, trbF, trbG, trbH, trbI, trbJ, trbK, trbL, and traF. In one embodiment, the first DNA lacks two or more genes selected from RP4 trbB, trbC, trbD, trbE, trbF, trbG, trbH, trbI, trbJ, trbK, trbL, and traF or homologs thereof. In one embodiment, the first DNA lacks two or more genes selected from RK2 trbB, trbC, trbD, trbE, trbF, trbG, trbH, trbI, trbJ, trbK, trbL, and traF or homologs thereof. In one example, the components are traK, traL, or traM genes. In one embodiment, the first DNA lacks two or more genes selected from RP4 traK, traL, and traM or homologs thereof. In one embodiment, the first DNA lacks two or more genes selected from RK2 traK, traL, and traM or homologs thereof. Optionally, in these embodiments, the first DNA is comprised in a RP4 or RK2 type plasmid.

[0153] R6K Mpf is encoded by the sltX1tivB1B2B3-4B5B6B7B8B9B10B11 operon, which also includes the clpX1 of the Dtr module. Thus, in one embodiment, the component is a gene contained in the RK6 sltX1tivB1B2B3-4B5B6B7B8B9B10B11 operon. In one embodiment, the component is the clpX1 of the RK6 Dtr module. In one embodiment, the component is a gene selected from clpX1 and dtrX1rlxX1. In one embodiment, the component is a gene selected from RK6 clpX1 and dtrX1rlxX1 or homologs thereof. Optionally, in these embodiments, the first DNA is contained in a RK6-type plasmid.

[0154] A carrier cell according to any of the preceding embodiments, wherein a chromosome of the carrier cell and / or an episome of the carrier cell (other than the episome comprising the first DNA) comprises an expressible tra1 and / or tra2 module or a homologue thereof. Any episome herein may be a plasmid.

[0155] 5. A carrier cell of any of the preceding embodiments, wherein a chromosome of the carrier cell and / or an episome of the carrier cell (other than the episome comprising the first DNA) comprises an expressible operon of the tra1 and / or tra2 module or a homologue thereof.

[0156] 6. The carrier cell of any one of embodiments 3 to 6, wherein said component is a tra1 component.

[0157] 7. The carrier cell of any one of embodiments 3 to 6, wherein said component is the tra2 component.

[0158] 8. The carrier cell of any one of embodiments 2 to 7, wherein the carrier cell chromosome encodes the first factor and comprises said component.

[0159] 9. The carrier cell of any of the previous embodiments, wherein the first factor is a rep protein, optionally wherein said protein is encoded by pir or trfA or a homologue thereof.

[0160] 10. The carrier cell of any of the preceding embodiments, wherein the first DNA is comprised in a RK2 or R6K plasmid.

[0161] 11. The carrier cell of any of the preceding embodiments, wherein the first DNA comprises oriV of the RK2 or R6K plasmid or a homologue thereof.

[0162] 12. The carrier cell of any of the preceding embodiments, wherein the first DNA comprises oriT of the RK2 or R6K plasmid or a homologue thereof.

[0163] 13. The carrier cell of any of the preceding embodiments, wherein the first DNA is comprised in a plasmid.

[0164] 14. The carrier cell of any of the preceding embodiments, wherein the second DNA is contained in a plasmid or is contained in the chromosome of the carrier cell.

[0165] 15. A carrier cell of any of the preceding embodiments, wherein the agent comprises one or more components of a CRISPR / Cas system operable in a target cell to cleave a protospacer sequence contained in the target cell, e.g. the protospacer sequence is contained in a cell chromosome.

[0166] In one embodiment, the cleaving herein kills the target cell, hi another embodiment, the cleaving inhibits the growth or proliferation of the target cell.

[0167] 16. A carrier cell of any of the preceding embodiments, wherein the agent encodes a guide RNA or crRNA of a CRISPR / Cas system operable in a target cell together with a Cas nuclease to cleave a protospacer sequence contained in the target cell, e.g. the protospacer sequence is contained in a cell chromosome.

[0168] In one example, the target cell is a Salmonella cell and the protospacer is comprised in a pipA, pipB, pipC, hilA, sicP, mart, or sopB gene. In one example, the protospacer is comprised in a gene that is a homolog or ortholog of a Salmonella sicP, sseF, pipA, pipB, pipC, hilA, sicP, mart, or sopB gene.

[0169] 17. The carrier cell of any of the preceding embodiments, wherein the first DNA comprises a gene encoding a product, said product being essential for the survival or proliferation of the carrier cell when in an environment lacking the product, and wherein the chromosome of the carrier cell does not comprise an expressible gene encoding the product, and optionally, the first DNA is the only episomal DNA contained in the carrier cell that encodes the product.

[0170] 18. The carrier cell of embodiment 17, wherein said gene is selected from aroA, argH, hisD, leuB, lysA, metB, proC, thrC, pheA, tyrA, trpC, and pflA genes, said gene being an antitoxin gene, and optionally, the first DNA encodes an associated toxin.

[0171] 19. The carrier cell of any of the preceding embodiments, which is an E coli (e.g., a Nissle, F18, or S17 E coli strain), a Bacillus (e.g., a B subtilis), an Enterococcus, or a Lactobacillus cell.

[0172] Optionally, the carrier cells are cells of a human, chicken, pig, sheep, cow, fish (eg, catfish or salmon), or crustacean (eg, shrimp or lobster) commensal bacterial strain (eg, a commensal E. coli strain).

[0173] 20. A carrier cell of any of the preceding embodiments, for administration to a microbial population of a human or animal subject for medical use.

[0174] For example, medical applications are for treating or preventing a disease as disclosed herein. For example, medical applications are for treating or preventing a condition as disclosed herein.

[0175] 21. The carrier of embodiment 20, wherein said medical use is for the treatment or prevention of a disease or condition mediated by said target cells.

[0176] 22. A carrier according to any one of embodiments 1 to 20, for administration to an animal to enhance the growth or weight of the animal.

[0177] In alternatives, the administration is to a human for enhancing the growth or weight of the human. Optionally, the enhancing is not a medical treatment. Optionally, the enhancing is a medical treatment.

[0178] 23. A carrier according to any one of embodiments 20 to 22, wherein said use comprises administration of a plurality of carrier cells to a microbial population (e.g., a gut microbial population) of a subject, the microbial population comprising target cells, and a first DNA is transferred to the target cells for expression in the target cells to produce an antibacterial agent, thereby killing or reducing the growth or proliferation of the target cells in the subject.

[0179] 24. DNA encoding an antibacterial agent that is toxic to target bacterial cells but not toxic to carrier cells, wherein a first DNA contains an origin of replication but does not contain or encode a first factor required for replication of the first DNA, and wherein the first DNA contains an origin of transfer but lacks components required for conjugative transfer of the first DNA into a target bacterial cell, and wherein the DNA can be conjugatively transferred into the target cell when said components are present.

[0180] Thus, when the DNA is present in a carrier cell, it can be conjugally transferred into a target cell.

[0181] 25. The DNA of embodiment 24, which is a DNA as recited in any one of embodiments 1 to 23.

[0182] 26. The DNA of embodiment 24 or 25, wherein the cell is a cell as recited in any one of embodiments 1 to 23.

[0183] 27. A method of enhancing the growth or weight of an animal subject (e.g., chickens), said method comprising administering a plurality of carrier cells according to any one of embodiments 1 to 23 to a microbial population of the subject, said microbial population comprising target cells, and a first DNA is transferred from the carrier cells to the target cells for expression in the target cells to produce an antibacterial agent, thereby killing or reducing the growth or proliferation of the target cells (e.g., Salmonella cells) in the subject.

[0184] In alternatives, the administration is to a human for enhancing the growth or weight of the human. Optionally, the enhancing is not a medical treatment. Optionally, the enhancing is a medical treatment.

[0185] 28. A method of enhancing the growth or weight of a plant (e.g., a tomato plant), said method comprising administering a plurality of carrier cells according to any one of embodiments 1 to 23 to a microbial population of the plant, said microbial population comprising a target cell, and a first DNA is transferred from the carrier cells to the target cell for expression in the target cell to produce an antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cell (e.g., a Pseudomonas cell) in the plant.

[0186] The plant may be any plant disclosed herein. For example, the plant herein in any configuration or embodiment of the present invention is selected from a tomato plant, a potato plant, a wheat plant, a corn plant, a maize plant, an apple tree, a bean-producing plant, a pea plant, a beetroot plant, a stone fruit plant, a barley plant, a hop plant, and a grass. For example, the plant is a tree, such as a palm, a horse chestnut, a pine, an oak, or a hardwood tree. For example, the plant is a fruit-producing plant selected from strawberry, raspberry, blackberry, red currant, kiwi, banana, apple, apricot, avocado, cherry, orange, clementine, tangerine, grapefruit, prune, date, fig, lime, lemon, melon, mango, pear, olive, or grape. Optionally, the plant is a dicotyledonous plant. Optionally, the plant is a flowering plant. Optionally, the plant is a monocotyledonous plant.

[0187] In any of the configurations, embodiments, or examples herein, the target bacterium is a P. syringae bacterium (e.g., in plants). Pseudomonas syringae pv. syringae is a common plant-associated bacterium that causes disease in both monocotyledonous and dicotyledonous plants worldwide. In one example, the target bacterium is a pathogenic type of P syringae bacterium selected from Pspv.aceris, Pspv.aptata, Pspv.atrofaciens, Pspv.dysoxylis, Pspv.japonica, Pspv.lapsa, Pspv.panici, Pspv.papulans, Pspv.pisi, Pspv.syringae, and Pspv.morsprunorum. · Pspv.aceris attacks maple species, Acer. · Pspv.actinidiae attacks the kiwi fruit Actinidia deliciosa. Pspv.aesculi attacks the horse chestnut Aesculus hippocastanum, causing a canker disease. · Pspv.aptata attacks the beet, Beta vulgaris. · Pspv. atrofaciens attacks wheat, Triticum aestivum. Pspv.dysoxylis attacks the Dysoxylum spectabile. · Pspv.japonica attacks barley, Hordeum vulgare. · Pspv.lapsa attacks wheat, Triticum aestivum. · Pspv.panici attacks millet species. Pspv.papulans attacks the crabapple species Malus sylvestris. · Pspv.phaseolicola causes bean blight. Pspv.pisi attacks the pea plant, Pisum sativum. · Pspv.syringae attacks Syringa, Prunus, and Phaseolus species. · Pspv. glycinea attacks soybean and causes soybean bacterial spot disease.

[0188] In one example, the target bacterium is P. syringae selected from the serovars listed in the immediately preceding paragraph, and the bacterium is included among the plants also listed in that bullet point.

[0189] In one example, the weight is dry weight. For example, the method is for increasing dry weight (e.g., within 1 or 2 weeks of said administration). Optionally, the increase is at least 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% increase compared to control plants of the same species or strain when all plants are kept under the same environmental conditions and no administration of carrier cells is performed. For example, such an increase is within 1, 2, 3, 4, 5, 6, or 8 weeks after the first administration of carrier cells. In one example, the method is for increasing dry weight of leaves and / or fruits of plants, such as tomato plants.

[0190] In one example, the weight is wet weight. For example, the method is for increasing wet weight (e.g., within 1 or 2 weeks of said administration). Optionally, the increase is at least 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% increase compared to control plants of the same species or strain when all plants are kept under the same environmental conditions and no administration of carrier cells is performed. For example, such an increase is within 1, 2, 3, 4, 5, 6, or 8 weeks after the first administration of carrier cells. In one example, the method is for increasing dry weight of leaves and / or fruits of plants, such as tomato plants.

[0191] 29. The method of embodiment 28, wherein the microbial population is contained in the leaves, stems, roots, or stems of a plant.

[0192] In one example, in any of the configurations or embodiments herein, the target bacteria (or target cells) are contained in the microbiome of a plant. In one example, the microbiome is contained in a leaf. In one example, the microbiome is contained in a xylem. In one example, the microbiome is contained in a phloem. In one example, the microbiome is contained in a root. In one example, the microbiome is contained in a tuber. In one example, the microbiome is contained in a bulb. In one example, the microbiome is contained in a seed. In one example, the microbiome is contained in an exocarp, epicarp, mesocarp, or endocarp. In one example, the microbiome is contained in a fruit, such as a simple, compound, or multi-flowered fruit. In one example, the microbiome is contained in a seed or embryo, such as a seed coat, cotyledons, cotyledons, or root. In one example, the microbiome is contained in a flower, such as a pedicel, sepals, petals, stamens, filaments, anthers, or pistils. In one example, the microbiome is contained in a root, such as a taproot system or a hair root system. In one example, the microbial community is contained in a leaf, e.g., in the leaf blade, petiole, or stipule. In one example, the microbial community is contained in a stem, e.g., in the bark, epidermis, phloem, cambium, xylem, or pith.

[0193] 30. A method for reducing a biofilm contained in an object or contained on a surface, said biofilm comprising target cells (e.g., Pseudomonas cells), said method comprising administering to the biofilm a plurality of carrier cells according to any one of embodiments 1 to 23, wherein a first DNA is transferred from the carrier cells to the target cells for expression in the target cells to produce an antimicrobial agent, thereby killing or reducing the growth or proliferation of the target cells in the biofilm.

[0194] In one example, "reducing a biofilm" includes reducing the coverage area of ​​a biofilm. In one example, "reducing a biofilm" includes reducing the growth of a biofilm. In one example, "reducing a biofilm" includes reducing the persistence of a biofilm. In one example, "reducing a biofilm" includes reducing the spread of a biofilm (e.g., in or on a subject, e.g., to an environment that includes the subject).

[0195] 31. The method of embodiment 30, wherein the subject is a human or animal.

[0196] For example, the biofilm is contained in the lungs of a subject and the target cells are, for example, Pseudomonas (e.g., P aeruginosa) cells. This can be useful when the subject is suffering from a pulmonary disease or condition, such as pneumonia or cystic fibrosis.

[0197] For example, the biofilm may be included in an animal or human organ as disclosed herein. For example, the biofilm may be included in a human or animal microbial community as disclosed herein.

[0198] 32. The method of embodiment 30, wherein the subject is a plant (e.g., any plant disclosed herein).

[0199] Optionally, in this embodiment, the target cell is a Pseudomonas syringae cell.

[0200] 33. The method of embodiment 31 or 32, wherein the biofilm is comprised on the leaves, stems, roots, or stems of a plant.

[0201] In one example, in any of the configurations or embodiments herein, the target bacteria (or target cells) are contained in a biofilm of a plant. In one example, the biofilm is contained in a leaf. In one example, the biofilm is contained in a xylem. In one example, the biofilm is contained in a phloem. In one example, the biofilm is contained in a root. In one example, the biofilm is contained in a tuber. In one example, the biofilm is contained in a bulb. In one example, the biofilm is contained in a seed. In one example, the biofilm is contained in an exocarp, epicarp, mesocarp, or endocarp. In one example, the biofilm is contained in a fruit, such as a simple, compound, or multi-flowered fruit. In one example, the biofilm is contained in a seed or embryo, such as a seed coat, cotyledons, cotyledons, or root. In one example, the biofilm is contained in a flower, such as a pedicel, sepals, petals, stamens, filaments, anthers, or pistils. In one example, the biofilm is contained in a root, such as a taproot system or a hair root system. In one example, the biofilm is present in a leaf, e.g., in the leaf blade, petiole, or stipule. In one example, the biofilm is present in a stem, e.g., in the bark, epidermis, phloem, cambium, xylem, or pith.

[0202] 34. The method of any one of embodiments 30 to 33 (eg, 30), wherein the surface is an ex vivo surface, such as a surface contained in a household or industrial device or container.

[0203] 35. A method for replicating a first DNA to produce multiple copies of said DNA, said method comprising culturing a plurality of carrier bacterial cells according to any one of embodiments 1 to 23, wherein the first DNA is replicated in the cells.

[0204] Optionally, the method further comprises isolating the first DNA after said culturing.Those skilled in the art are familiar with the techniques and conditions for culturing cells that can be used.

[0205] 36.(a) Obtaining a sample of carrier cells after culturing; (b) contacting the sample of carrier cells with a plurality of target bacterial cells to cause conjugation of the carrier cells with the target cells; and (c) transferring a copy of the first DNA from the carrier cell to the target cell by conjugative transfer, and an antimicrobial agent is provided in the target cell, killing the target cell or reducing the growth or proliferation of the target cell; (d) The method, wherein the first DNA is not replicable in the target cell.

[0206] For example, the first DNA is substantially non-replicable in the target cell (eg, less than 10, 5, 4, 3, 2, or 1% replication).

[0207] The first DNA is not replicable (or is not substantially replicable) in the target cell due to the absence in the target cell of the first factor or sequence that encodes it.

[0208] 37. A method for killing or reducing the growth or proliferation of multiple target bacterial cells, comprising: (a) obtaining a sample of carrier cells according to any one of embodiments 1 to 23 or obtained by the method of embodiment 35; (b) contacting the sample of carrier cells with a plurality of target bacterial cells to cause conjugation of the carrier cells with the target cells; and (c) transferring a copy of the first DNA from the carrier cell to the target cell by conjugative transfer, whereby an antimicrobial agent is provided in the target cell, killing the target cell or reducing the growth or proliferation of the target cell. Including, (d) The method, wherein the first DNA is not replicable (or substantially not replicable) in the target cell.

[0209] 38. The method of embodiment 36 or 37, wherein the target cell is comprised in a biofilm, such as a biofilm disclosed herein.

[0210] 39. A method for containing the action of an antimicrobial agent in the environment, said agent being toxic to target bacterial cells, said method comprising carrying out the method of embodiment 37 or 38, said agent being an agent recited in an embodiment.

[0211] 40. The method of embodiment 39, wherein the environment is comprised in a human or animal subject, the target cells are comprised in a biofilm in the subject, the method comprises administering a sample of carrier cells to the biofilm in the subject, the carrier cells being contacted with the target cells in step (b), and the method is a contained method for treating or preventing a disease or condition mediated by the target cells in the subject.

[0212] 41. The carrier cell, DNA, or method of any preceding embodiment, wherein the target bacterium is a Salmonella, Pseudomonas, Escherichia, Klebsiella, Campylobacter, Helicobacter, Acinetobacter, Enterobacteriacea, Clostridium, Staphylococcus, or Streptococcus bacterium.

[0213] 42. The carrier cell, DNA, or method of any preceding embodiment, wherein the target bacterium is a Salmonella enterica bacterium.

[0214] For example, the target bacterium is selected from the group consisting of Salmonella enterica subspecies enterica, serovar Typhimurium, Enteritidis, Virchow, Montevideo, Hadar, and Binza.

[0215] 43. The carrier cell, DNA, or method of any one of embodiments 1 to 41, wherein the target bacterium is a Pseudomonas (e.g. P syringae or P aeruginosa) bacterium.

[0216] 44. The carrier cell or method of any one of embodiments 1 to 41, wherein the target bacterium is an E. coli bacterium.

[0217] Optionally, the target bacterium is enterohemorrhagic E. coli (EHEC), E. coli serotype O157:H7, or Shiga toxin-producing E. coli (STEC). In one example, the target bacterium is Shiga toxin-producing E. coli (STEC) (also called verocytotoxin-producing E. coli (VTEC)), Enterohemorrhagic E. coli (EHEC) (this pathotype is the one most commonly heard in the news related to food poisoning), Enterotoxin-producing E. coli (ETEC), ·Enteropathogenic E. coli (EPEC), ·Enteroaggregative E. coli (EAEC), Enteroinvasive E. coli (EIEC), and ·Disseminated adherent E. coli (DAEC) is selected from.

[0218] Enterohemorrhagic Escherichia coli (EHEC) serotype O157:H7 is a human pathogen responsible for outbreaks of bloody diarrhea and hemolytic uremic syndrome (HUS) worldwide. Traditional antimicrobial agents induce an SOS response in EHEC, which promotes the release of potent Shiga toxins that are responsible for much of the morbidity and mortality associated with EHEC infection. Cattle are the natural reservoir of EHEC, and nearly 75% of EHEC outbreaks are associated with the consumption of contaminated cattle products. EHEC causes disease in humans but is asymptomatic in adult ruminants. E. coli serotype O157:H7 (EHEC) infection is characterized by abdominal cramps and bloody diarrhea, as well as the potentially fatal complication hemolytic uremic syndrome (HUS). There is currently a need for treatments for EHEC infection (Goldwater and Bettelheim, 2012). The use of conventional antibiotics exacerbates Shiga toxin-mediated cytotoxicity. In an epidemiological study conducted by the Centers for Disease Control and Prevention, patients treated with antibiotics for EHEC enteritis were at increased risk of developing HUS (Slutsker et al., 1998). Further studies support that antibiotics are contraindicated in EHEC infections, and children treated with antibiotics for EHEC-associated hemorrhagic enteritis were at increased risk of developing HUS (Wong et al., 2000; Zimmerhackl, 2000; Safdar et al., 2002; Tarr et al., 2005). Conventional antibiotics promote the production of Shiga toxins by enhancing the replication and expression of stx genes encoded in lambda-type prophage genomes integrated within the chromosome. The approach of some configurations of the present invention relies on nuclease cleavage. Induction of stx also promotes phage-mediated lysis of the EHEC cell envelope, allowing the release and dissemination of Shiga toxin into the environment (Karch et al., 1999; Matsushiro et al., 1999; Wagner et al., 2002). Advantageously, these compositions of the invention thus provide an alternative means for treating EHEC in human and animal subjects.This is illustrated below with surprising results regarding the speed and duration of anti-EHEC effect (as opposed to that of conventional antibiotics) produced by the action of nucleases.

[0219] In one example, a subject (eg, a human or animal) is suffering from or at risk for hemolytic uremic syndrome (HUS), eg, the subject is suffering from an E coli infection, eg, an EHEC E coli infection.

[0220] 45. A pharmaceutical composition, a composition for livestock growth promotion, a soil conditioner, a herbicide, a fertilizer for plants, a composition for food or foodstuff sterilization, a dental composition, a composition for personal hygiene, or a disinfectant composition (e.g., for household or industrial use) comprising a plurality of carrier cells according to any one of embodiments 1 to 23.

[0221] As used herein, a carrier cell is, for example, a probiotic cell for administration to a human or animal subject. For example, the carrier cell is commensal in the microbiome (e.g., gut or blood microbiome) of a human or animal subject, and the carrier is for administration to the subject. In one example, the carrier cell is a bacterial cell (and optionally the target cell is a bacterial cell). In one example, the carrier cell is an archaeal cell (and optionally the target cell is an archaeal cell).

[0222] Optionally, the carrier cell is a gram-positive bacterial cell and the target cell is a gram-positive bacterial cell.

[0223] Optionally, the carrier cell is a gram-positive bacterial cell and the target cell is a gram-negative bacterial cell.

[0224] Optionally, the carrier cell is a gram-negative bacterial cell and the target cell is a gram-positive bacterial cell.

[0225] Optionally, the carrier cell is a gram-negative bacterial cell and the target cell is a gram-negative bacterial cell.

[0226] Optionally, the carrier cell is a Bacillus bacterial cell and the target cell is a Gram-positive bacterial cell.

[0227] Optionally, the carrier cell is a Bacillus bacterial cell and the target cell is a Gram-negative bacterial cell.

[0228] Optionally, the carrier cell is a Bacillus bacterial cell and the target cell is a Salmonella bacterial cell.

[0229] Optionally, the carrier cell is a Bacillus bacterium and the target cell is an E coli bacterial cell.

[0230] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is a Pseudomonas bacterial cell.

[0231] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is a gram-positive bacterial cell.

[0232] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is a gram-negative bacterial cell.

[0233] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is a Salmonella bacterial cell.

[0234] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is an E. coli bacterial cell.

[0235] Optionally, the carrier cell is an E. coli bacterial cell and the target cell is a Pseudomonas bacterial cell.

[0236] As used herein, the Bacillus cell is optionally a B subtilis cell.

[0237] Optionally, the carrier cell is a probiotic or commensal E coli bacterial cell for administration to a human or animal subject. Optionally, the carrier cell is a probiotic or commensal Bacillus bacterial cell for administration to a human or animal subject.

[0238] As used herein, optionally the first DNA is comprised in a plasmid, for example a closed circular DNA.

[0239] In one embodiment, the first DNA is dsDNA.In one embodiment, the first DNA is ssDNA.

[0240] In an alternative configuration, the first DNA is instead a first RNA.

[0241] Optionally, the target cell is a Salmonella cell (eg, where the carrier cell is an E. coli cell), such as Salmonella enterica subspecies enterica, such as Salmonella enterica subspecies enterica serovar Typhimurium, Enteritidis, Virchow, Montevideo, Hadar, or Binza.

[0242] For example, the target bacterium is selected from the group consisting of S. enterica, S. typhimurium; P. aeruginosa; E. coli, K. pneumoniae; C. jujeni; H. pylori; A. baumanii; C. difficile; S. aureus; S. pyogenes; or S. thermophilus.

[0243] In one example, the target cells are cells of a species that causes nosocomial infections in humans.

[0244] Optionally, the target cell is comprised in the microbiome of an animal (e.g., a poultry animal (e.g., a chicken), a pig, a cow, a fish (e.g., a catfish or salmon), or a crustacean (e.g., a shrimp or lobster)). Optionally, the microbiome is a gut microbiome. For example, the target cell is a Salmonella cell comprised in a chicken gut biofilm. For example, the target cell is a Salmonella cell comprised in an ex vivo chicken gut biofilm sample.

[0245] In one embodiment, the first DNA comprises a bacterial oriV and / or oriT. In one embodiment, the first DNA is comprised in a plasmid, and the plasmid comprises oriV and / or oriT.

[0246] The first factor may be a protein or an RNA. For example, the first factor is pir or trfA. In one example, the first factor can operate with oriV contained in the first DNA for its replication.

[0247] In one embodiment, the first DNA is contained in a plasmid, the plasmid contains oriV and does not encode any replication protein (eg, pir or trfA) operable with oriV to initiate replication of the plasmid.

[0248] In one embodiment, the first DNA lacks a component required for conjugative transfer of the first DNA into the target bacterial cell. Optionally, the component is a protein. Optionally, the component is an RNA. Optionally, the component is a tra1 component. Optionally, the component is a tra2 component. In one example, the carrier cell comprises said component, the component being contained in or encoded by the carrier cell chromosome, the second DNA, or the third DNA in the carrier cell. Preferably, the component is contained in or encoded by the carrier cell chromosome.

[0249] Optionally, the component required for conjugal transfer is an RP4 plasmid component, such as a component of the RP4 tra module (eg the tra1 or tra2 module).

[0250] Optionally, the component required for conjugal transfer is an RK2 plasmid component, such as a component of the RK2 tra module (eg, the tra1 or tra2 module).

[0251] Optionally, the component required for conjugal transfer is an R6K plasmid component, such as a component of the R6Ktra module (eg, the tra1 or tra2 module).

[0252] Optionally, the first DNA is contained in a plasmid that does not contain an antibiotic resistance marker gene and / or a plasmid-dependent system gene. As explained in the Examples section, this can be advantageous in the rare case where an identical IncP plasmid providing trfA (or other components required for conjugation if this component is not encoded by the plasmid containing the first DNA) is present in the target cell, and both plasmids will compete for available trfA (or other components), resulting in the loss of one plasmid and therefore its rapid loss from any progeny target cells.

[0253] Optionally, the plasmid comprising the first DNA further comprises an anti-restriction gene that encodes a product for inhibiting a restriction enzyme (e.g., a type I restriction enzyme) of a target cell as an anti-restriction gene that inhibits a type I restriction enzyme (e.g., the anti-restriction gene product is ocr of T7, klcA of RK2, ard or ardB).

[0254] Additionally or alternatively, the plasmid contains genes encoding the essential components of a type IV secretion system and the chromosome of the carrier cell contains genes encoding the remaining parts of the secretion system, the essential components being necessary for conjugative transfer of the plasmid from the carrier cell to the target cell. For example, with the exception of the tra1 and tra2 genes encoding the essential components, the chromosome contains (preferably when the plasmid is an RK2-type plasmid) traKLM of RK2tra1, all the rest of the traJXIHGF gene, and all the rest of the trbBCEFGHJL gene of RK2tra2. In an alternative example, with the exception of the genes encoding the essential components, the chromosome contains (preferably when the plasmid is an RK6-type plasmid) traKLM of RK2tra1, all the rest of the RK6 homolog of the traJXIHGF gene, and all the rest of the RK6 homolog of the trbBCEFGHJL gene of RK2tra2. In one alternative, with the exception of genes encoding essential components, the chromosome contains (preferably when the plasmid is an RP4-type plasmid) all of the remainder of the RP4 homologues of the traKLM and traJXIHGF genes of RK2tra1, and all of the remainder of the RP4 homologues of the trbBCEFGHJL genes of RK2tra2.

[0255] For example, with the exception of the tra1 or tra2 genes encoding essential components, the chromosome comprises all of the remainder of the DNA fragment of the RK2 plasmid from traF to traM (preferably when the plasmid is an RK2-type plasmid), and all of the remainder of the DNA fragment of the RK2 plasmid from trbB to trK (preferably when the plasmid is an RK2-type plasmid). For example, with the exception of the tra1 or tra2 genes encoding essential components, the chromosome comprises all of the remainder of the RK2 plasmid genes from traF to traM, and all of the remainder of the RK2 plasmid genes from trbB to trK (preferably when the plasmid is an RK2-type plasmid). For example, the chromosome comprises (in the following order, 5' to 3', or 3' to 5'): RK2tra1 genes: traFGHIXJKLM, or traKLM, or traJXIHGF. For example, the chromosome comprises (in the following order, 5' to 3', or 3' to 5'): RK2tra2 genes: trbBCDEFGHIJKL or trbBCEFGHJL.

[0256] For example, with the exception of genes encoding essential components, the chromosome comprises all of the remainder of the DNA fragment of the RK6 plasmid from a homolog of RK2traF to a homolog of RK2traM (preferably when the plasmid is a RK6-type plasmid), and all of the remainder of the DNA fragment of the RK6 plasmid from a homolog of RK2trbB to a homolog of RK2trK (preferably when the plasmid is a RK6-type plasmid). For example, with the exception of genes encoding essential components, the chromosome comprises all of the remainder of the RK6 plasmid genes from a homolog of RK2traF to a homolog of RK2traM, and all of the remainder of the RK6 plasmid genes from a homolog of RK2trbB to a homolog of RK2trK (preferably when the plasmid is a RK6-type plasmid). For example, the chromosome comprises (in the following order, 5' to 3' or 3' to 5') the RK6 homologs of the following RK2tra1 genes: traFGHIXJKLM, or traKLM, or traJXIHGF. For example, a chromosome contains (in the following order, 5' to 3' or 3' to 5') the RK6 homolog of the RK2tra2 gene: trbBCDEFGHIJKL or trbBCEFGHJL.

[0257] For example, with the exception of genes encoding essential components, the chromosome comprises all of the remainder of the DNA fragment of the RP4 plasmid from a homolog of RK2traF to a homolog of RK2traM (preferably when the plasmid is an RP4-type plasmid), and all of the remainder of the DNA fragment of the RP4 plasmid from a homolog of RK2trbB to a homolog of RK2trK (preferably when the plasmid is an RP4-type plasmid). For example, with the exception of genes encoding essential components, the chromosome comprises all of the remainder of the RP4 plasmid genes from a homolog of RK2traF to a homolog of RK2traM, and all of the remainder of the RP4 plasmid genes from a homolog of RK2trbB to a homolog of RK2trK (preferably when the plasmid is an RP4-type plasmid). For example, the chromosome comprises (in the following order, 5' to 3' or 3' to 5') the RP4 homologs of the following RK2tra1 genes: traFGHIXJKLM, or traKLM, or traJXIHGF. For example, a chromosome contains the RP4 homolog of the following RK2tra2 genes (in the following order, 5' to 3' or 3' to 5'): trbBCDEFGHIJKL or trbBCEFGHJL.

[0258] Preferably, the second DNA or the chromosome comprising the second DNA lacks oriT. Preferably, the third DNA or the chromosome comprising the third DNA lacks oriT.

[0259] For example, oriT is contained only in the first DNA (or a plasmid containing it) and not in any other DNA in the carrier cell, thus restricting transfer to only the first DNA or its plasmid.

[0260] The first DNA in all embodiments and configurations may preferably not be included in a runaway-replicating plasmid. Naturally occurring plasmids are present in host cells at a characteristic concentration (herein referred to as the "copy number" of a particular plasmid). Mutations that disrupt control elements cause a hyperreplication phenotype ("copy-up" phenotype) that is manifested by an increase in plasmid copy number. In extreme cases of copy number mutations, plasmid replication becomes completely unrepressible due to loss of copy control mechanism. This is referred to as "runaway plasmid replication" or simply "runaway replication", and the plasmid involved in such runaway replication is a "runaway-replicating plasmid".

[0261] In one example, the present invention relates to a composition comprising a plurality of carrier cells of the present invention (e.g., a copy of the first DNA is contained in each plasmid). Optionally, all of the carrier cells contain the same said first and second DNA. Optionally, the plurality comprises a first subpopulation of carrier cells (first cells) and a second subpopulation of carrier cells (second cells), the first cells containing the same first DNA and the second cells containing the same first DNA (which are different from the first DNA of the first cells). For example, the former DNA contains a NSI that is different from the NSI contained in the other DNA. For example, the first DNA encodes a first guide RNA or crRNA and the second DNA encodes a second guide RNA or crRNA, the first guide RNA / crRNA can hybridize with a first protospacer sequence in the first target cell and the second guide RNA / crRNA can hybridize with a second protospacer sequence in the second target cell, the protospacers being different. Optionally, the first target cell is different from the second target cell. Optionally, the first target cell is the same species or strain as the second target cell. Alternatively, the first target cell is a different species or strain from the species or strain of the second target cell (thus providing a cocktail of carrier cells for administration to a human or animal or plant, for example to target and kill multiple target cells of different species or strains).

[0262] In one example, the or each first DNA comprises multiple (e.g., first and second) NSIs, where the first NSIs are different from the second NSIs (e.g., they encode different proteins or RNAs, e.g., different guide RNAs or crRNAs). In one example, the or each first DNA comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different types of NSIs. In one example, the or each first DNA comprises NSIs encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different guide RNAs. In one example, the or each first DNA comprises an NSI encoding 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different crRNAs. In one example, the or each first DNA comprises an NSI encoding at least 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different guide RNAs. In one example, the or each first DNA comprises an NSI encoding at least 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different crRNAs.

[0263] Optionally, the composition is contained in a liquid (e.g., an aqueous liquid or water), and the composition is 1×10 3 ~1×10 10 (For example, 1×10 4 ~1×10 10 , 1×10 4 ~1×10 9 , 1×10 4 ~1×10 8 , 1×10 4 ~1×10 7 , 1×10 3 ~1×10 10 , 1×10 3 ~1×10 9 , 1×10 3 ~1×10 8 , 1×10 3 ~1×10 7 , 1×10 5 ~1×10 10, 1×10 5 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~1×10 7 , 1×10 6 ~1×10 10 , 1×10 6 ~1×10 9 , 1×10 6 ~1×10 8 , or 1 × 10 6 ~1×10 7 ) cfu / ml. For example, the liquid is, for example, a beverage for human or animal consumption. For example, the beverage is a livestock beverage, for example a poultry beverage (i.e. a beverage for consumption by poultry such as chickens).

[0264] In one example, the composition is a food (e.g., food supplement) composition for human or animal consumption. In one example, the composition is a slimming composition for human or animal consumption. In one example, the composition is a growth promoting composition for human or animal consumption. In one example, the composition is a bodybuilding composition for human consumption. In one example, the composition is a probiotic composition for human or animal consumption. In one example, the composition is a biocidal composition for human or animal consumption. In one example, the composition is an insecticidal composition for human or animal consumption. In one example, the composition is a zoonotic disease control composition for animal consumption.

[0265] In one example, the composition includes the carrier cells plus vitamins. In one example, the composition includes the carrier cells plus vitamins A, B (e.g., B12), C, D, E, and / or K. In one example, the composition includes the carrier cells plus lipids. In one example, the composition includes the carrier cells plus carbohydrates. In one example, the composition includes the carrier cells plus proteins and / or amino acids. In one example, the composition includes the carrier cells plus minerals. In one example, the composition includes the carrier cells plus metal ions (e.g., Mg 2+ , Cu 2+ , and / or Zn2+ In one example, the composition includes sodium ions, potassium ions, magnesium ions, calcium ions, manganese ions, iron ions, cobalt ions, copper ions, zinc ions, and / or molybdenum ions.

[0266] In one example, the composition is a plant fertilizer composition. In one example, the composition is a herbicide. In one example, the composition is a pesticide composition for application to plants.

[0267] In any embodiment or example, where applicable, the plant is, for example, a crop. The plant is, for example, wheat. The plant is, for example, corn. The plant is, for example, maize. The plant is, for example, a fruit tree. The plant is, for example, a vegetable. The plant is, for example, a tomato plant. The plant is, for example, a potato plant. The plant is, for example, a grass plant. The plant is, for example, a flowering plant. The plant is, for example, a tree. The plant is, for example, a shrub.

[0268] In one example, the composition is for environmental use, and the environment is an outdoor environment (eg, outdoors or for use in a waterway or reservoir).

[0269] In one example, the composition is included in a food product or food ingredient (e.g., for human or animal consumption). In one example, the composition is included in a beverage or beverage ingredient (e.g., for human or animal consumption).

[0270] In one example, the target cell is a human biofilm cell, for example, the biofilm is a biofilm of the intestine, skin, lung, eye, nose, ear, gastrointestinal tract (GI tract), stomach, hair, kidney, urethra, bronchus, oral cavity, mouth, liver, heart, anus, rectum, bladder, large intestine, small intestine, penis, vagina, or scrotum. In one example, the target cell is an animal biofilm cell, for example, the biofilm is a biofilm of the intestine, skin, lung, eye, nose, ear, gastrointestinal tract (GI tract), cecum, jejunum, ileum, colon, stomach, hair, feathers, scales, kidney, urethra, bronchus, oral cavity, mouth, liver, spleen, heart, anus, rectum, bladder, large intestine, small intestine, penis, vagina, or scrotum. For example, the biofilm is a biofilm of the cecum of an avian (e.g., chicken). For example, the biofilm may be a biofilm in the gastrointestinal tract (GI tract), cecum, jejunum, ileum, colon, or stomach of an avian (eg, chicken).

[0271] In one example, any method herein is ex vivo. In one example, any method herein is in vivo. In one example, any method herein is in vitro. In one example, any method herein is performed in an environment, such as a domestic (e.g., indoors), industrial (e.g., in a factory), or agricultural environment (e.g., outdoors). In one example, any method herein is performed in or on a container, or on a surface.

[0272] In one example, the NSI (or its RNA product) can recombine with a chromosome or episome of a target cell contained in the target cell to modify the chromosome or episome. Optionally, this is done by a method in which the chromosome or episome is cleaved (e.g., at a predetermined site using a guided nuclease such as Cas, TALEN, zinc finger nuclease, or meganuclease) and simultaneously or sequentially a first DNA is introduced into the target cell by conjugation with a carrier cell and the NSI or sequence thereof is inserted into the chromosome or episome at or near the site of the cleavage.

[0273] In one example, the first DNA comprises one or more components of a CRISPR / Cas system operable to effect protospacer cleavage in a target cell (e.g., a protospacer comprises 10-20, 10-30, 10-40, 10-100, 12-15, or 12-20 contiguous nucleotides that can hybridize in a target cell to a crRNA or gRNA encoded by the NSI).

[0274] For example, the system is a type I, II, III, IV, or V CRISPR / Cas system.

[0275] In one example, the NSI encodes Cas9 (and optionally a second, different Cas, e.g., Cas3, Cas9, Cpf1, Cas13a, Cas13b, or Cas10). In one example, the NSI encodes Cas3 (and optionally a second, different Cas, e.g., Cas3, Cas9, Cpf1, Cas13a, Cas13b, or Cas10). In one example, the NSI encodes a Cas selected from Cas3, Cas9, Cpf1, Cas13a, Cas13b, and Cas10. Additionally or alternatively, the first DNA (e.g., the NSI) encodes a guide RNA or crRNA or tracrRNA. For example, the guide RNA or crRNA or tracrRNA is associated with (i.e., operable with) the first Cas in the target cell.

[0276] In one example, the Cas herein is Cas9. In one example, the Cas herein is Cas3. The Cas may be identical to the Cas encoded by the target bacterium.

[0277] In one embodiment, the presence of the NSI or the protein or RNA encoded thereby in the target bacterium mediates the killing of the target cell or the downregulation of the growth or proliferation of the target cell. In one embodiment, the presence of the NSI or the protein or RNA encoded thereby in the target bacterium mediates the switching off or downregulation of the expression of one or more RNAs or proteins encoded by the genome of the target cell.

[0278] In one embodiment, the presence of the NSI or the protein or RNA encoded thereby in the target bacterium mediates the upregulation of the growth or proliferation of the target cell. In one embodiment, the presence of the NSI or the protein or RNA encoded thereby in the target bacterium mediates the switching on or upregulation of the expression of one or more RNAs or proteins encoded by the genome of the target cell.

[0279] In one embodiment, the NSI encodes a component of the CRISPR / Cas system that is toxic to the target bacterium.

[0280] In one embodiment, the first DNA is contained in a plasmid or shuttle vector. In one embodiment, the second DNA is contained in a vector (e.g., a plasmid or shuttle vector), a helper phage (e.g., a helper phagemid), or integrated into the genome of the host bacterial cell.

[0281] Optionally, the target cell lacks a functional endogenous CRISPR / Cas system prior to transfer therein of the first DNA, e.g., the first DNA comprising components of an exogenous CRISPR / Cas system that is functional in and toxic to the target cell. One embodiment provides an antimicrobial composition comprising a plurality of the carrier cells of the invention, each of which optionally comprises a target cell according to this paragraph, for administration to a human or animal subject for medical use.

[0282] In one example, the composition of the present invention is a herbicide, a pesticide, an insecticide, a plant fertilizer, or a cleaning agent.

[0283] Optionally, the target bacteria herein are contained in the microbiome of a subject, such as the gut microbiome. Alternatively, the microbiome is the microbiome of the skin, scalp, hair, eye, ear, mouth, throat, lung, blood, rectum, anus, vagina, scrotum, penis, nose, or tongue.

[0284] In one example, the subject (e.g., a human or animal) is further administered a pharmaceutical agent, either simultaneously or sequentially with administration of the carrier cells. In one example, the pharmaceutical agent is an antibiotic, an antibody, an immune checkpoint inhibitor (e.g., an anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody), an adoptive cell therapy (e.g., CAR-T therapy), or a vaccine.

[0285] In one embodiment, the NSI encodes a guided nuclease, such as a Cas nuclease, a TALEN, a zinc finger nuclease, or a meganuclease.Thus, the toxic agent may comprise a guided nuclease, such as a Cas nuclease, a TALEN, a zinc finger nuclease, or a meganuclease.Optionally, the NSI encodes a restriction nuclease that can cut the chromosome of the target cell.

[0286] Optionally, the composition is a pharmaceutical composition for use in medical practice in human or animal subjects.

[0287] In one example, the animal is a livestock or companion pet animal (e.g., a cow, pig, goat, sheep, horse, dog, cat, or rabbit). In one example, the animal is an insect (an insect at any stage of its life cycle, e.g., egg, larva, or pupa). In one example, the animal is a protozoan. In one example, the animal is a cephalopod.

[0288] Optionally, the composition is a herbicide, a pesticide, a food or beverage processing agent, a food or beverage additive, a petrochemical or fuel processing agent, a water purification agent, a cosmetic additive, a detergent additive, or an environmental (e.g. soil) additive or cleaning agent.

[0289] The invention also provides a target bacterial cell or a plurality of target bacterial cells each comprising said first DNA.

[0290] For example, the carrier bacterium is a Lactobacillus (e.g., L reuteri or L lactis), E coli, Bacillus, or Streptococcus (e.g., S thermophilus) bacterium. Usefully, the carrier can protect the first DNA from the surrounding environment. The use of the carrier can be useful for oral administration or other routes, when the carrier can protect the first DNA from the acidic stomach or other harsh environment in the subject. Furthermore, the carrier can be incorporated into beverages, such as probiotic beverages, such as adapted Yakult™, Actimel™, Kevita™, Activa™, Jarrow™, or similar beverages for human consumption.

[0291] Optionally, the carrier cell or composition is for administration to humans or animals for medical use, including killing target bacteria using drugs or expression products of NSI, the target bacteria mediating a disease or condition in the subject. In one example, when the subject is a human, the subject is not an embryo. In one example, the carrier cell is a probiotic in the subject.

[0292] The present invention also provides a method for killing target bacterial cells in an environment, optionally the method is not performed in a human or animal body, the method comprises exposing the environment to a carrier cell or composition of the present invention to express a product of NSI in the target cells, and the target bacteria is killed in the presence of said product. For example, the product encodes a CRISPR / Cas system or a component thereof, such as the system or component disclosed herein. Thus, the system can recognize and cleave the chromosomal protospacer sequence of the target cell, thereby killing the target cell. Optionally, the killed target cells are isolated in a further step.

[0293] The invention also provides the use of a composition or cell of the invention in the manufacture of an antibacterial agent which kills a target bacterium, for the treatment of a disease or condition in a human or animal subject which involves the target bacterium.

[0294] Optionally, the environment is a soil microbiome; a plant, a plant part (e.g., a leaf, fruit, vegetable, or flower) or a plant product (e.g., pulp); water; a waterway; a fluid, a foodstuff or component thereof; a beverage or component thereof; a medical device; a cosmetic; a detergent; blood; a bodily fluid; a medical apparatus; an industrial apparatus; an oil rig; a petrochemical process; a storage or transport apparatus; a vehicle or a container.

[0295] Optionally, the environment is an ex vivo bodily fluid (eg, urine, blood, blood products, sweat, tears, sputum, or saliva), bodily solids (eg, feces), or tissue of a human or animal subject to which the composition has been administered.

[0296] Optionally, the environment is an in vivo bodily fluid (e.g., urine, blood, a blood product, sweat, tears, sputum, or saliva), bodily solids (e.g., feces), or tissue of a human or animal subject to which the composition has been administered.

[0297] In one embodiment, the first DNA is contained in a phagemid or a cloning vector (eg, a shuttle vector, such as a pUC vector).

[0298] In one embodiment, the second DNA is contained in the chromosome of the bacterial carrier cell.

[0299] Optionally, the toxic agent comprises a DNA sequence encoding one or more components of a CRISPR / Cas system, such as one or more components of a Type I Cascade (e.g., CasA).

[0300] Optionally, the toxic agent comprises a DNA sequence encoding a guided nuclease, such as a Cas nuclease, a TALEN, a zinc finger nuclease, or a meganuclease.

[0301] In one example, the carrier cell or composition is contained in a medical container, such as a syringe, vial, IV bag, inhaler, eye dropper, or nebulizer. In one example, the carrier cell or composition is contained in a sterile container. In one example, the carrier cell or composition is contained in a container adapted for medical use. In one example, the carrier cell or composition is contained in a fermentation vessel, such as a metal, glass, or plastic vessel. In one example, the carrier cell or composition is contained in an agricultural device. In one example, the carrier cell or composition is contained in a food manufacturing or processing device. In one example, the carrier cell or composition is contained in a horticultural device. In one example, the carrier cell or composition is contained in a farming device. In one example, the carrier cell or composition is contained in a petrochemical recovery or processing device. In one example, the carrier cell or composition is contained in a distillation device. In one example, the carrier cell or composition is contained in a cell culture vessel (e.g., having a volume of at least 50, 100, 1000, 10000, or 100000 liters). Additionally or alternatively, the target cell is contained in any of these devices, etc.

[0302] In one example, the carrier cell or composition is included in a pharmaceutical, e.g., in combination with instructions or a package label that includes instructions for administering the pharmaceutical to a human or animal subject, e.g., by oral, IV, subcutaneous, intranasal, intraocular, vaginal, topical, rectal, or inhalation administration. In one example, the carrier cell or composition is included in an oral pharmaceutical formulation. In one example, the carrier cell or composition is included in an intranasal or ophthalmic pharmaceutical formulation. In one example, the carrier cell or composition is included in a personal hygiene composition (e.g., shampoo, soap, or deodorant) or a cosmetic formulation. In one example, the carrier cell or composition is included in a detergent formulation. In one example, the carrier cell or composition is included in a cleaning formulation, e.g., for cleaning medical or industrial devices or equipment. In one example, the carrier cell or composition is included in a foodstuff, foodstuff ingredient, or foodstuff processing agent. In one example, the carrier cell or composition is included in a beverage, beverage ingredient, or beverage processing agent. In one example, the carrier cell or composition is included in a medical bandage, textile, plaster, or swab. In one example, the carrier cell or composition is included in a herbicide or insecticide. In one example, the carrier cell or composition is included in an insecticide.

[0303] In one example, the CRISPR / Cas component is a component of a type I CRISPR / Cas system. In one example, the CRISPR / Cas component is a component of a type II CRISPR / Cas system. In one example, the CRISPR / Cas component is a component of a type III CRISPR / Cas system. In one example, the CRISPR / Cas component is a component of a type IV CRISPR / Cas system. In one example, the CRISPR / Cas component is a component of a type V CRISPR / Cas system. In one example, the CRISPR / Cas component comprises a nucleotide sequence encoding Cas9 (e.g., S pyogenes Cas9, S aureus Cas9, or S thermophilus Cas9). In one example, the CRISPR / Cas component comprises a nucleotide sequence encoding Cas3 (e.g., E coli Cas3, C dificile Cas3, or Salmonella Cas3). In one example, the CRISPR / Cas component comprises a nucleotide sequence encoding Cpf. In one example, the CRISPR / Cas component comprises a nucleotide sequence encoding CasX. In one example, the CRISPR / Cas component includes a nucleotide sequence encoding CasY.

[0304] In one example, each carrier cell encodes a CRISPR / Cas component or protein of interest from a nucleotide sequence (NSI) that includes a promoter operable in the target bacterium.

[0305] Optionally, the target bacterium is a Gram-negative bacterium (e.g., Spirulina or Vibrio). Optionally, the target bacterium is a Gram-positive bacterium. Optionally, the target bacterium is a Mycoplasma, Chlamydia, Spirochete, or Mycobacterium bacterium. Optionally, the target bacterium is a Streptococcus (e.g., Pyogenes or Thermophilus). Optionally, the target bacterium is a Staphylococcus (e.g., Aureus, e.g., MRSA). Optionally, the target bacterium is E. coli (e.g., O157:H7), e.g., Cas is encoded by the vector, or endogenous target cell Cas nuclease (e.g., Cas3) activity is derepressed. Optionally, the target bacterium is a Pseudomonas (e.g., Syringae or Aeruginosa). Optionally, the target bacterium is a Vibro (e.g., cholerae (e.g., O139) or Vulnificus). Optionally, the target bacterium is Neisseria (e.g., gonorrhoeae or meningitidis). Optionally, the target bacterium is Bordetella (e.g., pertussis). Optionally, the target bacterium is Haemophilus (e.g., influenzae). Optionally, the target bacterium is Shigella (e.g., dysenteriae). Optionally, the target bacterium is Brucella (e.g., abortus). Optionally, the target bacterium is a Francisella host. Optionally, the target bacterium is Xanthomonas. Optionally, the target bacterium is Agrobacterium. Optionally, the target bacterium is Erwinia. Optionally, the target bacterium is Legionella (e.g., pneumophila). Optionally, the target bacterium is Listeria (e.g., monocytogenes). Optionally, the target bacterium is Campylobacter (e.g., jejuni). Optionally, the target bacterium is Yersinia (e.g., pestis). Optionally, the target bacterium is a Borelia (e.g., burgdorferi). Optionally, the target bacterium is a Helicobacter (e.g., pylori). Optionally, the target bacterium is a Clostridium (e.g., dificile or botulinum). Optionally, the target bacterium is an Erlichia (e.g., chaffeensis).Optionally, the target bacterium is Salmonella (e.g., typhi or enterica, e.g., serovar typhimurium, e.g., DT104). Optionally, the target bacterium is Chlamydia (e.g., pneumoniae). Optionally, the target bacterium is a Parachlamydia host. Optionally, the target bacterium is Corynebacterium (e.g., amycolatum). Optionally, the target bacterium is Klebsiella (e.g., pneumoniae). Optionally, the target bacterium is Enterococcus (e.g., faecalis or faecim, e.g., linezolid resistant). Optionally, the target bacterium is Acinetobacter (e.g., baumannii, e.g., multidrug resistant).

[0306] Further examples of target cells are as follows: 1. Optionally, the target bacteria is a Staphylococcus aureus cell that is resistant to an antibiotic selected from, for example, methicillin, vancomycin, linezolid, daptomycin, quinupristin, dalfopristin, and teicoplanin. 2. Optionally, the target bacteria is a Pseudomonas aeruginosa cell that is resistant to an antibiotic selected from, for example, cephalosporins (e.g., ceftazidime), carbapenems (e.g., imipenem or meropenem), fluoroquinolones, aminoglycosides (e.g., gentamicin or tobramycin), and colistin. 3. Optionally, the target bacterium is, for example, a Klebsiella (eg, pneumoniae) cell that is resistant to a carbapenem. 4. Optionally, the target bacterium is a Streptococcus (eg, thermophilus, pneumoniae, or pyogenes) cell that is resistant to an antibiotic selected from, for example, erythromycin, clindamycin, beta-lactams, macrolides, amoxicillin, azithromycin, and penicillin. 5. Optionally, the target bacterium is a Salmonella (eg, serovar Typhi) cell that is resistant to an antibiotic selected from, for example, ceftriaxone, azithromycin, and ciprofloxacin. 6. Optionally, the target bacterium is a Shigella cell that is resistant to an antibiotic selected from, for example, ciprofloxacin and azithromycin. 7. Optionally, the target bacterium is a mycobacterium tuberculosis cell that is resistant to an antibiotic selected from, for example, resistance to isoniazid (INH), rifampicin (RMP), fluoroquinolones, amikacin, kanamycin, and capreomycin, and azithromycin. 8. Optionally, the target bacterium is an Enterococcus cell, for example, resistant to vancomycin. 9. Optionally, the target bacterium is an Enterobacteriaceae cell that is resistant to an antibiotic selected from, for example, cephalosporins and carbapenems. 10. Optionally, the target bacteria is an E. coli cell that is resistant to an antibiotic selected from, for example, trimethoprim, itrofurantoin, cephalexin, and amoxicillin. 11. Optionally, the target bacterium is a Clostridium (e.g., dificile) cell that is resistant to an antibiotic selected from, for example, a fluoroquinolone antibiotic and a carbapenem. 12. Optionally, the target bacteria is a Neisseria gonnorrhoea cell that is resistant to an antibiotic selected from, for example, cefixime (eg, an oral cephalosporin), ceftriaxone (an injectable cephalosporin), azithromycin, and tetracycline. 13. Optionally, the target bacterium is an Acinetobacter baumannii cell that is resistant to an antibiotic selected from, for example, beta-lactams, meropenems, and carbapenems. 14. Optionally, the target bacterium is a Campylobacter (eg, jejuni) cell that is resistant to an antibiotic selected from, for example, ciprofloxacin and azithromycin. 15. Optionally, the target cell produces beta (β)-lactamase (e.g., ESBL-producing E coli or ESBL-producing Klebsiella). 16. Optionally, the target cell is a bacterial cell resistant to an antibiotic recited in any one of Examples 1 to 14.

[0307] In one example, the target cell is a cell of a species selected from Shigella, E. coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas, and Enterobacter.

[0308] Optionally, the composition includes a carrier cell capable of conjugatively transferring the first DNA into a target cell of a species selected from two or more of Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas, and Enterobacter, either individually or in combination.

[0309] In one example, the reduction in growth or proliferation of carrier cells is at least 50, 60, 70, 80, 90, or 95%. Optionally, the composition or carrier cells are administered simultaneously or sequentially with an antibiotic that is toxic to target cells. For example, the antibiotic can be any antibiotic disclosed herein.

[0310] Optionally, expression of the NSI is under the control of an inducible promoter operable in the target cell. Optionally, expression of the NSI is under the control of a constitutive promoter operable in the target cell.

[0311] In embodiments, the first DNA (e.g., contained in a plasmid) comprises a screenable or selectable marker gene, for example, a selectable marker gene is an antibiotic resistance gene.

[0312] The carrier bacteria may be a species or genus of bacteria selected from the species or genera appearing in Table 5. For example, the species is found in warm-blooded animals (e.g., domestic vertebrates). For example, the species is found in humans. For example, the species is found in plants. Preferably, non-pathogenic bacteria that colonize non-sterile parts of the human or animal body (e.g., skin, gastrointestinal tract, urogenital area, mouth, nasal passages, throat and upper respiratory tract, ears, and eyes) are utilized as carrier cells, and in one example, the method of the present invention is used to combat target cell bacterial infections in such parts of the human or animal body. In another embodiment, the infection is a systemic infection. Examples of particularly preferred carrier bacterial species include, but are not limited to, non-pathogenic strains of Escherichia coli (E. coli F18, S17, and E. coli Nissle strains), various species of Lactobacillus (e.g., L. casei, L. plantarum, L. paracasei, L. acidophilus, L. fermentum, L. zeae, and L. gasseri), or other skin- or GI-colonizing non-pathogenic or probiotic bacteria, such as Lactococcus, Bifidobacteria, Eubacteria, and bacterial minicells, which are anucleoid cells that are destined to die but can still transfer plasmids (e.g., Adler et al., Proc. Natl. Acad. Sci. USA 57;321-326, 1970; Frazer and Curtiss III, Current Topics in Microbiology and Immunology 69:1-84, 1975; Curtiss (See U.S. Patent No. 4,968,619 to Ill.). In some embodiments, the target recipient cells are pathogenic bacteria contained in humans, animals, or plants, for example on the skin or in the gastrointestinal tract, genitourinary area, mouth, nasal passages, throat and upper respiratory tract, eyes, and ears.Of particular interest for targeting and eradication are pathogenic strains of Pseudomonas aeruginosa, Escherichia coli, Staphylococcus pneumoniae, and other species, Enterobacter spp., Enterococcus spp., and Mycobacterium tuberculosis. In one example, the genus or species of the target cell is any of the genus or species listed in Table 5.

[0313] The present invention finds use in a wide variety of settings or environments, such as therapeutic, agricultural or other settings, including but not limited to those described in U.S. Patent Nos. 6,271,359, 6,261,842, 6,221,582, 6,153,381, 6,106,854, and 5,627,275. Other uses are discussed herein, and still other uses will be readily apparent to those of skill in the art.

[0314] Numerous kinds of plasmids containing the first DNA are suitable for use in the present invention. In this respect, those skilled in the art will recognize that a single carrier bacterial strain may contain two or more such plasmids (e.g., different antibacterial agents that they encode). In addition, in another example, two or more different carrier bacterial strains, each containing one or more such plasmids, may be combined for multi-target effect, i.e., to kill two or more different target species or strains, or to kill cells of the same species or strain of target cells.

[0315] The present invention has applications in human treatment and various veterinary, agricultural, horticultural, and food processing applications. For human and veterinary applications, the following modes of administration of the carrier bacteria of the present invention are contemplated depending on the cell population or tissue targeted for protection: topical, oral, nasal, ocular, otic, pulmonary (e.g., via inhaler), ophthalmic, rectal, genitourinary, subcutaneous, intraperitoneal, and intravenous. The bacteria can be provided as a pharmaceutical composition in a delivery vehicle suitable for the mode of administration selected for the patient to be treated. The term "patient" or "subject" as used herein refers to a human or an animal (e.g., an animal is particularly useful as a model for the clinical efficacy of a particular donor strain, or is a domesticated or livestock animal). Commercially relevant animals are chickens, turkeys, ducks, catfish, salmon, cod, herring, lobsters, shrimp, prawns, cattle, sheep, goats, pigs, goats, geese, or rabbits.

[0316] For example, to deliver the carrier bacteria to the gastrointestinal tract or nasal passages, preferred modes of administration may be oral ingestion or nasal aerosol, or feeding (alone or incorporated into the subject's feed or food, and / or beverage, e.g., drinking water). In this regard, the carrier cells may be included in the food of livestock (or farmed or companion animals), e.g., the carrier bacteria may be included in a food additive for livestock. Alternatively, the additive is a beverage (e.g., drinking water) additive for livestock. It is noted that probiotic bacteria such as Lactobacillus acidophilus are sold as gel capsules containing a freeze-dried mixture of bacterial cells and a solid support such as mannitol. When the gel capsule is ingested with liquid, the freeze-dried cells are rehydrated and become viable colony-forming bacteria. Thus, in a similar manner, the carrier bacterial cells of the present invention may be supplied as a powdered freeze-dried formulation, in gel capsules or in bulk, e.g., for sprinkling on food or beverages. The rehydrated, viable bacterial cells then reside and / or colonize sites throughout the upper and / or lower gastrointestinal system and subsequently come into contact with the target bacteria.

[0317] For topical application, the carrier bacteria can be formulated as an ointment or cream to be applied onto the affected skin surface. The ointment or cream formulations are also suitable for rectal or vaginal delivery, along with other standard formulations such as suppositories. Appropriate formulations for topical, vaginal, and rectal administration are well known to medicinal chemists.

[0318] The present invention is particularly useful for topical or transmucosal administration to treat a variety of bacterial infections or unwanted conditions associated with bacteria. Some representative examples of these uses include: (1) conjunctivitis caused by Haemophilus sp. and corneal ulcers caused by Pseudomonas aeruginosa; (2) otitis externa caused by Pseudomonas aeruginosa; (3) chronic sinusitis caused by many gram-positive cocci and gram-negative bacilli, or general decontamination of the bronchial tubes; (4) cystic fibrosis associated with Pseudomonas aeruginosa; (5) enteritis caused by Helicobacter pylori, Escherichia coli, Salmonella typhimurium, Campylobacter, or Shigella sp. (e.g., to treat or prevent gastric ulcers); (6) open wounds, e.g., surgical or non-surgical, as a preventative measure; (7) burns to remove Pseudomonas aeruginosa or other gram-negative pathogens; (8) treatment of inflammatory bowel disease, e.g., in the setting of inflammation, such as in the setting of inflammation ... These include the treatment of acne caused by, for example, Propionibacterium acnes, (9) nasal or skin infections caused, for example, by Methicillin-resistant Staphylococcus aureus (MSRA), (10) body odor caused, for example, by gram-positive anaerobic bacteria (i.e., the use of carrier cells in deodorants), (11) bacterial vaginosis, for example, associated with Gardnerella vaginalis or other anaerobic bacteria, and (12) gingivitis and / or dental caries caused by various organisms.

[0319] In one example, the target cells are E. coli cells and the disease or condition to be treated in humans is an infection of the uterine tract or a respiratory related infection, such as pneumonia.

[0320] In other embodiments, the carrier cells of the present invention have application in treating surfaces to remove or attenuate undesirable target bacteria, for example, in a method for treating such surfaces or environments containing target bacteria, which method includes contacting the surface or environment with the carrier bacteria of the present invention to conjugately transfer the first DNA of the present invention from the carrier to the target bacteria, and allowing the antibacterial agent to kill the target cells. For example, surfaces used in surgery, catheter insertion, and other invasive procedures may be treated to prevent infection of subjects by bacterial contamination on the surface. It is contemplated that the methods and compositions of the present invention can be used to treat numerous surfaces, objects, materials, etc., such as medical or emergency equipment, nursing facilities, and kitchen equipment and surfaces, to control bacterial contamination thereon.

[0321] Pharmaceutical preparations or other compositions containing carrier bacteria can be formulated into dosage unit forms for ease of administration and uniformity of dosage. Dose unit form, as used herein, refers to a physically discrete unit of pharmaceutical preparation suitable for the patient or plant or environment or surface to be treated. Each dose must contain a calculated amount of carrier bacteria to produce the desired antimicrobial effect in association with the selected carrier. Procedures for determining appropriate dosage units are well known to those skilled in the art. Dose units may be proportionally increased or decreased based on the weight of the patient, plant, surface, or environment. Appropriate concentrations for achieving eradication of pathogenic target cells (e.g., contained in the patient's tissue) may be determined by calculation of dose-concentration curves known in the art.

[0322] Other uses of the carrier bacteria of the invention are also contemplated. These include various agricultural, horticultural, environmental, and food processing applications. For example, in agriculture and horticulture, various plant pathogenic bacteria can be targeted to minimize plant disease. One example of a plant pathogen suitable for targeting is Erwinia (e.g., E amylovora, the causative agent of fire blight). A similar strategy can be utilized to reduce or prevent wilting of cut flowers. For veterinary or animal husbandry, the carrier cells of the invention may be incorporated into animal feed (chicken, pig, poultry, goat, sheep, fish, shellfish, or cattle feed) to reduce bioburden or to eliminate certain pathogenic organisms (e.g., Salmonella in chickens, turkeys, or other poultry). In other embodiments, the invention may be applied to meat or other foods to eliminate undesirable or pathogenic bacteria (e.g., E coli O157:H7 in meat, or Proteus spp., which contribute to the "fishy" odor of seafood).

[0323] Environmental applications include engineering a carrier bacterium, such as Bacillus thurengiensis and one of its conjugative plasmids, to deliver and conditionally express, for example, an insecticide in addition to or instead of an antimicrobial (e.g., to control mosquitoes that spread malaria or West Nile virus). In such applications, formulation of the carrier bacterium as a solution, aerosol, or gel capsule is contemplated, as are the agricultural and horticultural applications described above or other applications.

[0324] In preferred embodiments of the present invention, certain features are employed in the DNA, plasmids, and carrier cells of the present invention to minimize potential risks associated with the use of engineered DNA or genetically modified organisms in the environment. For example, in environmentally sensitive situations, it would be advantageous to utilize DNA or plasmids that are not self-transmissible. Instead, the DNA or plasmid is rendered mobile by the conjugation machinery but not self-transmissible. This can be accomplished in some embodiments by integrating all or part of the tra genes, whose products are necessary for assembly of the conjugation machinery, into the chromosome of the carrier cell. In such embodiments, the DNA or plasmid of the present invention is constructed with an origin of transfer (oriT) but no tra genes provided to the chromosome of the cell. This feature prevents the recipient killer cell from further transferring the killer DNA or plasmid before or even after it has been killed. Another biosafety feature includes utilizing a conjugation system with a defined host range. Some elements are known to function only in a few related bacteria (narrow host range), while others are known to function in many unrelated bacteria (broad host range or promiscuous) (del Solar et al., Mol. Microbiol. 32:661-666, 1996; Zatyka and Thomas, FEMS Microbiol. Rev. 21:291-319, 1998). Also, many of these conjugation systems can function in either Gram-positive or Gram-negative bacteria, but generally not in both (del Solar, 1996, supra; Zatyka and Thomas, 1998).

[0325] The inadvertent propagation of antibiotic resistance can be minimized in embodiments by avoiding the use of antibiotic resistance markers in the DNA or plasmids of the invention that are conjugatively transferred into target cells. In an alternative approach, a gene involved in the synthesis of an amino acid (i.e., serine) can be mutated to generate a requirement for this amino acid in the donor. Such mutant bacteria will grow in media lacking serine, provided that they contain a plasmid whose product has the ser gene required for growth. Thus, the present invention contemplates the advantageous use of plasmids that contain a ser gene or another nutritional gene marker. These markers allow for the selection and maintenance of the DNA or plasmid in the carrier cell. Another biosafety approach involves the use of restriction modification systems to regulate the host range of the DNA or plasmid. Conjugation and plasmid establishment are expected to occur more frequently between taxonomically related species in which the plasmid can replicate evading the restriction system. Type II restriction endonucleases create double-stranded breaks in or near a specific recognition sequence in double-stranded DNA. Related modification enzymes can methylate the same sequence to protect it from cleavage. Restriction modification systems (RM) are ubiquitous in bacteria and archaea, but not in eukaryotic cells. Some RM systems are encoded by plasmids, while others are located on bacterial chromosomes (Roberts and Macelis, Nucl. Acids Res. 24:223-235, 1998). Restriction enzymes cleave foreign DNA, such as viral or plasmid DNA, if this DNA has not been modified by the appropriate modification enzyme. In this way, cells are protected from the invasion of foreign DNA. Thus, cleavage by one or more restriction enzymes can be avoided by using carrier strains that produce one or more methylases. Site-directed mutagenesis is used to produce plasmid DNA that lacks a specific restriction site or contains a novel site, making the plasmid DNA protected or vulnerable to endonucleases, respectively.Broad host range plasmids (e.g., RP4) can escape restriction systems by simply not having many of the restriction cleavage sites typically present on narrow host range plasmids (Willkins et al., 1996, J. Mol. Biol 258, 447-456). Preferred embodiments of the present invention also utilize environmentally safe bacteria as carriers. For example, delivery of DNA vaccines by attenuated intracellular gram-positive and gram-negative bacteria has been reported (Dietrich et al., 2001 Vaccine 19, 2506-2512; Grillot-Courvalin et al, 1999 Current Opinion in Biotech. 10, 477-481). Furthermore, the donor strain may be one of the thousands of harmless bacteria that colonize non-sterile parts of the body (e.g., skin, gastrointestinal, genitourinary, oral, nasal passages, throat, and upper respiratory systems). Examples of preferred donor (i.e., carrier) bacterial species are described herein above.

[0326] In another strategy, carrier cells that do not divide or grow are used instead of living cells. Minicells and maxicells are well-studied model systems of bacterial cells that are metabolically active but cannot survive on their own. Minicells lack chromosomal DNA and are generated by special mutant cells that undergo cell division without DNA replication. If the cell contains a multicopy plasmid, many of the minicells will contain the plasmid. Minicells do not divide or grow. However, minicells carrying conjugative plasmids can transfer plasmid DNA to living recipient cells by conjugative replication (Adler et al., 1970, supra; Frazer and Curtiss, 1975, supra; U.S. Pat. No. 4,968,619, supra). Maxicells can be obtained from strains of E. coli that carry mutations in key DNA repair pathways (recA, uvrA, and phr). Because maxicells lack many DNA repair functions, they are killed by low doses of UV irradiation. Importantly, plasmid molecules that are not UV-irradiated (e.g., pBR322) continue to replicate. Under such conditions, (plasmid-directed) replication and translation can occur efficiently (Sancar et al., J. Bacteriol. 137:692-693, 1979), and proteins produced before irradiation are sufficient to maintain conjugation. This is supported by two observations: i) cells killed by streptomycin remain active donors; ii) transfer of conjugative plasmids can occur in the presence of antibiotics that prevent de novo gene expression (Heineman and Ankenbauer, 1993, J. Bacteriol. 175, 583-588; Cooper and Heineman, 2000. Plasmid 43, 171-175). Thus, UV-treated maxicells are able to transfer plasmid DNA into living recipients. It should also be noted that the conservation of recA and uvrA genes among bacteria allows maxicells of donor strains other than E. coli to be obtained.

[0327] Any modified bacteria that are unable to function because they contain temperature sensitive mutations in genes encoding essential cellular functions (e.g., cell wall, protein synthesis, RNA synthesis as described in U.S. Pat. No. 4,968,619, supra) are also contemplated for use in the present invention.

[0328] In one option, archaea are used instead of bacteria for the carrier cells. Additionally or alternatively, the target cells are archaea cells.

[0329] As used herein, the term "carrier cells" includes dividing and / or non-dividing bacterial cells (minicells and maxicells), or conditionally non-functional cells.

[0330] In one example, the first DNA is contained in an engineered RK2 plasmid (i.e., an RK2 plasmid modified by recombinant DNA techniques, or a descendant of such a modified plasmid). Plasmid RK2 is a promiscuous plasmid capable of replicating in 29 (and possibly more) Gram-negative species (Guiney and Lanka, 1989, p27-54. In CMThomas (ed) Promiscuous plasmids in gram-negative bacteria. London, Ltd London United Kingdom). Plasmid RK2 is a 60 kb self-transmissible plasmid whose complete nucleotide sequence is known (Pansegrau et al., 1994, J. Mol. Biol. 239, 623-663). Derived from this large plasmid, a minimal replicon has been obtained that lacks all genes except for the trfA gene, which encodes the Rep protein of the plasmid, called TrfA, and oriV, the origin of vegetative replication. For a review of RK2 replication and its regulation by the TrfA protein, see Helinski et al., 1996 (In Escherichia coli and Salmonella Cellular and Molecular Biology, Vol. 2 (ed. F. Neidhardt, et al., 2295-2324, ASM Press, Washington DC).

[0331] In one example, the first DNA is contained in an engineered R6K plasmid (ie, an R6K plasmid that has been modified by recombinant DNA techniques, or a progeny of such a modified plasmid).

[0332] The present invention is optionally for or used in a method for industrial or domestic use, for example for or in the agriculture, oil or petroleum industry, food or beverage industry, clothing industry, packaging industry, electronics industry, computer industry, environmental industry, chemical industry, aerospace industry, automotive industry, biotechnology industry, medical industry, health care industry, dental industry, energy industry, consumer products industry, pharmaceutical industry, mining industry, cleaning industry, forestry industry, fishery industry, leisure industry, recycling industry, cosmetics industry, plastics industry, pulp or paper industry, textile industry, clothing industry, leather or suede or animal leather industry, tobacco industry, or steel industry.

[0333] Optionally, the invention is for use in industry, or the environment is an industrial environment, the industries being medical and healthcare, pharmaceutical, human food, feed, fertilizer for plants, beverages, dairy, meat processing, agriculture, livestock, poultry, fish and seafood, veterinary medicine, oil, gas, petrochemical, water treatment, sewage treatment, packaging, electronics and computers, personal healthcare and toiletries, cosmetics, dentistry, non-medical dentistry, ophthalmology, non-medical ophthalmology, mining and mineral processing, metal mining and metal processing, quarrying, aviation, automotive, railways, The industry is in a sector selected from the group consisting of the sectors of transportation, space, environment, soil treatment, pulp and paper, clothing manufacturing, dyes, printing, adhesives, air conditioning, solvents, biodefense, vitamin supplementation, cryopreservation, textile steeping and production, biotechnology, chemicals, industrial cleaning products, household cleaning products, soaps and detergents, consumer products, forestry, fisheries, leisure, recycling, plastics, leather, leather and suede, waste management, funerals and contracting, fuels, construction, energy, steel, and tobacco.

[0334] In one example, the first DNA comprises a CRISPR array targeted to a target bacterium, and the array comprises one or two or more different spacers (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more spacers) targeted to the genome of the target bacterium.

[0335] In one example, the target bacteria is included in an environment, as follows: In one example, the environment is a human microbiome, such as the oral or gut microbiome, or the bloodstream. In one example, the environment is not an environment in or on a human. In one example, the environment is not an environment in or on a non-human animal. In one embodiment, the environment is an air environment. In one embodiment, the environment is an agricultural environment. In one embodiment, the environment is an oil or petroleum recovery environment, such as an oil or petroleum field or well. In one example, the environment is an environment in or on food or beverages for consumption by humans or non-human animals. In one example, the environment is a marine environment, such as seawater or on a ship (e.g., ballast water of a ship or boat).

[0336] In one example, the environment is a human or animal microbiome (e.g., the gut, vagina, scalp, axilla, skin, or oral microbiome). In one example, the target bacteria is contained in a human or animal microbiome (e.g., the gut, vagina, scalp, axilla, skin, or oral microbiome).

[0337] In one example, the carrier bacteria or composition of the present invention is administered or intended for administration to humans or non-human animals intranasally, topically, or orally. Those skilled in the art who wish to treat the microbiome of a human or animal can determine the best route of administration depending on the microbiome of interest. For example, if the microbiome is a gut microbiome, administration can be nasal or oral. If the microbiome is a scalp or axillary microbiome, administration can be topical. If the microbiome is an oral or pharyngeal microbiome, administration can be oral.

[0338] In one example, the environment includes drinking water (e.g., waterways or drinking water for human consumption) or soil. The water is optionally in a heating, cooling, or industrial system, or in a drinking water storage vessel.

[0339] In one example, the carrier and / or target bacteria are Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospir a, Lactobacillus, Leuconostoc, Megamonas, Moryella, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira, Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococc The Firmicutes are selected from Us, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter, and Weisella.

[0340] In one example, the carrier bacteria, composition, use, or method is for reducing pathogenic infection or for balancing intestinal or oral biofilms, such as for treating or preventing obesity or disease in humans or animals, or for treating or preventing GI conditions (e.g., Crohn's disease, IBD, or enteritis).For example, the DNA, carrier bacteria, composition, use, or method is for knocking down Salmomnella, Campylobacter, Erwinia, Xanthomonous, Edwardsiella, Pseudomonas, Klebsiella, Pectobacterium, Clostridium dificile, or E coli bacteria in intestinal biofilms of humans or animals or plants, preferably humans or animals.

[0341] In one example, the animal is, for example, a chicken, and the target bacterium is Salmomnella or Campylobacter. In one example, the animal is, for example, a fish (for example, a catfish or salmon) or a crustacean (for example, a shrimp or lobster), and the target bacterium is Edwardsiella. In one example, the plant is, for example, a potato plant, and the target bacterium is Pectobacterium. In one example, the plant is, for example, a cabbage plant, and the target bacterium is Xanthomonous (for example, X campestris). In one example, the plant is, for example, a marijuana plant, and the target bacterium is, for example, Pseudomonas (for example, P cannabina or P amygdali), Agrobacterium (for example, Atumefaciens), or Xanthomonas (for example, X campestris). In one example, the plant is a hemp plant and the target bacterium is, for example, a Pseudomonas (eg, P cannabina or P amygdali), Agrobacterium (eg, Atumefaciens) or Xanthomonas (eg, X campestris).

[0342] In one example, the disease or condition is cancer, an inflammatory or autoimmune disease or condition, such as obesity, diabetes IBD, a GI tract condition, or an oral condition.

[0343] Optionally, the environment or target bacteria is comprised in an intestinal biofilm, a skin biofilm, an oral biofilm, a throat biofilm, a hair biofilm, an axillary biofilm, a vaginal biofilm, a rectal biofilm, an anal biofilm, an ocular biofilm, a nasal biofilm, a tongue biofilm, a lung biofilm, a liver biofilm, a kidney biofilm, a genital biofilm, a penile biofilm, a scrotal biofilm, a mammary biofilm, an ear biofilm, a urethral biofilm, a labial biofilm, an organ biofilm, or a dental biofilm. Optionally, the environment or target bacteria is comprised in a plant (e.g., tobacco, a crop, a fruit tree, a vegetable, or a tobacco, e.g., on the surface of a plant or comprised in a plant) or in the environment (e.g., soil or water or a waterway or an aqueous liquid).

[0344] In one example, the carrier cell or composition is for treating a disease or condition in an animal or human. In one example, the disease or condition is caused or mediated by infection of target cells contained in a subject or patient. In one example, the disease or condition is associated with infection of target cells contained in a subject or patient. In one example, a symptom of the disease or condition is infection of target cells contained in a subject or patient.

[0345] Optionally, the disease or condition of the human or animal subject is (a) a neurodegenerative disease or condition, (b) a brain disease or condition; (c) a CNS disease or condition; (d) memory loss or damage; (e) a cardiac or cardiovascular disease or condition, such as a heart attack, stroke, or atrial fibrillation; (f) liver disease or condition; (g) kidney disease or condition, e.g., chronic kidney disease (CKD); (h) a disease or condition of the pancreas; (i) a pulmonary disease or condition, such as cystic fibrosis or COPD; (j) gastrointestinal disease or condition; (k) any disease or condition of the throat or mouth; (l) eye disease or condition; (m) a disease or condition of the reproductive organs, such as a disease or condition of the vagina, labia, penis, or scrotum; (n) A sexually transmitted disease or condition, such as gonorrhea, HIV infection, syphilis, or chlamydia infection; (o) ear disease or condition; (p) skin diseases or conditions; (q) a heart disease or condition; (r) nasal diseases or conditions; (s) a blood disease or condition, such as anemia, e.g. anemia of chronic disease or cancer; (t) viral infection, (u) pathogenic bacterial infection; (v) cancer, (w) an autoimmune disease or condition, e.g., SLE; (x) an inflammatory disease or condition, such as rheumatoid arthritis, psoriasis, dermatitis, asthma, ulcerative colitis, colitis, Crohn's disease, or IBD; (y) autism; (z) ADHD,

[0346] (aa) bipolar disorder, (bb) ALS (amyotrophic lateral sclerosis), (cc) osteoarthritis, (dd) congenital or developmental defects or conditions; (ee) miscarriage, (ff) blood coagulation status; (gg) bronchitis, (hh) dry or wet AMD, (ii) neovascularization (e.g., in tumors or the eye); (jj) the common cold, (kk) epilepsy, (ll) fibrosis, e.g. liver or lung fibrosis, (mm) fungal diseases or conditions, such as thrush; (nn) a metabolic disease or condition, such as obesity, anorexia, diabetes, type I or type II diabetes, (oo) ulcers, e.g. gastric or skin ulcers, (pp) dry skin, (qq) Sjögren's syndrome, (rr) Cytokine storm, (ss) deafness, loss of or damage to hearing; (tt) a slowed or accelerated metabolism (hence slowed or accelerated compared to the average for the subject's weight, sex, and age); (uu) Fertility disorders, e.g. infertility or subfertility; (vv) Jaundice; (lol) Skin rash, (xx) Kawasaki disease, (yy) Lyme disease, (zz) allergies, e.g., allergies to nuts, grass, pollen, house dust mites, cat or dog fur or dander;

[0347] (aaa) malaria, typhoid fever, tuberculosis, or cholera; (bbb) Depression, (ccc) Mental retardation, (ddd)microcephaly, (eee) Malnutrition, (fff) conjunctivitis, (ggg) pneumonia, (hhh) Pulmonary embolism, (iii) pulmonary hypertension, (jjj) Bone disorders, (kkk) Sepsis or septic shock, (lll) sinusitis, (mmm) stress (e.g. occupational stress), (nnn) thalassemia, anemia, von Willebrand disease, or hemophilia, (ooo) Shingles or herpes, (ppp) Menstruation, (qqq) Decrease in sperm count is selected from.

[0348] Neurodegenerative or CNS Diseases or Conditions for Treatment or Prevention According to the Invention In one example, the neurodegenerative or CNS disease or condition is selected from the group consisting of Alzheimer's disease, geriatric psychosis, Down's syndrome, Parkinson's disease, Creutzfeldt-Jakob disease, diabetic neuropathy, Parkinsonism, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt-Creutzfeldt-Jakob disease. For example, the disease is Alzheimer's disease. For example, the disease is Parkinsonism.

[0349] In an example where the method of the present invention is carried out on a human or animal subject to treat a CNS or neurodegenerative disease or condition, the method induces the downregulation of Treg cells in the subject, thereby promoting the entry of systemic monocyte-derived macrophages and / or Treg cells across the choroid plexus into the subject's brain, thereby treating, preventing, or reducing the progression of the disease or condition (e.g., Alzheimer's disease). In one embodiment, the method induces an increase in IFN-gamma in the subject's CNS system (e.g., in the brain and / or CSF). In one example, the method restores nerve fibers and / or reduces the progression of nerve fiber damage. In one example, the method restores nerve myelin and / or reduces the progression of nerve myelin damage. In one example, the methods of the present invention treat or prevent a disease or condition disclosed in WO2015136541 and / or the methods can be used in conjunction with any of the methods disclosed in WO2015136541 (the disclosures of this document are incorporated by reference in their entirety herein to provide disclosure of such methods, diseases, conditions, and potential therapeutic agents, e.g., agents such as immune checkpoint inhibitors, e.g., anti-PD-1, anti-PD-L1, anti-TIM3, or other antibodies disclosed herein, that can be administered to a subject to effect treatment and / or prevention of CNS and neurodegenerative diseases and conditions).

[0350] Cancer for treatment or prevention by the method The cancers that can be treated include non-vascularized or substantially non-vascularized tumors, as well as vascularized tumors.Cancers can include non-solid tumors (such as hematological tumors, e.g., leukemia and lymphoma) or can include solid tumors.The types of cancers that can be treated by the present invention include, but are not limited to, carcinomas, blastomas, and sarcomas, as well as certain leukemia or lymphatic malignancies, benign and malignant tumors, and malignant diseases, e.g., sarcomas, carcinomas, and melanomas.Adult tumors / cancers and pediatric tumors / cancers are also included. Hematological cancers are cancers of the blood or bone marrow. Examples of hematological (or hematopoietic) cancers include leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myeloid leukemia, acute myelogenous leukemia, and myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemias (such as chronic myelogenous (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and high-grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndromes, hairy cell leukemia, and myelodysplasia.

[0351] A solid tumor is an abnormal mass of tissue that usually does not contain cysts or areas of fluid. Solid tumors can be benign or malignant. The names of the various types of solid tumors are derived from the type of cells that form them (such as sarcoma, carcinoma, and lymphoma). Examples of solid tumors, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovial tumors, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, lymphoid malignancies, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytic lipocarcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, cholangiocarcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, , testicular tumors, seminoma, bladder cancer, melanoma, and CNS tumors (e.g., gliomas (such as brain stem gliomas and mixed gliomas), glioblastomas (also known as glioblastoma multiforme), astrocytomas, CNS lymphomas, germinomas, medulloblastomas, schwannomas, craniopharyogiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas, oligodendrogliomas, meningiomas, neuroblastomas, retinoblastomas, and brain metastases).

[0352] Autoimmune Diseases for Treatment or Prevention by the Method 1. Acute disseminated encephalomyelitis (ADEM) 2. Acute necrotizing hemorrhagic leukoencephalitis 3. Addison's disease 4. Agammaglobulinemia 5. Alopecia areata 6. Amyloidosis 7. Ankylosing spinal cord disease 8. Anti-GBM / anti-TBM nephritis 9. Antiphospholipid syndrome (APS) 10. Autoimmune angioedema 11. Autoimmune aplastic anemia 12. Autoimmune autonomic neuropathy 13. Autoimmune hepatitis 14. Autoimmune hyperlipidemia 15. Autoimmune immunodeficiency 16.Autoimmune inner ear disease (AIED) 17. Autoimmune myocarditis 18. Autoimmune oophoritis 19. Autoimmune pancreatitis 20. Autoimmune retinitis 21. Autoimmune thrombocytopenic purpura (ATP) 22. Autoimmune thyroid disease 23. Autoimmune urticaria 24. Axonal and neuronal neuropathy 25. Barrow's disease 26. Behcet's disease 27. Bullous pemphigoid 28. Cardiac myopathy 29. Castleman's disease 30. Celiac disease 31. Chagas Disease 32. Chronic Fatigue Syndrome 33. Chronic inflammatory demyelinating polyneuropathy (CIDP) 34. Chronic recurrent multifocal ostomyelitis (CRMO) 35. Churg-Strauss syndrome 36. Cicatricial pemphigoid / benign mucous membrane pemphigoid 37. Crohn's disease 38. Kogans Syndrome 39.Cold agglutinin disease 40. Congenital heart block 41. Coxsackie myocarditis 42.CREST disease 43. Essential mixed cryoglobulinemia 44. Demyelinating neuropathy 45. Dermatitis herpetiformis 46. ​​Dermatomyositis 47. Devic's disease (neuromyelitis optica) 48. Discoid Loops 49. Dressler syndrome 50. Endometriosis

[0353] 51. Eosinophilic esophagitis 52. Eosinophilic fasciitis 53. Erythema nodosum 54. Experimental allergic encephalomyelitis 55. Evans syndrome 56.Fibromyalgia 57. Fibrinating alveolitis 58.Giant cell arteritis (temporal arteritis) 59. Giant cell myocarditis 60. Glomerulonephritis 61. Goodpasture syndrome 62. Polyangiitis endoblastomatosis (GPA) (previously called Wegener's endoblastomatosis) 63. Graves' disease 64. Guillain-Barre syndrome 65. Hashimoto's encephalitis 66. Hashimoto's thyroiditis 67.Hemolytic anemia 68. Henoch-Schonlein purpura 69. Herpes gestationis 70. Hypogammaglobulinemia 71. Idiopathic thrombocytopenic purpura (ITP) 72. IgA nephropathy 73. IgG4-related sclerosing disease 74. Immunomodulatory Lipoproteins 75. Inclusion body myositis 76.Interstitial cystitis 77. Juvenile arthritis 78. Juvenile diabetes (type 1 diabetes) 79. Juvenile myositis 80. Kawasaki syndrome 81. Lambert-Eaton Syndrome 82.Leukocytoclastic vasculitis 83. Lichen planus 84. Lichen sclerosus 85.Ligny conjunctivitis 86. Linear IgA disease (LAD) 87. Lupus (SLE) 88. Lyme disease, chronic 89. Meniere's disease 90. Microscopic polyangiitis 91.Mixed connective tissue disease (MCTD) 92. Mooren's ulcer 93. Mucca-Habermann Disease 94. Multiple sclerosis 95.Myasthenia gravis 96. Myositis 97. Narcolepsy 98. Neuromyelitis Optica (Debicchi's) 99. Neutropenia 100. Ocular cicatricial pemphigoid

[0354] 101.Optic neuritis 102. Relapsing rheumatism 103. PANDAS (Pediatric autoimmune neuropsychiatric disorders associated with streptococcus) 104. Paraneoplastic cerebellar degeneration 105. Paroxysmal nocturnal hemoglobinuria (PNH) 106. Parry-Romberg syndrome 107. Parsonage-Turner syndrome 108. Pars planitis (peripheral uveitis) 109. Pemphigus 110. Peripheral neuropathy 111. Perivenous encephalomyelitis 112. Pernicious anemia 113. POEMS syndrome 114. Polyarteritis nodosa 115. Autoimmune polyglandular syndromes types I, II, and III 116. Rheumatic polymyalgia 117. Polymyositis 118. Post-myocardial infarction syndrome 119. Postpericardiotomy syndrome 120. Progesterone dermatitis 121. Primary biliary cirrhosis 122. Primary sclerosing cholangitis 123. Psoriasis 124. Psoriatic arthritis 125. Idiopathic pulmonary fibrosis 126. Pyoderma gangrenosum 127. Erythroblastic aplasia 128. Raynaud's phenomenon 129. Reactive arthritis 130. Reflex sympathetic dystrophy 131. Reiter's syndrome 132. Relapsing polychondritis 133.Restless legs syndrome 134. Retroperitoneal fibrosis 135. Rheumatic fever 136. Rheumatoid arthritis 137. Sarcoidosis 138. Schmidt syndrome 139.Scleritis 140. Scleroderma 141. Sjögren's syndrome 142. Sperm and testicular autoimmunity 143. Stiff-person syndrome 144. Subacute bacterial endocarditis (SBE) 145. Susac syndrome 146.Sympathetic ophthalmia 147.Takayasu arteritis 148.Temporal arteritis / Giant cell arteritis 149. Thrombocytopenic purpura (TTP) 150. Tolosa-Hunt Syndrome

[0355] 151. Transverse myelitis 152.1 diabetes 153.Ulcerative colitis 154.Undifferentiated Connective Tissue Disease (UCTD) 155. Uveitis 156. Vasculitis 157. Vesicular bullous skin disease 158. Vitiligo 159. Wegener's granulomatosis (now called granulomatosis with polyangiitis (GPA))

[0356] Inflammatory Diseases for Treatment or Prevention by the Method 1. Alzheimer's Disease 2. Ankylosing spondylitis 3. Arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis) 4. Asthma 5. Atherosclerosis 6. Crohn's disease 7. Colitis 8. Dermatitis 9.Diverticulitis 10. Fibromyalgia 11.Hepatitis 12.Irritable Bowel Syndrome (IBS) 13. Systemic lupus erythematosus (SLE) 14. Nephritis 15. Parkinson's disease 16. Ulcerative colitis

[0357] Growth promoters and reduced feed conversion ratio This example demonstrates that antimicrobial agents can be used to target target bacteria to promote growth and enhance FCR in poultry. In this example, a guided nuclease system was used to specifically target Salmonella in poultry. In a first aspect, Provided is a method for promoting the growth of an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering a guided nuclease system or components thereof to the animal and introducing the system or components into a target bacterium contained in the animal, wherein the guided nuclease is capable of recognizing and modifying (e.g., cleaving) a target nucleotide sequence contained in the target bacterium, thereby killing or inhibiting the growth or proliferation of the target bacterium and promoting the growth of the animal. The method is a non-medical method, in which the presence of the target bacteria in an animal can inhibit the growth of the animal, thus reducing the burden of such bacteria in the animal and promoting growth.

[0358] In a second aspect, Provided is a method for increasing feed conversion ratio (FCR) in an animal (e.g., a livestock animal, e.g., a poultry animal), the method comprising administering a guided nuclease system or components thereof to the animal and introducing the system or components into a target bacterium contained in the animal, wherein the guided nuclease is capable of recognizing and modifying (e.g., cleaving) a target nucleotide sequence contained in the target bacterium, thereby killing or inhibiting the growth or proliferation of the target bacterium and increasing the FCR of the animal. The method is a non-medical method, in which the presence of target bacteria in an animal can increase the FCR of the animal, thus reducing the burden of such bacteria in the animal and enhancing the FCR (i.e., reducing the FCR count).

[0359] In a third aspect, Provided is a method for promoting the growth of an animal (e.g., a livestock animal, e.g., a poultry animal), comprising administering to the animal an antimicrobial agent that is toxic to Salmonella bacteria, whereby Salmonella target bacteria contained in the animal are exposed to the agent and killed or the growth or proliferation of the target bacteria is inhibited, thereby promoting the growth of the animal. The method is a non-medical method, in which the presence of the target bacteria in an animal can inhibit the growth of the animal, thus reducing the burden of such bacteria in the animal and promoting growth.

[0360] In a fourth aspect, A method of increasing the feed conversion ratio (FCR) in an animal (e.g., a livestock animal, e.g., a poultry animal) is provided which comprises administering to the animal an antimicrobial agent that is toxic to Salmonella bacteria, whereby Salmonella target bacteria contained in the animal are exposed to the agent and killed or the growth or proliferation of the target bacteria is inhibited, thereby increasing the FCR of the animal.

[0361] The method is a non-medical method, in which the presence of target bacteria in an animal can increase the FCR of the animal, thus reducing the burden of such bacteria in the animal and enhancing the FCR (i.e., reducing the FCR number).

[0362] In any of these embodiments, optionally the animal is a livestock animal. Optionally, the animal is a bird, such as a poultry animal, such as a chicken, turkey, goose, or duck. Preferably, the animal is a chicken.

[0363] In any of these embodiments, optionally the bacterium is an Enterobacteriaciae bacterium, such as Salmonella. For example, the bacterium is Salmonella enterica, typhimurium, or enteritidis. For example, the Salmonella is any Salmonella species or strain disclosed herein.

[0364] For example, the system, component, or agent may be provided to the animal in the animal feed and / or beverage (e.g., mixed into drinking water). When provided in beverages, the system, component, or agent may be contained in a carrier bacterium, and the carrier bacterium may be present in the beverage at a concentration of 1×10 3 ~1×10 10 (For example, 1×10 4 ~1×10 10 , 1×10 4 ~1×10 9 , 1×10 4 ~1×10 8 , 1×10 4 ~1×10 7 , 1×10 3 ~1×10 10 , 1×10 3 ~1×10 9 , 1×10 3 ~1×10 8 , 1×10 3 ~1×10 7 , 1×10 5 ~1×10 10 , 1×10 5 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~1×10 7 , 1×10 6 ~1×10 10 , 1×10 6 ~1×10 9 , 1×10 6 ~1×10 8 , or 1 × 10 6 ~1×10 7 When provided in a beverage, the system, component, or agent is contained in a carrier bacteria, and the carrier bacteria is present in the beverage at a concentration of at least 1×108 cfu / ml, for example the animal is poultry, such as chickens.

[0365] Optionally, the guided nuclease is any guided nuclease disclosed herein, such as Cas, TALEN, meganuclease, or zinc finger nuclease.In one example, the component is a crRNA or guide RNA that can be operated in target cells with associated Cas nuclease.The Cas nuclease can be any Cas nuclease disclosed herein.The Cas nuclease can be the endogenous Cas of the target cell, or can be encoded by exogenous nucleic acid administered to the animal.

[0366] The systems, components and agents of the invention are introduced into the target bacteria by bacterial conjugation (e.g. conjugative transfer from a carrier cell to the target cell) or by phage transducing into the target cell nucleic acid encoding the system, component or agent.

[0367] Optionally, the target bacterium is included in any of the microbial communities disclosed herein found in animals. Preferably, the microbial community is the gut microbiome (e.g., the chicken gut microbiome).

[0368] The livestock animal can be any livestock animal disclosed herein, such as chickens, pigs, cows, sheep, farmed fish (eg, salmon or catfish), or farmed crustaceans (eg, lobsters, prawns, or shrimp).

[0369] It will be understood that the specific embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of the invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize or be able to ascertain, without more than routine investigation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the invention and are encompassed by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains. All publications and patent applications, and all equivalent U.S. patent applications and patents, are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually incorporated by reference. The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and / or specification may mean "one," but this is consistent with the meanings of "one or more," "at least one," and "one or more than one." Although the disclosure supports a definition meaning only alternatives and "and / or," use of the term "or" in the claims is used to mean "and / or" unless expressly indicated to mean only alternatives or the alternatives are mutually exclusive. Throughout this application, the term "about" is used to indicate that a value includes inherent error variation for the device, and methods are employed to determine the variation that exists between the values ​​or subjects.

[0370] As used in this specification and the claims, the words "comprising" (and any form of "comprising", e.g., "comprise" and "comprises"), "having" (and any form of "having", e.g., "have" and "has"), "including" (and any form of "including", e.g., "includes" and "include"), or "containing" (and any form of "containing", e.g., "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0371] The term "or combinations thereof" or similar terms, as used herein, refers to all permutations and combinations of the items listed preceding the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of A, B, C, AB, AC, BC, or ABC, and also at least one of BA, CA, CB, CBA, BCA, ACB, BAC, or CAB, where order is important in a particular context. Continuing with this example, combinations that include repeats of one or more items or terms, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, etc., are expressly included. Those of skill in the art will understand that there is typically no limit to the number of items or terms in any combination, unless otherwise clear from the context.

[0372] Unless otherwise clear from the context, any part of this disclosure may be read in combination with any other part of this disclosure.

[0373] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that modifications can be made to the compositions and / or methods, and to the steps or permutations of the steps of the methods described herein, without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. EXAMPLES

[0374] [Example 1] Evaluation of target gene sequences and design of crRNA arrays List of putative target genes in Salmonella Through careful analysis and determination, the inventors edited the following target genes for evaluation by excision using CRISPR / Cas components delivered by conjugative plasmids from carrier cells according to the present invention: 1) Proteins encoded by the pipA pathogenicity island: SPI5 2) mViM putative virulence factor 3) mViN putative virulence factor 4) phoP: Transcribing genes (OmpR family) that are expressed under low Mg+ concentrations; Pathogenicity transcriptional regulatory protein PHOP 5) hilA, a transcriptional activator of invasion genes 6) BigA: putative surface-exposed virulence protein 7) sugR ATP-binding protein; protein encoded by pathogenicity island: SPI3 8) Protein encoded by the rhuM pathogenicity island: SPI3 9) pipC Invasion gene E protein / pathogenicity island-encoded protein: SPI5 10) Proteins encoded by the pipB pathogenicity island: SPI5 11) sicP: Chaperone involved in pathogenicity 12) sopB invasion gene D protein / protein encoded by pathogenicity island: SPI5 13) marT putative transcriptional regulator / protein encoded by pathogenicity island: SPI3

[0375] Target Selection Initial target selection of Salmonella-specific genes identified 13 putative candidates located almost exclusively in the Salmonella pathogenicity island (listed at the beginning of this example). After detailed inspection, the list of targets was reduced to seven genes, namely pipA, pipB, pipC, hilA, marT, sicP, and sopB, which, importantly, we found did not show significant sequence homology to other Enterobacterial genes, thus allowing high Salmonella cell targeting specificity in vivo and in microbiomes containing different (non-Salmonella) species of non-targeted Enterobacteria. Target sites for S. pyogenes Cas9, defined by the presence of PAM motifs (NGG), were extracted using the respective functions available in molecular biology software. A number of 6 to 14 putative target sites were identified in each of the seven selected genes.

[0376] Design and synthesis of crRNA To select target sites most likely to result in efficient restriction of dsDNA, all potential sequences were screened for the presence of nucleotides at key positions that have been described in the available literature to have a positive or negative effect on the efficiency of the double-stranded break introduced by Cas9. Three publications reported such data, but for sgRNAs. (1)Doench et al. 2014, Nature Biotechnology (2)Gagnon et al. 2014, PLoS One (3)Liu et al. 2016, Scientific Reports

[0377] One target sequence from each gene that was subject to most of the parameters described to affect the efficiency of restriction in each of these three publications was selected for incorporation into the crRNA array, resulting in three arrays being tested. The crRNA array was designed based on the sequence data of S. pyogenes (Deltcheva et al. 2011, published in Nature). The following sequences were constructed: SEQ ID NO: 1-3.

[0378] Two of these sequences encoding crRNAs were assembled with sequences encoding the cognate tracrRNA and Cas9.

[0379] Cas9 construct (tracrRNA-Cas9-crRNA) The selected sequences encoding crRNA were combined with different versions of the tracrRNA-Cas9 module, resulting in an altered set of plasmids.

[0380] For constitutive expression of all components (tracrRNA, Cas9, and crRNA), a tracr-Cas fragment based on plasmid pCas9 (Jiang et al. 2013, Nature Biotechnology, sequence shown in SEQ ID NO: 4) was amplified from gDNA of S. pyogenes. We linked this fragment with an available crRNA coding fragment and cloned it into a high copy number general cloning plasmid pJet1.2. This series of constructs is named pFS1.

[0381] To determine whether this constitutive expression of the CRISPR / Cas construct in a low copy number background works efficiently, we transfer the above system to a low copy number plasmid. The pFS2 construct is therefore based on the low copy number pSC101 origin from pZS21MCS (Expressys).

[0382] To control the expression of at least one of the CRISPR / Cas components by an inducible promoter, we replace the constitutive Cas9 promoter with the TetR-regulated promoter PLtetO-1. The resulting plasmid of pFS3 is also based on the low copy number pSC101 origin of pZS21MCS. The changes introduced are as follows: - The space between the RBS and the initiating ATG has been shortened to 7bp (TAAATAC) - The stop codon is changed from the less efficient TGAC to a tandem TAATAAT sequence.

[0383] Finally, we generate mobilizable versions of constitutively expressed plasmids such as pFS1 and pFS2 described above. To this end, we clone the origin of transfer (oriT) of plasmid RP4 into a medium copy number plasmid (p15A origin) with chloramphenicol resistance. This construct should be able to be mobilized and transferred by a chromosomally integrated conjugation mechanism such as that present in RP4 and other mobilizable plasmids.

[0384] Further Constructions To determine the efficiency of dsDNA restriction by the selected crRNA before final selection and transformation into Salmonella, we aim to clone the target gene (or a large part of it) into a compatible plasmid. The selected plasmid is pZA31MCS (Expressys) with a p15A origin compatible with the pFS1 / pFS2 / pFS3 constructs described above. The efficiency can then be tested in E. coli by loss of chloramphenicol resistance (or loss of fluorescence if a yfp derivative is present as a reporter). The best performing target sequence can then be used in the future as a more targeted plasmid.

[0385] We have constructed the following plasmids: pFSmob-C tracrRNA / Cas9-mob-pZA31MCS pFSmobSal7 tracrRNA / Cas9-Salcr7-3-mob-pZA31MCS pFSmobSal3 tracrRNA / Cas9-Salcr3.2-mob-pZA31MCS pFSmob-C * Control based on Salcr7-3-mob-pZA31MCS

[0386] Plasmid details Plasmid name: pFSmob-C Description: p15A origin plasmid based on pZA31MCS (Expressys) with a 4768bp insert (tracrRNA-Cas9-oriT / mob) Plasmid length: 6685bp Sequence verification: Yes; insert sequence verified by primer walking sequencing Further note: There is no crRNA array; control plasmid

[0387] Plasmid details Plasmid name: pFSmobSal7 Description: p15A origin plasmid based on pZA31MCS (Expressys) with a 5598bp insert (tracrRNA-Cas9-crRNA-oriT / mob) Plasmid length: 7515bp Sequence verification: Yes; insert sequence verified by primer walking sequencing

[0388] Plasmid details Plasmid name: pFSmobSal3 Description: p15A origin plasmid based on pZA31MCS (Expressys) with a 5341bp insert (tracrRNA-Cas9-crRNA-oriT / mob) Plasmid length: 7258bp Sequence verification: Yes; insert sequence verified by primer walking sequencing

[0389] Plasmid details Plasmid name: pFSmob-C * Description: p15A origin plasmid based on pZA31MCS (Expressys) Plasmid length: 7348bp Sequence verification: Yes; insert sequence verified by primer walking sequencing

[0390] [Example 2] Selective elimination of unwanted Salmonella strains by guided nuclease-based conjugation. Research Objective The aim of this study was to selectively eliminate undesirable Salmonella strains by conjugation experiments. We transferred the pFSMobSal7 plasmid from E. coli S17 to Salmonella spp. This plasmid carries tracr-Cas9, an array encoding crRNA (Sal7-3), and an origin of transfer (oriT).

[0391] overview As a proof of concept, E. coli to E. coli conjugation experiments were first performed prior to transfer to Salmonella spp. Plasmid pFSMobSal7 (chloramphenicol resistance, CmR) was first transformed into a carrier strain that allows transfer. In this experiment, the piliated strain was E. coli S17 (ATCC® 47055™). The conjugation function is provided by the RP4 plasmid integrated into the chromosome. The recipient cells should be resistant to nalidixic acid (25 μg / ml), where we used E. coli JM109 (ATCC® 53323™). The targeted Salmonella was FS26 from our Salmonella spp collection. The results showed good conjugation efficiency from E. coli S17 to E. coli JM109 and from E. coli S17 to Salmonella enteritidis (FS26). After conjugation into recipient Salmonella, killing with pFSMob-3 was efficient.

[0392] introduction The pFSmobSal7 plasmid was derived from the intermediate copy number pZA31MCS (Expressys). An origin of transfer (OriT) sequence was synthesized (called mob2) and cloned into pZA31MCS by assembly method along with the tracr-Cas9 and crRNA array fragments.

[0393] Before starting the conjugation experiments, E. coli S17 strains were made electrocompetent by standard protocols (O'Challahan and Charbit, 1990). Plasmids pFSMobsal7 and pFSMobC * was then transformed into E. coli S17 by electroporation and selected in chloramphenicol (Cm30, 30 μg / mL).

[0394] pFSMobSal7 and pFSMobC *were transferred from donor E. coli S17 to recipient E. coli JM109 and nalidixic acid resistant (NalR) and chloramphenicol sensitive (CmS) Salmonella spp. by mating on filters and then incubated at 37° C. The mixture was then plated on Cm30, Nal25, and Cm30+Nal25. Exconjugants were selected in the double antibiotic Cm30+Nal25 (Phornphisutthimas et al, 2007).

[0395] It should be noted that before initiating the conjugation experiments, the killing efficiency of the pFSMob plasmid was first tested by transformation in Salmonella.

[0396] methodology material: - Donor strain: pFSMobSal7 / pFSMobC * E. coli S17 transformed with - Recipient strain: JM109 / Salmonella enteritidis FS26 - Luria-Bertani Broth (LB) (product number L3522, Sigma-Aldrich), LB Cm 30μg / ml - LB agar 1% plates - LB agar 1% Cm 30μg / ml plate - LB agar 1% NaL25μg / ml plate - LB agar 1% Cm30+NaL25 plates - Whatman® membrane filter nylon, pore size 0.45 μm to 1 μm, diameter 25 mm. Reference number 28420770 supplied by Sigma-Aldrich.

[0397] Experiment 1: pFSMobC from E. coli S17 to E. coli JM109 * Movement As a proof of concept, a control plasmid (pFSMobC *We first performed a conjugation experiment from E. coli S17 carrying the 14-kDa plasmid to E. coli JM109, following the protocol of Phornphisutthimas (Phornphisutthimas et al., 2007). 1. Donor pFSMobC from our collection in LB+Cm30 * A culture of (S17) and a culture of the recipient strain JM109 in LB broth are grown overnight. 2. In the morning, before starting the experiment, pre-warm the LB agar (1%) plates for at least 30 minutes. 3. Mix donor and recipient strains in a 1:1 ratio as follows: 4. 50 μl pFSMobC * (S17) + 50 μl of JM109 5. 50 μl pFSMobC * (S17) + 50 μl LB 6. 50 μl LB + 50 μl JM109 7. For each reaction, place a filter membrane (0.45 μM to 1 μM) on top of a pre-warmed LB agar plate (1%). 8. Load each mating sample onto a filter 9. Leave the plates for 3 hours at 37°C without shaking; the LB will be absorbed and the bacteria will remain on the filter. 10. After incubation, place each filter in a universal tube containing 1 ml of LB medium and vortex thoroughly. 11. Inoculate 100 μl (and serial dilutions) onto Cm30, Nal25, and Cm30+Nal25 and leave ON at 37°C.

[0398] The Cm30 plate provides the number of donors. The Nal25 plate provides the number of recipients, and the Nal25+Cm30 plate provides the number of exconjugants (i.e., plasmid transferred from donor to recipient). Plates with only donor and recipient (no mating) are negative controls.

[0399] result 1) After 18 h at 37°C, colonies were counted separately at different dilutions, if countable, and the number of colonies was expressed as cfu / mL. As expected, no colonies were recovered from the negative control plates (data not shown). The results (Table 1) show good conjugation efficiency from E. coli S17 to E. coli JM109.

[0400] [Table 1]

[0401] 2) pFSmobC in the recipient strain * Plasmid transfer was confirmed by PCR. Primers spCas9-6 forward (5'-ATTGTTTGTGGAGCAGCATAAGC) (SEQ ID NO: 8) and mob2 reverse (5'-GCCTCTAGCACGCGTACCATGGGAT) (SEQ ID NO: 9) were used with an annealing temperature of 50°C. Two colonies from the plate with exconjugants were tested by PCR. A positive control was also included (Figure 1).

[0402] Conclusion 1: E. coli to E. coli conjugation experiments show good transfer efficiency. Further optimization studies for E. coli conjugation showed higher conjugation efficiency when the mating was incubated at 37°C for 6 hours at a 1:4 ratio.

[0403] Experiment 2: Conjugation of pFSMobSal7 from E. coli S17 to Salmonella spp. This experiment follows the protocols of Phornphisutthimas (Phornphisutthimas et al., 2007) and Carraro et al., 2017, with some modifications: 1. pFSMobSal7(S17) and control pFSMobC from our collection in LB+Cm30 *A culture of (S17), as well as a culture of the recipient strain Salmonella enteritidis FS26 in LB broth, are grown overnight. 2. In the morning, before starting the experiment, pre-warm the LB agar (1%) plates for at least 30 minutes. 3. Mix donor and recipient strains in a 1:4 ratio as follows: 4. 100 μl pFSMobC * (S17) + 400 μl of Salmonella FS26 5. 100 μl pFSMobSal7(S17) + 400 μl Salmonella FS26 6. 100 μl pFSMobC * (S17) + 400 μl LB 7. 100 μl pFSMobSal7(S17) + 400 μl LB 8. 100 μl LB + 400 μl Salmonella 9. Spin at 2000 x g for 3 minutes 10. Resuspend in 200 μl LB 11. Spin at 2000 x g for 3 minutes 12. Resuspend in 25 μl LB 13. For each reaction, place a filter membrane (0.45 μM to 1 μM) on top of a pre-warmed LB agar plate (1%). 14. Load each mating sample onto a filter 15. Leave the plates for 6 hours at 37°C without shaking; the LB will be absorbed and the bacteria will remain on the filter. 16. After incubation, place each filter in a universal tube containing 1 ml of LB medium and vortex thoroughly. 17. Plate 100 μl (and serial dilutions) onto Cm30, Nal25, and Cm30+Nal25 and leave ON at 37°C.

[0404] The plates on Cm30 plates provide the number of donors, the plates on Nal25 provide the number of recipients, and the plates on Nal25+Cm30 provide the number of exconjugants (i.e., plasmids transferred from donor to recipient).

[0405] result After 18 h at 37°C, colonies were counted individually at dilution-3 and the number of colonies was expressed as cfu / mL (Table 2). As expected, no colonies were recovered on the negative control plates (data not shown).

[0406] [Table 2]

[0407] - Plasmid control pFSMobC * In comparison, these data indicate that the plasmid pFSMobSal7 delivered to the target strain by conjugation can eliminate 100% of the strain Salmonella enteritidis (FS26) (Fig. 2 ).

[0408] conclusion This study demonstrated that conjugation was a good delivery method from E. coli S17 to Salmonella enteritidis (FS26) and that pFSMobSal7 was still efficiently lethal when delivered to a recipient by conjugation: the conjugation was able to eliminate (kill) 100% of the Salmonella.

[0409] References Carraro N, Durand R, Rivard N, Anquetil C, Barrette C, Humbert M, Burrus V. (2017). Salmonella genomic island 1(SGI1) reshapes the mating apparatus of IncC conjugative plasmids to promote self-propagation. PLOS Gen. O'Challahan D,Charbit A. (1990). High efficiency transformation of Salmonella typhimurium and Salmonella typhi by electroporation. Mol. Gen. Genet., 223; 156-8. Phornphisutthimas S, Thamchaipenet A, and Panijpan B. (2007). Conjugation in Escherichia coli. Biochem and Mol Bio Education Vol. 35, No. 6, 440-445

[0410] [Example 3] Pan-serotype conjugation transfer and killing of Salmonella Research Objective The objective of this study was to test the in vitro ability of the pFSmobSal7 and pFSmobSal3 plasmids to selectively cure Salmonella enterica subsp. enterica serovars by conjugation.

[0411] overview Eighteen Salmonella enterica subspecies enterica strains, namely serovars Typhimurium (4), Enteritidis (1), Virchow (1), Montevideo (1), Heidelberg (1), Hadar (1), Binza (1), Bredeney (1), Infantis (1), Kentucky (1), Seftenberg (1), Mbandaka (1), Anatum (1), Agona (1), and Dublin (1), were selected from our Salmonella spp. collection (Table 3). Bacteria were made competent and transformed with two versions of pFSmob plasmids, namely pFSmobSal7 and pFSmobSal3, and two versions of pFSmob control plasmids, namely pFSmob-C and pFSmob-D. *and pFSmob-C, as well as pZA31MCS (Expressys) as an additional control. After electroporation and incubation in SOC Outgrowth medium (NEB, B90205, LOT-10019857) for 2 hours at 37°C, different dilutions of the original solution were transformed with chloramphenicol (Cm 30 The bacteria were plated onto 1% LB agar supplemented with 1000 μg / mL of 100% erythrocyte sedimentation buffer (LB buffer, 30 μg / mL). Plates were incubated at 37° C. for 18 hours. Results were interpreted as colony forming units / mL (CFU / mL).

[0412] introduction The pFSmobSal7 and pFSmobSal3 plasmids carry seven target genes (pipA, pipB, pipC, hilA, sicP, mart, sopB) and three target genes (pipC, hilA, mart) in their crRNA arrays, respectively. The positive control pFSmob-C derived from the pFSmobSal7 plasmid was used, notably pFSmob-C does not carry a crRNA array. The control pFSmob-C derived from the intermediate copy number pZA31MCS (Expressys) was used as an additional control. The selection of positive colonies was performed using chloramphenicol (Cm 30 , 30 μg / mL). The in vitro ability of pFSmobSal7 to selectively eliminate Salmonella enterica serovars Typhimurium, Enteritidis, Virchow, Montevideo, Hadar, and Binza by transformation was previously shown. The aim of this study was to evaluate all Salmonella spp. serovars present in our collection to assess the in vitro ability of both pFSmobSal7 and pFSmobSal3 plasmids to select for undesirable bacteria. In order to collect a large number of results, 18 different serovars were selected from our collection and tested by electroporation (Table 3). Plasmids pFSmob-C, pFSmob-C * , and pZA31MCS (Expressys) were used as controls.

[0413] methodology Bacterial strains were recovered from frozen stocks maintained at -80°C and cultured at 37°C for 24 h (Edwards and Ewing, 1986). 30 Susceptibility to 100 μg / mL of pFSmobSal7, pFSmobSal3, pFSmob-C, pFSmob-C, pFSmob-D, pFSmob-E, pFSmob-F, pFSmob-G, pFSmob-H, pFSmob-I ... * , and pZA31MCS (Expressys). A negative control was also included (competent cells with no added DNA) (Table 4). After 18 h of incubation, countable colonies (number of colonies between 30 and 300) were expressed as colonies per mL (CFU / mL) (Table 4).

[0414] [Table 3]

[0415] result All selected bacteria were classified according to EUCAST breakpoints (EUCAST, 2013). 30 Electroporation and Cm 30 Different dilutions (undiluted, 10 -1 , 10 -2 After inoculation of C. cephalosporin B ... 30Transformed strains were considered to be transformed if they grew on 100 μg / mL agar plates. Countable colonies (between 30 and 300) were expressed as CFU / ml (Table 4). As expected, no colonies were recovered from the negative control plates. All serotypes except one (FS67, S. Dublin) were efficiently transformed with pZA31MCS (Expressys). Nearly all serotypes were efficiently transformed with two control plasmids (pFSmob-C * and pFSmob-C) were efficiently transformed, and 10 2 From 10 6 There were many colonies between CFU / mL.

[0416] For pFSmobSal7 and pFSmobSal3, the killing effects occurred in all serotypes and were found to be similar. In most serotypes, the reduction in colony numbers was relatively obvious compared to those transformed with the control plasmid. Except for one strain (FS38, S. Montevideo), no significant difference was found in their killing effects between pFSmobSal7 and pFSmobSal3.

[0417] [Table 4]

[0418] conclusion All Salmonella spp. serotypes used in this experiment were efficiently rendered competent, and pZA31MCS (Expressys), pFSmob-C, and pFSmob-C, which was used as a control, were transformed into * As previously observed, Salmonella Typhimurium serovars were transformed with pFSmob-C. * More generally, no specific differences were found between the two pFSmob-derived control plasmids used in this study (10 2 From 10 6CFU / mL). Meanwhile, the killing effects of pFSmobSal7 and pFSmobSal3 were found to be similar (10 1 From 10 3 In conclusion, this study demonstrated that pFSmobSal7 and pFSmobSal3 could selectively eliminate different Salmonella spp. serotypes compared to the control plasmid.

[0419] References Edwards PR, Ewing WH. (1986). Identification of Enterobateriaceae (4 th ed.). Elsevier, New York. EUCAST, European Committee on Antimicrobial Susceptibility Testing. (2013). Breakpoint tables for interpretation of MICs and zone diameters. Available at: http: / / www.eucast.org (last accessed August 16, 2013., Version 3.1. O'Challahan D, Charbit A. (1990). High efficiency transformation of Salmonella typhimurium and Salmonella typhi by electroporation. Mol. Gen. Genet., 223;156-8.

[0420] [Example 4] Improving feed conversion in chickens. A second combined 2-week efficacy, 2-week safety, and 6-week productivity trial. Research Objective - To determine the effects of an antimicrobial conjugative plasmid (pFSmobSal7) on chicken health, welfare, and productivity over a 6-week period.

[0421] methodology Ross 308 birds were housed under controlled biosecurity conditions and had free access to water and standard commercial feed.

[0422] Birds were continuously dosed with either: 1. Water without additives (60 birds) 2. 10 8 cfu / ml of strain S17 in drinking water (30 birds). 3. 10 8 cfu / ml of pFSmob-C * Drinking water containing strain S17 (30 birds) 4. 10 8 drinking water containing strain S17 carrying pFSmobSal7 at cfu / ml (60 birds); 5. 10 9 drinking water containing strain S17 carrying pFSmobSal7 at cfu / ml (30 birds); 6. 10 10 drinking water containing strain S17 carrying pFSmobSal7 at cfu / ml (30 birds);

[0423] Bacterial strains were harvested from frozen stocks maintained at -78°C and grown on LB agar at 37°C for 24 hours. To prevent loss of plasmids, cultures were prepared once a day in LB broth containing antibiotics for 16 hours at 37°C with shaking at 180 rpm, then centrifuged at 4000 x g for 10 minutes. The medium was removed and the pellet was resuspended in PBS and then diluted in PBS to obtain a solution for administration to chickens.

[0424] In parallel, 30 birds were fed 10 5CFU / mL of Salmonella Enteritidis strain FS26 (Folium), 0.5 ml, was administered orally on day 1. Birds were confirmed for Salmonella colonization by cloacal swabs using the ISO 6759 method on day 3 of the experiment (1). On day 5 of the experiment, three of these confirmed, Salmonella-colonized birds (seeder birds) were marked and added to each of groups 1-6. Birds were weighed weekly and feed consumption and mortality were recorded.

[0425] Fifteen birds from each group were euthanized on days 12 and 19 (7 and 14 days after mixing with the transmission birds). The cecum was removed for testing for Salmonella by ISO 6759. Knee and foot marks were recorded. Samples of 1 g of liver and cecal contents were flash frozen in liquid nitrogen.

[0426] Thirty birds from each of groups 1 and 4 were then observed for behavior and weight once a week until day 42, at which point the birds were euthanized and examined as described above.

[0427] Results were recorded on paper or dictated over the phone or radio in biosecure accommodation and transcribed into Microsoft Excel™. For data conversion purposes, birds with no detectable bacteria were assigned a count of 1 bacteria per gram. Counts and weights were log transformed and statistical analysis was performed using GraphPad Prism™. Data were assessed for normality of distribution using the D'Agostino and Pearson omnibus normality test and, for non-normality, analysed using the Kruskal-Wallis test with Dunn's multiple comparison post-hoc test. Differences in proportions of birds were analysed using Fisher's exact test.

[0428] result All transmission birds were colonized with Salmonella by day 3. Birds used to transmit infection in the experimental flocks had >10 Salmonella / g feces. 5The cfu counts were:

[0429] On day 7, 15 birds per group were euthanized and Salmonella was measured in the cecum (Figure 3). Figure 4 shows the data representing Salmonella positive / negative birds.

[0430] S17-pFSmobSal7 (lowest dose) and pFSmob-C * Birds receiving the drug had significantly lower numbers of Salmonella in their cecum than controls (Figure 3) and were significantly less likely to have detectable Salmonella in their cecum 7 days after mixing with transmission birds.

[0431] No mortality was observed in any group. No morbidity was observed and the high dose of S17-mobSal7 was well tolerated. Birds were scored for positive and negative behavior and no differences were found between the groups.

[0432] Thirty birds from each of groups 1 and 4 were further observed until 42 days of age. Again, no significant differences in behavior were found during this period. Feed consumption between groups was not significantly different, and weights were not significantly different between groups measured while alive. After mortem, Salmonella was undetectable in the cecum by direct counting. No knee or foot marks were observed. The median carcass weight of birds in the S17-pFSmobSal7 group was 205 g greater than that in the control group, a significant increase (Figure 5). This was accompanied by comparable feed consumption between groups, so that the S17-pFSmobSal7 group had a significantly improved feed conversion ratio (FCR).

[0433] References ISO. 2007. ISO 6579:2007: Microbiology of food and animal feeding stuffs - Horizontal method for the detection of Salmonella spp. (ISO 6579:2002+Amd 1:2007). Geneva, Switzerland

[0434] [Example 5] Non-replicative conjugative plasmids carrying conditionally essential gene markers To meet regulatory requirements, all plasmids used preferably do not have antibiotic selection markers and are non-replicative in most, if not all, cells except the host cell (i.e., carrier cell). To render the plasmids non-replicative, we utilize the replication system of the broad-host-range plasmid RK2, which is an extremely low-copy-number plasmid. Replication of RK2 relies on the presence of a replication protein, TrfA, encoded by trfA on RK2, and binding of TrfA to the plasmid's origin of replication (oriV), and does not utilize the host machinery for initiation of replication. Physical separation of trfA from the plasmid and integration of this gene into the chromosome results in a plasmid with RK2 oriV that relies on host-encoded functions. This prevents the plasmid from actively replicating in the target strain after delivery via conjugation. In the rare case where an identical IncP plasmid is present in a target cell that provides trfA, both plasmids compete for available TrfA, resulting in the loss of one plasmid. Our plasmid in this example does not carry any additional advantageous antibiotic resistance markers or the like, and since it lacks a plasmid-dependent system, the plasmid is quickly lost from the progeny.

[0435] The aroA gene, which codes for an enzyme in the biosynthetic pathway of aromatic amino acids, is used as a selection marker in the absence of antibiotic resistance. It is a conditionally essential gene that is essential if the host cell grows in the absence of available aromatic amino acids or intermediates of the reaction catalyzed by aroA. Transfer of the aroA gene from the host genome to the plasmid backbone results in this selection marker. The chromosomal aroA gene is replaced by a copy of trfA in the host (carrier cell) strain.

[0436] A knockout of aroA in the E. coli laboratory strain DH10B and replacement of the chromosomal copy with a trfA expression cassette is performed to generate a test bacterial strain for testing the plasmids. The trfA expression cassette used has the sequence of SEQ ID NO:10.

[0437] The definitive host (carrier) strain, a commensal E. coli isolate derived from a chicken, is subjected to the same strain construction procedure.

[0438] The aroA coding sequence (SEQ ID NO:11) is amplified with a similar promoter and terminator region and assembled into a plasmid together with the Cas9, tracrRNA, crRNA, and oriV modules of RK2.

[0439] Additionally, alternative modules can be tested in this plasmid conformation, such as anti-restriction genes that inhibit type I restriction enzymes (ocr in T7, klcA in RK2, ardA in conjugative plasmids / transposons, ardB in conjugative plasmids) to improve DNA stability after transfer to target cells.

[0440] Additionally or alternatively, a module encoding the essential parts of the type IV secretion system present for conjugation is located on the plasmid, since this results in a non-functional transfer system present in the cell in the absence of the plasmid. To facilitate conjugation by the host cell, the type IV secretion system present on plasmid RK2 must be integrated into the host genome. The essential components of this system are encoded in three operons at two positions on the plasmid, tra1 and tra2. Tra1 encodes the traKLM and traJXIHGF operons, and tra2 encodes the trbBCEFGHJL genes. During the integration process, the regulatory region present in tra1, located between the traKLM and traJXIHGF operons, is modified. This sequence contains an origin of transfer (oriT) that has a binding site for the TraJ protein, which is responsible for initiating DNA transfer. If this binding site is not modified by mutagenesis to prevent TraJ binding, transfer of chromosomal DNA fragments during the conjugation process is initiated, resulting in the transfer of undesired genetic information.

[0441] The sequences of the tra1 and tra2 modules of RK2 used are shown in SEQ ID NOs:13 and 14.

[0442] [Example 6] Construction and testing of anti-Salmonella plasmids. overview The E. coli K12 (MG1655) IE-type Cas system is an RNA-guided specific DNase mechanism, known as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein system (CRISPR-Cas), that represents an adaptive immune system in prokaryotes that targets invading foreign genetic material for degradation. The Escherichia coli IE-type Cascade system is composed of different Cas proteins (casABCDE12 and cas3) and recognizes a wide range of PAM sequences with varying degrees of efficiency. The predominant PAM sequence is 5'-AAG, AGG, ATG, GAG-3'. The E. coli K12 IE-type Cas system was used to selectively eliminate Salmonella species. The system was modified as in E. coli MG1655, where the main components of the cas protein complex are expressed from two transcription units, cas3 and casABCDE12, respectively. Modifications introduced during the plasmid construction process included the exchange of the native regulated promoter elements of the casABCDE operon with the constitutive J23114 promoter, and the replacement of the cas1 and cas2 genes with the cas3 gene, including its native ribosome binding site. These changes essentially resulted in a constitutively expressed CRISPR-Cas module, which was then tested for functionality by the addition of a crRNA array for specific targeting of Salmonella species.

[0443] Two versions of Guided Biotic® plasmids were constructed, differing in origin of replication (oriV) and antibiotic selection markers. The resulting plasmids were named pFS-Sal-08-rm and pFS-Sal-09-rm, and were tested in vitro for selective inhibition of growth of Salmonella enterica subsp. enterica serovar Enteritidis by transfer of conjugative DNA. In the conjugation experiments, pFS-EcoCas3-01-rm and pFS-EcoCas3-03-rm were used as control plasmids for Salmonella-specific growth inhibition.

[0444] A plasmid was constructed containing nucleotide sequences encoding IE type E. coli Cas3 and the cognate casA, B, C, D, and E; a CRISPR array operable with Cas3 and including a first spacer complementary to the sequence of the invB gene of S. enterica, a second spacer complementary to the sequence of the sicP gene of S. enterica, and a third spacer complementary to the sequence of the sseE gene of S. enterica; RP4 oriT; p15A ori; E. coli proA gene; and E. coli proB gene. For further details, see Table 7.

[0445] methodology Design of crRNA array The selection of target genes for designing CRISPR spacers was focused on Salmonella-specific pathogenicity islands (SPIs), which are major virulence factors for Salmonella. The selection criteria were conservation within Salmonella enterica and low to very low presence and conservation of the respective genes in other bacteria. These analyses were performed using the Basic Local Alignment Search Tool (BLAST). The cutoff for the number of hits in non-Salmonella species was set at 1000. The conservation level was considered high if the search yielded >1000 hits. Between 100 and 1000 was moderate, between 20 and 100 was low, and <20 hits was very low. Specifically, genes related to the type III protein secretion system T3SS of SPI-1 and SPI-2 were investigated as targets, with care taken to include gene candidates conserved among Salmonella species but exclude those conserved among other bacterial species. First, the search was focused on secreted effectors and chaperones, avoiding regulators and functional components of the T3SS.

[0446] The three selected highly conserved gene targets, sicP, invB, and sseE, are all part of the T3SS loci encoded by Salmonella pathogenicity islands (SPIs), i.e., SPI-1 in the case of sicP and invB (both chaperones) and SPI-2 in the case of sseE (a secreted effector). All of these gene targets occur in only one copy in Salmonella enterica subspecies enterica serovar Typhimurium strain LT2, which is true for all Salmonella enterica, although it cannot be ruled out that they are duplicated in some strains.

[0447] The candidate target genes (a) and then the spacers (b) were searched with Blast to ensure that they were specific to Salmonella and to minimize off-targets. The search was performed using the RefSeq database, which contains approximately 10600 Salmonella enterica genomes. a) Blast search parameters for gene selection: - Salmonella conservation: RefSeq DB restricted to Salmonella enterica (taxid: 28901), megablast, max hits: 20000, standard parameters - Presence outside Salmonella: RefSeq DB restricted to bacteria (taxid:2) excluding Salmonella (taxid:590), Blastn, max hits 1000, standard parameters b) Blast search parameters for spacer sequences (including PAM): - Salmonella conservation: RefSeq DB restricted to Salmonella enterica (taxid: 28901), blastn, max hits: 20000, standard parameters - Presence outside Salmonella: RefSeq DB restricted to bacteria (taxid:2) except Salmonella enterica (taxid:28901), Blastn, max hits 1000, standard parameters but expectation value was set to 100 in order to capture sequences with low but still significant homology.

[0448] A number of spacers targeting different Salmonella enterica genes were first screened in silico, selected, cloned, and individually tested in vitro for their efficacy targeting Salmonella enterica subspecies enterica serovar Enteritidis FS26 (see overview for target gene and spacer selection and Rep-21: Construction and in vitro testing of spacer reporter system). The three best-performing spacer sequences active against Salmonella species were selected and combined into a short crRNA array. The spacer sequences were derived from three highly conserved genes present in the Salmonella pathogenicity island (SPI): invB, sicP, and sseE. Briefly, limited potential spacer sequences characterized by the presence of a strong consensus 5'-PAM sequence that could initiate DNA restriction were selected and ranked according to sequence features with efficient target DNA restriction, conservation within Salmonella isolates, and lack of DNA homology outside Salmonella enterica. Three spacer sequences that fulfilled these criteria were finally selected and incorporated into a functional crRNA array. The finalized crRNA array was arranged as a synthetic gene sequence inserted into a standard cloning plasmid (GeneArt, Thermo Fisher Scientific).

[0449] The sequences of the selected genes are shown in SEQ ID NOs: 20-22. In each gene, the spacer is highlighted in bold and the respective PAM is written in italics (in the case of invB, the spacer was selected on the negative DNA strand (antisense), so the PAM is on the 3' side of the spacer). The PAM sequences used for the selection of the spacers were AAG, ATG, AGG, and GAG. A Blast search of the spacers with their respective PAMs was performed (Table 10).

[0450] Non-Salmonella hits were further analyzed for their conservation level (spacers were accepted if the conservation level in the off-target was <75%). Sequence selection also depended on where the mismatch was located in the off-target hit, with those showing conserved PAM and seeds (first 8 bp of the spacer) being excluded. One additional criterion for our selection also included the type of bacteria in which the hit was present; if present in a pathogen, the spacer was still considered a possible candidate.

[0451] Each spacer was tested individually in vitro for their efficacy in targeting Salmonella enterica subsp. enterica serovar Enteritidis S26, and then they were combined together in the array present in plasmid pFS-Sal-09-rm.

[0452] Plasmid assembly For homology-based DNA assembly, each DNA module had a 5' and / or 3' extension with exact homology to the neighboring modules. The extensions were introduced during the PCR amplification step of the modules or were built in during the design of the synthetic DNA modules. The constitutive J23114 promoter was introduced.

[0453] CasA-E: The 4464 bp casA-casB-casC-casD-casE module was amplified from E. coli K12 (MG1655) genomic DNA.

[0454] Cas3: The 2709bp Cas3 module was amplified.

[0455] crRNA: The crRNA array module Sal-crRNA1 (546 bp) has a 25 bp stretch of homology to the 3' end of the Cas3 module. The sequence of Sal-crRNA array1 is shown in SEQ ID NO: 15, with the -10 region of the promoter in italics, the direct repeats underlined, and the spacer regions corresponding to the selected Salmonella target sequences of invB, sicP, and seeE in bold.

[0456] Validation of pFS-Sal-08-rm and pFS-Sal-09-rm and in vitro testing by conjugation The sequences of both constructs were verified and the plasmids were transformed into a carrier strain that allowed plasmid mobilization via conjugation to evaluate the efficacy of the Cas3 system to selectively kill Salmonella in the presence of Sal-crRNA array1. In this study, E. coli strain S17-1ΔTn7 was used. 100 ng of pFS-Sal-08-rm and pFS-Sal-09-rm were used to transform 50 μl of electrocompetent cells of E. coli S17-1ΔTn7 by electroporation and selection with kanamycin and chloramphenicol, respectively. Transformation with both plasmids resulted in good transformation efficiency of E. coli S17-1 ΔTN7 (10 5 ~10 6Transformed CFU / mL). Control plasmids lacking the crRNA array, pFS-EcoCas3-01-rm and pFS-EcoCas3-03, were also transformed into the S17-1 ΔTn7 carrier strain to serve as controls in FS26 transformation of pFS-Sal-09-rm and pFS-Sal-08-rm. To confirm the mobilization ability of the new plasmids, S17-1 carrier cells were first used to conjugate E. coli JM109 cells (resistant to nalidixic acid, Nal). The results reported in Table 8 show similar conjugation efficiencies between pFS-EcoCas3-01 and pFS-Sal-09-rm, and between pFS-EcoCas3-03 and pFS-Sal-08-rm in E. coli JM109. Mating efficiency is calculated by dividing the number (CFU / mL) of transconjugants (selected on plates with double antibiotics) by the number of recipients (selected on plates with Nal).

[0457] Then, the E. coli carrier strain S17-1 ΔTn7 pre-transformed with the plasmid was used to evaluate whether there was a significant growth inhibition of Salmonella Enteritidis FS26 by the conjugation of pFS-Sal-08-rm compared to the control plasmid pFS-EcoCas3-03-rm, ​​and by the conjugation of pFS-Sal-09-rm compared to pFS-EcoCas3-01-rm. Conjugation was performed from E. coli S17-1 ΔTn7 to nalidixic acid (Nal)-resistant Salmonella Enteritidis FS26. The results showed a significant reduction (CFU / mL) in both S. Enteritidis strain FS26 conjugated with pFS-Sal-08-rm and S. Enteritidis strain FS26 conjugated with pFS-Sal-09-rm compared to the respective control plasmids (Table 9).

[0458] In conclusion, the inhibition of Salmonella growth by both plasmids carrying Sal-crRNA array1 generated in this study indicated that the modified Cas module was functional and could express all the individual components, IE-type Cascade complex, Cas3 nuclease, and crRNA array, without negatively affecting the growth of the non-target E. coli host strains S17-1 and JM109. We demonstrated the ability of plasmids based on the E. coli IE-type Cas system to be transferred by conjugation from the E. coli S17-1 carrier strain to the S. Enteritidis strain FS26. We observed significant growth inhibition (>99.9%) in Salmonella transconjugants of the selected strains via both pFS-Sal-08-rm and pFS-Sal-09-rm conjugations compared to the controls used. These data therefore highlighted the potential of these E. coli IE cascade-based constructs to eliminate unwanted bacteria, for example for the control of zoonotic diseases.

[0459] [Example 7] Testing the stability and efficacy of Folium E. coli based products in chickens fed diets containing Salmonella. In Example 4, we tested Guided Biotic® plasmids contained in E. coli carrier cells of the S17 strain. In this Example 7, we instead tested Guided Biotic® plasmids (GB plasmid pFS-Sal-09-proAB-rm, Example 6 and Table 7) contained in a different strain of E. coli carrier (strain X). The helper plasmid pCon_aroA contained a functional copy of the conjugation machinery of plasmid RP4 (traJXIHGF-traKLM-trbBCDEFGHIJKL), which has been shown in vitro to facilitate the transfer of oriT-containing plasmids from host cells to recipient cells.

[0460] Research Objective - Determine the stability of Guided Biotic® E. coli strain X in drinking water over a 24 hour period. - To measure the contamination of the intestines and organs with Salmonella given in the feed. - To determine the effectiveness of E. coli strain X, containing an active GB plasmid, in chickens challenged with Salmonella in the feed.

[0461] overview - E. coli strain X was found to have expected levels of 5×log-8 CFU / mL immediately after administration in deionized water containing stabilizers, which declined to 8×log-7 CFU / mL at 24 hours. - 24-hour dietary challenge (10 per gram of diet) 4 Following challenge, low levels (approximately log-2 to 5 CFU / g) of Salmonella were found in the crop and cecum on days 1, 3, and 7 after challenge. Lower levels (approximately log-1 CFU / g) were also found in the ileal contents, liver, and spleen 7 days after challenge. - Active Guided Biotic®, E. coli strain X containing an active GB plasmid, reduced Salmonella numbers in crops by approximately log-1 CFU / g 7 days after challenge (P<0.03).

[0462] methodology Ross 308 birds (30 birds) were housed under controlled biosecurity conditions and were allowed free access to water and standard commercial diet. Each experimental group was kept in individual cages with sawdust bedding. Birds were kept on an 18-hour light / 6-hour dark regimen. Temperature and humidity were maintained between the standard levels shown in Table 11.

[0463] Treatment Group: - Low control - no water additive, 10 / g feed on day 7 4 CFU of Salmonella for 24 hours (15 birds) - GB-Sal- 10 mg / kg / day in drinking water on days 1-14 8E. coli strain X Guided Biotic® containing active GB plasmid (pFS-Sal-09-proAB-rm) at 10 CFU / mL per gram of feed on day 7. 4 CFU of Salmonella for 24 hours (15 birds)

[0464] Guided Biotic® strains were harvested daily from frozen stocks maintained at -78°C and grown on LB agar supplemented with chloramphenicol (30 μg / mL) for 24 hours at 37°C. Strain X, carrying an active GB plasmid strain, was prepared in Terrific broth and grown for 16 hours at 37°C with shaking at 180 rpm. OD 600 After estimating the cell number by measuring the concentration, the cells were centrifuged and resuspended in deionized water containing stabilizers to obtain a solution for administration to chickens (10 8 CFU / mL). A Vac Pac containing blue dye was included 3 hours prior to collection on the day of sampling to verify water and GB intake. Water samples with additives were collected at the time of GB addition and 24 hours later on study days 4-14 to measure GB. Water samples were diluted 10-fold in PBS and then plated on MacConkey Agar No. 3 (Oxoid CM0115) and then incubated at 37°C for 24 hours.

[0465] A Salmonella strain (FS26, with a nalidixic acid marker) was recovered from frozen stocks maintained at -78°C and grown on LB agar at 37°C for 24 h. Test cultures were prepared once a day in LB broth for 16 h at 37°C with shaking at 180 rpm. OD 600 After estimating cell number by measuring the β-amino acid concentration, the cells were centrifuged, resuspended and diluted in phosphate-buffered saline to a concentration of 1 × 10 7 A solution of CFU / ml was obtained and added dropwise to the feed at a ratio of 1 ml of bacterial suspension per 100 g of feed while thoroughly mixing the feed. Four feed samples were collected for measuring the Salmonella content.

[0466] Collection and seeding of animal samples No bird mortality was recorded. Light levels, bedding addition, temperature, humidity, and stocking density were recorded and did not differ between treatments. Three birds from each group on days 1 and 3, and nine birds on day 7 post-challenge, were euthanized and samples were obtained from the crop, ileum, cecum, liver, and spleen. Times of euthanasia, death, and dissection were recorded. Feathers were wetted by spraying with water. Birds were opened with a disposable scalpel, which was discarded after opening, and gloves were changed. One gram of liver and samples of the contents of the crop, ileum, and cecum were taken and flash frozen in liquid nitrogen. The scalpel was discarded after each organ was collected. Samples were homogenized in 9 volumes of phosphate-buffered saline, diluted 10-fold in phosphate-buffered saline, and examined by incubating agar at 37°C for 16–18 h. Samples that were negative by direct plating were tested for Salmonella by enrichment in nine volumes of selenite-cystine broth (Oxoid CM0699) for 16-18 hours at 37°C. The enriched broth was then streaked onto XLD agar (CM0469) containing the antibiotics listed in Table 12 and incubated at 37°C for 16-18 hours.

[0467] Birds with no detectable bacteria by direct count were assigned a count of 0 bacteria / g, whereas birds with negative direct counts but positive augmented methods were assigned a count of 50 CFU / g. Results were recorded on paper or dictated over telephone or radio in biosecure accommodation and transcribed into Microsoft Excel. Data were analyzed in GraphPad Prism. Data were assessed for normality of distribution using the D'Agostino and Pearson omnibus normality test and, for non-normality, analyzed using the Mann-Whitney U test. Paired data were analyzed using paired T-tests.

[0468] result 1. Salmonella in Feed - The presence of Salmonella in the feed (mean 9 × log-4 CFU / g) was as expected.

[0469] 2. Guided Biotic® Levels in Drinking Water - The levels of GB analyzed in the drinking water immediately after mixing (mean 5×log-8 CFU / mL) were as expected. Samples taken after 24 hours showed a mean reduction to 8×log-7 CFU / mL.

[0470] 3. Effect of Salmonella dose - Overall, low levels of Salmonella were found in the crop (approximately log1-3 CFU / g) and cecum (approximately log4-5 CFU / g) on ​​days 1 and 3 postchallenge. No Salmonella were found in ileum, liver, or spleen samples at these time points. - On day 7 post-challenge, similar levels of Salmonella were again found in the crop and cecum, and lower levels (approximately log1) were found in the ileum, liver, and spleen.

[0471] 4. Effect of active Guided Biotic® (control vs. GB) - GB reduced (P<0.03) Salmonella numbers in crops 7 days after challenge (Figure 6).

[0472] - There was a weak trend for GB to reduce Salmonella in the crop (P=0.40) and cecum (P=0.50) on day 3, and in the ileum (P=0.58) and cecum (P=0.60) on day 7.

[0473] [Table 5] JPEG0007588602000006.jpg223135JPEG0007588602000007.jpg233135JPEG0007588602000008.jpg226136 JPEG0007588602000009.jpg228134JPEG0007588602000010.jpg228134JPEG0007588602000011.jpg225138

[0474]

Table 6

[0475]

Table 7

[0476]

Table 8

[0477]

Table 9

[0478]

Table 10

[0479]

Table 11

[0480]

Table 12

[0481]

Table 13

[0482]

Table 14

Claims

1. A non-medical method for enhancing the growth or weight of a livestock animal, comprising: said method comprising administering to said animal a plurality of E. coli carrier cells, said animal comprising bacterial target cells, each E. coli carrier cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to target cells but not toxic to said E. coli carrier cells, said E. coli carrier cells capable of conjugatively transferring said first episomal DNA into said target cells for expression in said target cells of said antimicrobial agent, said first episomal DNA being transferred from said E. coli carrier cells to said target cells for expression in said target cells to produce said antimicrobial agent, thereby killing or reducing the growth or proliferation of target cells in said animal and increasing the growth or weight of said animal; wherein the target cell is a Salmonella enterica cell; The method, wherein the antibacterial agent encodes a guide RNA or crRNA of a CRISPR / Cas system that operates with a Cas nuclease in the target cell to cleave one or more chromosomal protospacer sequences contained in the target cell, and the protospacer sequences comprise one or more nucleotide sequences of genes selected from invB, sseE, and sicP.

2. 10. The method of claim 1, wherein said method improves feed conversion ratio (FCR) in said animal.

3. 3. The method of claim 2, wherein the target cell is S. enterica subspecies enterica.

4. 4. The method of any one of claims 1 to 3, wherein a plurality of different S. enterica subspecies enterica serovars are killed, and optionally each serovar is selected from the group consisting of Typhimurium, Enteritidis, Virchow, Montevideo, Heidelberg, Hadar, Binza, Bredeney, Infantis, Kentucky, Seftenberg, Mbandaka, Anatum, Agona, and Dublin.

5. The method of any one of claims 1 to 4, wherein the E. coli carrier cells are F18, Nissle, or S17 E. coli cells.

6. 6. The method of any one of claims 1 to 5, wherein the method reduces target cells in the gastrointestinal tract of the animal, optionally wherein the animal is a bird and the method reduces target cells in the cecum, crop, liver, spleen, and / or ileum of the bird.

7. The method according to any one of claims 1 to 6, wherein the first DNA is contained in a plasmid, the plasmid comprising the RP4 origin of transfer (oriT) and / or the p15A ori.

8. 8. The method of any one of claims 1-7, wherein the antimicrobial agent comprises one or more components of a CRISPR / Cas system operable in a target cell to cleave a protospacer sequence contained in the target cell, the target cell comprising a first and a second strain of S. enterica, each strain comprising the protospacer sequence, and killing target cells of said strains.

9. 9. The method of claim 8, wherein the CRISPR / Cas system is operable to cleave at least three different protospacer sequences contained in the target cell genome.

10. The antibacterial agent is a guided nuclease capable of recognizing and modifying a target nucleic acid sequence, said target sequence being contained in an endogenous chromosome of said target cell but not in said carrier cell, said nuclease modifying said chromosome such that said target cell is killed or inhibits growth or proliferation of said target cell; The method according to any one of claims 1 to 9.

11. 11. A carrier cell for use in the method of any one of claims 1 to 10, wherein the carrier cell is a bacterial cell comprising a first episomal DNA encoding an antimicrobial agent that is toxic to a bacterial target cell but not toxic to the carrier cell, the carrier cell being capable of conjugatively transferring the DNA into the target cell for expression of the antimicrobial agent in the target cell, thereby killing the target cell, the target cell being a Salmonella enterica cell, the carrier cell being an E. coli cell, the antimicrobial agent encoding a guide RNA or crRNA of a CRISPR / Cas system that operates with a Cas nuclease in the target cell to cleave one or more protospacer sequences contained in the target cell, and the protospacer sequences comprise one or more nucleotide sequences of a gene selected from invB, sseE, and sicP.

12. A composition comprising a plurality of carrier cells for use in a method comprising administering carrier cells to a subject for treating infection by a pathogenic bacterial target cell, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antibacterial agent that is toxic to a target cell but not toxic to said carrier cell, said carrier cell being capable of conjugatively transferring said first episomal DNA into said target cell for expression in said target cell of said antibacterial agent, said first episomal DNA being transferred from said carrier cell to said target cell for expression in said target cell to produce said antibacterial agent thereby killing or reducing the growth or proliferation of said target cell in said livestock animal, said target cell being a Salmonella cell, and said carrier cell being an E. coli cell, wherein the antimicrobial agent encodes a guide RNA or crRNA of a CRISPR / Cas system that operates with a Cas nuclease in the target cell to cleave one or more protospacer sequences contained in the target cell, and the protospacer sequences comprise one or more nucleotide sequences of a gene selected from invB, sseE, and sicP.

13. A non-medical method for killing zoonotic bacterial target cells in a livestock animal, said method comprising administering to said animal a plurality of carrier cells, each carrier cell being a bacterial cell comprising a first episomal DNA encoding an antibacterial agent that is toxic to said target cells but not toxic to said carrier cells, said carrier cells capable of conjugatively transferring said first episomal DNA into said target cells for expression in said target cells of said antibacterial agent, and said first episomal DNA being transferred from said carrier cells to said target cells for expression in said target cells to produce said antibacterial agent, thereby killing said target cells or reducing the growth or proliferation of said target cells in a livestock animal, said target cells being Salmonella enterica cells and said carrier cells being E. coli cell, wherein the antimicrobial agent encodes a guide RNA or crRNA of a CRISPR / Cas system that operates with a Cas nuclease in the target cell to cleave one or more protospacer sequences contained in the target cell, and the protospacer sequences comprise one or more nucleotide sequences of a gene selected from invB, sseE, and sicP.

14. 13. The composition of claim 12, wherein the method reduces Salmonella in the gastrointestinal tract of the subject.

15. The method of claim 13, wherein the method reduces Salmonella in the gastrointestinal tract of the subject.

16. 15. The composition of claim 12 or 14, wherein the method is performed on a group of animals (optionally a pack or herd), some or all of the animals containing the target cells, and the spread of target cells of the target species is reduced in the group, or the spread from the group to a second group of animals is reduced.

17. A method according to claim 13 or 15, wherein the method is carried out in a group of animals (optionally a pack or herd), some or all of the animals contain the target cells, and the spread of target cells of the target species is reduced in the group or the spread from the group to a second group of animals is reduced.

18. 17. The composition of any one of claims 12, 14 and 16, wherein the target cells comprise a variety of Salmonella spp. types that are killed.

19. The method of any one of claims 13, 15, and 17, wherein the target cells comprise various Salmonella spp. types to be killed.

20. The carrier cell of claim 11, the composition of any one of claims 12, 14, 16 and 18, wherein the carrier cell, target cell or DNA is a carrier cell, target cell or DNA defined in any one of claims 1 to 10, respectively.

21. A method described in any one of claims 13, 15, 17, and 19, wherein the carrier cell, target cell, or DNA is a carrier cell, target cell, or DNA defined in any one of claims 1 to 10, respectively.

22. A DNA for use in the method of any one of claims 1 to 10 or 13, 15, 17, 19 and 21, a carrier cell of claim 11 or 20, or a composition of any one of claims 12, 14, 16, 18 and 20, wherein said DNA can be introduced into a target cell and encodes a plurality of guide RNAs or crRNAs of a CRISPR / Cas system, said guide RNAs or crRNAs being operable with Cas nuclease in said target cell to recognise a plurality of chromosomal protospacer sequences comprised in the genome of said target cell, said target cell being a Salmonella enterica cell, The DNA, carrier cell, or composition, wherein the protospacer sequence comprises one or more nucleotide sequences of a gene selected from a gene selected from invB, sicP, or sseE.

23. 23. The DNA of claim 22, contained in a plasmid containing an operable origin of transfer (oriT) and an origin of replication (oriV) for replication of said DNA in a bacterial host cell.

24. 24. The DNA of claim 22 or 23, wherein the DNA comprises SEQ ID NO: 15, optionally contained in a plasmid in a carrier bacterial cell for conjugation into a Salmonella enterica target cell.

25. CRISPR repeat sequences and spacer sequences, (a) each of the repeat sequences comprises SEQ ID NO: 16; and / or (b) the spacer sequence comprises one, two or three sequences selected from SEQ ID NOs: 17-19 and their complementary sequences, optionally contained in a plasmid in the carrier bacterial cell for conjugation into the Salmonella enterica target cell, according to claim 22 or 23.

26. 26. The DNA of claim 25, comprising (optionally in 5' to 3' order) SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:

19.

27. 22. The method of any one of claims 1-10, 13, 15, 17, 19, and 21, wherein the target cell is a Salmonella enterica cell and the DNA is contained in a plasmid, the plasmid being selected from IncFI, IncFII, IncFIII, IncFIV, IncFV, IncM, Inc9, IncIO, Incl, IncA, IncB, IncC, IncH, IncIa, InclIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and IncW plasmids.

28. The carrier cell of claim 11 or 21, the composition of any one of claims 12, 14, 16, 18, and 20, or the DNA of any one of claims 22 to 26, wherein the target cell is a Salmonella enterica cell and the DNA is contained in a plasmid, the plasmid being selected from IncFI, IncFII, IncFIIl, IncFIV, IncFV, IncM, Inc9, InclO, Incl, IncA, IncB, IncC, IncH, IncIa, InclIc, IncI2, IncIy, IncJ, IncL, IncN, Inc2e, IncO, IncP, IncS, IncT, and IncW plasmids.

29. The method of any one of claims 1 to 10, 13, 15, 17, 19, 21 and 27, wherein the livestock animal is a chicken (e.g., a broiler or layer).

30. The carrier cell of claim 11, 21, or 28, the composition of any one of claims 12, 14, 16, 18, 20, and 28, or the DNA of any one of claims 22 to 26, and 28, wherein the livestock animal is a chicken (e.g., a broiler or a layer hen).

Citation Information

Patent Citations

  • Methods for reducing conjugative plasmids in bacteria

    JP2017012203A

  • Methods and genetic systems for cell engineering

    JP2017512500A

  • Treating and preventing microbial infections

    US20180273940A1

  • Bacillus subtilis strain with probiotic activity

    WO2019002471A1